nctid,status,why_stop,label,phase,diseases,icdcodes,drugs,smiless,criteria
NCT02579681,completed,,1,phase 3,"['multiple sclerosis, relapsing-remitting']","[""['G35', 'G93.81', 'K74.1', 'Q85.1', 'G12.21', 'G12.23', 'M34.0']""]",['dimethyl fumarate'],['COC(=O)C=CC(=O)OC'],"
        Key Inclusion Criteria:

          -  Must have a confirmed diagnosis of RRMS according to McDonald criteria (Polman,
             Reingold et al. 2005).

          -  Must have a baseline EDSS between 0.0 and 5.0, inclusive.

          -  Must have experienced at least 1 relapse within the 12 months prior to randomization,
             with a prior brain MRI demonstrating lesion(s) consistent with MS, or show evidence of
             gadolinium-enhancing lesion(s) of the brain on an MRI performed within the 6 weeks
             prior to randomization.

        Key Exclusion Criteria:

        Candidates will be excluded from study entry if any of the following exclusion criteria
        exist at the time of screening:

          -  Primary progressive, secondary progressive, or progressive relapsing MS, as defined by
             Lublin and Reingold (Lublin and Reingold 1996)

          -  Severe depression (MADRS score >34) (Montgomery and Asberg 1979)

          -  History of malignancy (except basal cell carcinoma that has been completely excised
             prior to study enrollment)

          -  An MS relapse that has occurred within the 30 days prior to inclusion AND/OR the
             participant has not stabilized from a previous relapse prior to inclusion.
      "
NCT02722603,terminated,"
    the study was early terminated due to insufficient recruitment
  ",0,phase 3,['chronic pain'],"[""['G89.29', 'G89.4', 'R39.82', 'G89.22', 'G89.28', 'G89.21', 'G89.3']""]","['gabapentin', 'tramadol']","['C1CCC(CC1)(CC(=O)O)CN', 'CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O']","
        Inclusion Criteria:

          1. Male or female, aged 3 months to less than 18 years at screening.

          2. Informed consent by parent(s) and/or legal guardian according to each country legal
             requirement.

          3. Assent by the patient, where applicable, according to each country legal requirement.

          4. Subjects that meet the diagnostic criteria for neuropathic or mixed pain.

          5. Subjects that present with chronic pain defined as the recurrent or continuous pain
             persisting more than 3 months. Duration of pain will be determined from the date of
             the first pain experienced.

          6. Subjects that present with at least moderate pain as defined by average pain intensity
             of ≥4/10 as assessed during a 3-day screening period

          7. Stable underlying disease condition and treatment.

          8. In presence of malignant diseases, subjects in clinical remission and/or no expected
             changes in their therapeutic protocol during participation to the present study.

        Exclusion Criteria:

          1. Pain duration of more than 5 years.

          2. Current use of gabapentin or tramadol.

          3. History of failure to respond to adequate treatment by gabapentin or tramadol/opioids
             for neuropathic pain.

          4. History of epileptic condition except febrile seizure disorder.

          5. Subjects with sleeping apnoea syndrome of any origin or subjects with history of
             severe respiratory impairment.

          6. Subjects with diagnosis of sickle cell disease.

          7. Subjects that present significant cognitive impairment.

          8. Subjects that present current, controlled or uncontrolled, co-morbid psychiatric
             diagnosis that can impair pain diagnosis and assessment such as severe depressive
             conditions or psychosis.

          9. Subjects with history of suicidal ideation or behaviour.

         10. History of substance abuse in particular opioids.

         11. Subjects under prohibited concomitant medication

         12. Subjects in need for corticosteroid oral treatment or corticosteroid infiltrations to
             treat pain caused by infiltration or compression of neural structures, e.g. peripheral
             nerves or spinal cord.

         13. Subjects born prematurely at ≤ 36 weeks gestational age, if recruited during the first
             year of age.

         14. Subjects with a body mass index (BMI) for age and gender of < 5th percentile or > 95th
             percentile.

         15. Subjects with glomerular filtration rate < 90 mL/min/1.73 m2 (Schwarz equation).

         16. Subjects with significant hepatic impairment or with Aspartate Transaminase (AST) or
             Alanine Transaminase (ALT) enzymes 3 times the upper limit of the age-specific
             reference range.

         17. Subjects with known allergy, hypersensitivity or clinically significant intolerance to
             gabapentin or tramadol or any component found in the study drugs.

         18. Subjects with fructose intolerance, diabetes, glucose-galactose malabsorption or
             lactase-isomaltase deficiency.

         19. Subjects with clinically relevant abnormal ECG at the screening visit in the
             discretion of the Investigator/cardiologist.

         20. Subjects participating in another clinical interventional trial.

         21. Subjects scheduled for surgery or in recovery from surgery occurring within 3 months
             of baseline assessment.

         22. Female subjects who are pregnant or currently lactating.

         23. Subjects that failed screening or were previously enrolled in this study.
      "
NCT02512510,completed,,1,phase 3,['chronic obstructive pulmonary disease (copd)'],"[""['G91.1', 'I42.1', 'N11.1', 'J05.0', 'P28.42', 'G47.33', 'J44.9']""]","['td-4208', 'placebo']",['CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N'],"
        Inclusion Criteria:

          -  Subject is a male or female subject 40 years of age or older

        Exclusion Criteria:

          -  Females who are pregnant, lactating, breast-feeding or planning to become pregnant
             during the study
      "
NCT02518139,completed,,1,phase 3,['chronic obstructive pulmonary disease (copd)'],"[""['G91.1', 'I42.1', 'N11.1', 'J05.0', 'P28.42', 'G47.33', 'J44.9']""]","['td-4208', 'tiotropium']","['CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N', 'C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C']","
        Inclusion Criteria:

          -  Subject is a male or female subject 40 years of age or older

        Exclusion Criteria:

          -  Females who are pregnant, lactating, breast-feeding or planning to become pregnant
             during the study
      "
NCT02004392,terminated,"
    study has been suspended due to clinical hold.
  ",0,phase 3,"[""alzheimer's disease"", 'dementia']","[""['G30.8', 'G30.9', 'G30.0', 'G30.1']"", ""['F01.A11', 'F01.A4', 'F01.B11', 'F01.B4', 'F01.C11', 'F01.C4', 'F03.A11']""]",['evp-6124'],['C1CN2CCC1C(C2)NC(=O)C3=CC4=C(S3)C(=CC=C4)Cl'],"
        Inclusion Criteria:

          -  Male or female subjects of any race, aged ≥55 and ≤85 years at time of entry into
             study EVP-6124-024 or EVP-6124-025

          -  Informed consent form (ICF) for this extension study signed by the subject or legally
             acceptable representative and an ICF signed by the support person/caregiver before
             initiation of any study-specific procedures

          -  Successful completion (Day 182) of study EVP-6124-024 or EVP-6124-025

          -  No clinically significant change in the judgment of the investigator in the subject's
             medical status during study EVP-6124-024 or EVP-6124-025

          -  In the judgment of the investigator, extension treatment is in the best interest of
             the subject

          -  Fertile, sexually active subjects (men and women) must use an effective method of
             contraception during the study. Female subjects and the female partner of male
             subjects must be surgically sterile (hysterectomy or bilateral tubal ligation),
             postmenopausal for at least 1-year, or willing to practice adequate methods of
             contraception if of childbearing potential (defined as consistent use of combined
             effective methods of contraception [including at least 1 barrier method])

          -  Reliable and capable support person/caregiver, who if not living in the same
             household, interacts with the subject approximately 4 times per week and will be
             available to attend clinic visits in person when possible

        Exclusion Criteria:

          -  Significant risk of suicidal or violent behavior in the judgment of the investigator

          -  Adverse events from the previous study (EVP-6124-024 or EVP-6124-025) that have not
             resolved, are moderate or severe, judged to be possibly related or related to study
             drug, and considered by the investigator to be a contraindication to extension study
             participation

          -  Any condition that would make the subject in the judgment of the investigator
             unsuitable for the study

          -  Female subjects who are pregnant, nursing, or planning to become pregnant during the
             extension study
      "
NCT02006654,completed,,0,phase 3,"[""alzheimer's disease""]","[""['G30.8', 'G30.9', 'G30.0', 'G30.1']""]","['placebo', 'idalopirdine']",['C1=CC(=CC(=C1)OCC(C(F)F)(F)F)CNCCC2=CNC3=C2C=CC(=C3)F'],"
        Inclusion Criteria:

          -  The patient has a knowledgeable and reliable caregiver.

          -  The patient is an outpatient.

          -  The patient has probable AD.

          -  The patient has mild to moderate AD.

          -  Stable treatment with an AChEI.

          -  The patient, if a woman, must have had her last natural menstruation ≥24 months prior
             to baseline, OR be surgically sterile.

          -  The patient, if a man, agrees to protocol-defined use of effective contraception if
             his female partner is of childbearing potential, OR must have been surgically
             sterilised prior to the screening visit.

        Exclusion Criteria:

          -  The patient has evidence of any clinically significant neurodegenerative disease, or
             other serious neurological disorders other than AD.

          -  The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition,
             Text Revision (DSM-IV-TR) Axis I disorder other than AD.

          -  The patient has evidence of clinically significant disease.

          -  The patient's current AChEI therapy is likely to be interrupted or discontinued during
             the study.

          -  The patient is currently receiving memantine or has taken memantine within 2 months
             prior to screening.

        Other inclusion and exclusion criteria may apply.
      "
NCT02006121,completed,,1,phase 3,"[""parkinson's disease""]","[""['G20']""]","['apomorphine hydrochloride', 'placebo']",['CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O.Cl'],"
        Inclusion Criteria:

          -  Male or female patients aged ≥30 years

          -  Diagnosis of idiopathic PD of >3 years' duration, defined by the UK Brain Bank
             criteria (with the exception of >1 affected relative being allowed), without any other
             known or suspected cause of Parkinsonism

          -  Hoehn & Yahr stage up to 3 in the ON and 2 to 5 in the OFF state

          -  Motor fluctuations not adequately controlled on medical treatment including levodopa
             which was judged by the treating physician to be optimal

          -  Average of OFF time > 3 hours/day based on screening and baseline diary entries with
             no day with < 2 hours of OFF time recorded

          -  Stable medication regimen, with a stable dose of levodopa administered in at least 4
             intakes, for at least 28 days prior to baseline. All oral or transdermal
             antiparkinsonian drugs were permitted, with the exception of budipine. This regimen
             might include the use of levodopa/DDCI rescue medication, if this occurred up to 2
             times a day, at doses of up to 200 mg levodopa/day

          -  Patients must be able to differentiate between the ON and OFF state and between
             troublesome and non-troublesome dyskinesias

          -  Male and female patients must be compliant with a highly effective contraceptive
             method (oral hormonal contraception alone is not considered highly effective and must
             be used in combination with a barrier method) during the study and for the 12-month
             OLP, if sexually active

          -  Females of childbearing potential must have a negative serum human chorionic
             gonadotropin (hCG) or urine pregnancy test at screening

          -  Ability to accurately complete a paper diary on designated days (with assistance from
             caregivers, if required), recording periods when they are ""ON without troublesome
             dyskinesia"", ""ON with troublesome dyskinesia"", OFF, and sleeping

          -  Written informed consent prior to enrolment, after being provided with detailed
             information about the nature, risks, and scope of the clinical trial as well as the
             expected desirable and adverse effects of the study treatments

          -  Patients considered reliable and capable of adhering to the protocol, visit schedule,
             and medication intake according to the judgment of the investigator

        Exclusion Criteria:

          -  History of respiratory depression

          -  Hypersensitivity to apomorphine or any excipients of the medicinal product

          -  High suspicion of other parkinsonian syndromes

          -  Presence of severe freezing or clinically relevant postural instability leading to
             falls during the ON state

          -  Concomitant therapy or within 28 days prior to baseline with: apomorphine pen
             injections; alpha-methyl dopa, metoclopramide, reserpine, neuroleptics,
             methylphenidate, or amphetamine; intrajejunal levodopa

          -  Previous use of apomorphine pump treatment

          -  History of deep brain stimulation or lesional surgery for PD

          -  Any medical condition that is likely to interfere with an adequate participation in
             the study, including e.g. current diagnosis of unstable epilepsy; clinically relevant
             cardiac dysfunction and/or myocardial infarction or stroke within the last 12 months

          -  Symptomatic, clinically relevant and medically uncontrolled orthostatic hypotension

          -  Patients with a borderline QT interval corrected for heart rate according to Bazett's
             formula (QTcB) of >450 msec for male and >470 msec for female at screening or history
             of long QT syndrome; or >450 msec absolute duration

          -  Clinically relevant hepatic dysfunction (total bilirubin >2.0 mg/dL, alanine
             transaminase [ALT] and aspartate transaminase [AST] >2 times the upper limit of
             normal)

          -  Clinically relevant renal dysfunction (serum creatinine >2.0 mg/dL)

          -  Pregnant and breastfeeding women

          -  Clinically relevant cognitive decline, defined as MMSE ≤24 or according to Diagnostic
             and Statistical Manual of Mental Disorders (DSM) IV criteria for dementia

          -  Active psychosis or history of at least moderate psychosis in the past year, or with
             medically uncontrolled severe depression; very mild illusions or hallucinations in the
             sense of ""feelings of passage or presence"" with fully retained insight are not an
             exclusion criterion

          -  Known history of melanoma

          -  Any investigational therapy in the 4 weeks prior to randomization

          -  History or current drug or alcohol abuse or dependencies
      "
NCT02006641,completed,,0,phase 3,"[""alzheimer's disease""]","[""['G30.8', 'G30.9', 'G30.0', 'G30.1']""]","['placebo', 'idalopirdine']",['C1=CC(=CC(=C1)OCC(C(F)F)(F)F)CNCCC2=CNC3=C2C=CC(=C3)F'],"
        Inclusion Criteria:

          -  The patient has a knowledgeable and reliable caregiver.

          -  The patient is an outpatient.

          -  The patient has probable AD.

          -  The patient has mild to moderate AD.

          -  Stable treatment with donepezil.

          -  The patient, if a woman, must have had her last natural menstruation ≥24 months prior
             to baseline, OR be surgically sterile.

          -  The patient, if a man, agrees to protocol-defined use of effective contraception if
             his female partner is of childbearing potential, OR must have been surgically
             sterilised prior to the screening visit.

        Exclusion Criteria:

          -  The patient has evidence of any clinically significant neurodegenerative disease, or
             other serious neurological disorders other than AD.

          -  The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition,
             Text Revision (DSM-IV-TR) Axis I disorder other than AD.

          -  The patient has evidence of clinically significant disease.

          -  The patient's donepezil therapy is likely to be interrupted or discontinued during the
             study.

          -  The patient is currently receiving memantine or has taken memantine within 2 months
             prior to screening.

        Other inclusion and exclusion criteria may apply.
      "
NCT02038179,completed,,0,phase 2/phase 3,"['pre-hypertension', 'jnc 7 stage i hypertension']","[""['O11.1', 'O11.2', 'O11.3', 'O11.4', 'O11.9', 'O11.5', 'O10.02']"", ""['I15.0', 'I97.3', 'K76.6', 'P29.2', 'G93.2', 'H40.053', 'I10']""]","['allopurinol', 'placebo']",['C1=NNC2=C1C(=O)NC=N2'],"
        Inclusion Criteria:

          -  Pre-hypertension or stage I hypertension, defined as the following after the mean of
             two clinic measurements:

          -  Systolic blood pressure (SBP) ≥ 120 and <160 or;

          -  Diastolic blood pressure (DBP) ≥ 80 and < 100

          -  Serum urate ≥ 5.0 mg/dL for men or ≥ 4.0 mg/dL for women

          -  Age 18-40

        Exclusion Criteria:

          -  Any current pharmacological treatment for hypertension, including diuretics (calcium
             channel blockers at stable doses were later allowed)

          -  Estimated glomerular filtration rate < 60 mL/min/1.73m2

          -  Current use of any urate-lowering therapy or statins

          -  Prior diagnosis of gout or past use of urate-lowering therapy for gout

          -  Prior diagnosis of diabetes

          -  Pregnancy, or recent delivery or last trimester pregnancy loss more recent than 3
             months

          -  Active smokers

          -  Immune-suppressed individuals including transplant recipients or current use of
             azathioprine.

          -  Leucopenia with absolute white cell count < 3000 /mL, anemia with hemoglobin < 12
             g/dL, or thrombocytopenia with platelet count < 150,000/mL

          -  Individuals of Han Chinese or Thai descent with HLAB5801 genetic phenotype

          -  Serious medical condition that at investigator's judgment precludes utilization of a
             fixed dose of allopurinol
      "
NCT02382939,completed,,1,phase 3,"['adult growth hormone deficiency', 'growth hormone disorder']","[""['D81.810', 'E53.0', 'E53.1', 'E61.0', 'E61.1', 'E61.2', 'E61.3']"", ""['F20.81', 'F21', 'F34.0', 'F34.1', 'F42.3', 'F45.0', 'F51.5']""]","['somapacitan', 'somatropin']",['C(CCCCCCCC1=NNN=N1)CCCCCCCC(=O)NS(=O)(=O)CCCC(=O)NCCOCCOCC(=O)NC(CCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NC(CCCCNC(=O)CSCC(C(=O)O)N)C(=O)N)C(=O)O)C(=O)O'],"
        Inclusion Criteria: - Male or female of at least 18 years of age and not more than 79 years
        of age at the time of signing informed consent - Adult growth hormone deficiency diagnosed
        for 6 months or longer (defined as 180 days) prior to screening - Treatment with hGH (human
        growth hormone) for at least 6 months at screening - If applicable, hormone replacement
        therapies for any other hormone deficiencies, adequate and stable for at least 90 days
        prior to randomisation as judged by the investigator Exclusion Criteria: - Active malignant
        disease or history of malignancy. Exceptions to this exclusion criterion: Resected in situ
        carcinoma of the cervix and squamous cell or basal cell carcinoma of the skin with complete
        local excision. / Subjects with GHD (growth hormone deficiency) attributed to treatment of
        intracranial malignant tumours or leukaemia, provided that a recurrence-free survival
        period of at least 5 years is documented in the subject's file - For patients with surgical
        removal or debulking of pituitary adenoma or other benign intracranial tumour within the
        last 5 years: Evidence of growth of pituitary adenoma or other benign intracranial tumour
        within the last 12 months (defined as below or equal to 365 days) before randomisation.
        Absence of growth must be documented by two post-surgery MRI or CT scans. The most recent
        MRI or CT scan must be performed below or equal to 9 months (defined as below or equal to
        270 days) prior to randomisation
      "
NCT02952820,completed,,1,phase 3,['insomnia disorder'],"[""['F51.05']""]","['lemborexant', 'placebo']",['CC1=NC(=NC=C1OCC2(CC2C(=O)NC3=NC=C(C=C3)F)C4=CC(=CC=C4)F)C'],"
        Inclusion Criteria:

          -  Male or female, age 18 years or older at the time of informed consent

          -  Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5)
             criteria for Insomnia Disorder, as follows:

               -  Complains of dissatisfaction with nighttime sleep in the form of difficulty
                  getting to sleep, difficulty staying asleep, and/or awakening earlier in the
                  morning than desired despite adequate opportunity for sleep

               -  Frequency of complaint ≥3 times per week

               -  Duration of complaint ≥3 months

               -  Associated with complaint of daytime impairment

          -  History of (Subjective Sleep Onset Latency) sSOL ≥30 minutes on at least 3 nights per
             week in the previous 4 weeks and/or subjective Wake after Sleep Onset (sWASO) ≥60
             minutes on at least 3 nights per week in the previous 4 weeks

          -  History of regular time spent in bed, either sleeping or trying to sleep, between 7
             and 9 hours

          -  Regular bedtime, between 21:00 and 01:00 and regular wake time, the time the
             participant gets out of bed for the day, between 05:00 and 10:00

          -  Insomnia Severity Index (ISI) score ≥15

          -  Confirmation of current insomnia symptoms as determined from the Sleep Diary completed
             on at least 7 consecutive mornings (minimum 5 of 7 for eligibility), such that sSOL
             ≥30 minutes on at least 3 of the 7 nights and/or sWASO ≥60 minutes on at least 3 of
             the 7 nights

          -  Confirmation of time spent in bed, as determined from on the Sleep Diary completed on
             7 mornings between the first and second screening visit, such that there are not more
             than 2 nights with duration of time spent in bed 7 hours and 10 hours

          -  Confirmation of regular bedtimes and wake times such that the participant has a
             regular time spent in bed, either sleeping or trying to sleep, between 7 and 10 hours
             for the final 7 nights of the before visit 3.

          -  Confirmation of regular bedtime between 21:00 and 01:00 and time of getting out of bed
             for the day between 05:00 and 10:00 for the final 7 nights of the before visit 3.

          -  Willing and able to comply with all aspects of the protocol, including staying in bed
             for at least 7 hours each night

          -  Willing to not start a behavioral or other treatment program for insomnia during the
             participants participation in the study

        Exclusion Criteria:

          -  A current diagnosis of sleep-related breathing disorder, periodic limb movement
             disorder, restless legs syndrome, circadian rhythm sleep disorder, or an exclusionary
             score on screening instruments to rule out individuals with symptoms of certain sleep
             disorders other than insomnia.

               -  STOPBang score greater than or equal to (>=) 5

               -  International Restless Legs Scale (IRLS) score >=16

               -  Epworth Sleepiness Scale (ESS) score >15

          -  Reports symptoms potentially related to narcolepsy that in the clinical opinion of the
             investigator indicates the need for referral for a diagnostic evaluation for the
             presence of narcolepsy

          -  Reports a history of sleep-related violent behavior, or sleep driving, or any other
             complex sleep-related behavior, eg, making phone calls, or preparing and eating food
             while asleep

          -  For participants who underwent polysomnography (PSG) within the previous year:

               -  Age 18 to 64 years: Apnea Hypopnea Index ≥10, or Periodic Limb Movements with
                  Arousal Index ≥10

               -  Age ≥65 years: Apnea Hypopnea Index >15, or Periodic Limb Movements with Arousal
                  Index >15

          -  Beck Depression Inventory - II (BDI II) score >19 at Screening

          -  Beck Anxiety Inventory (BAI) score >15 at Screening

          -  Habitually naps more than 3 times per week

          -  Females who are breastfeeding or pregnant at Screening or Study Baseline

          -  Females of childbearing potential who are not practicing acceptable pregnancy
             prevention methods (NOTE: All females will be considered to be of childbearing
             potential unless they are postmenopausal or have been sterilized surgically.)

          -  Excessive caffeine use that in the opinion of the investigator contributes to the
             participant's insomnia, or habitually consumes caffeine-containing beverages after
             18:00 and is unwilling to forego caffeine after 18:00 for the duration of his/her
             participation in the study

          -  History of drug or alcohol dependency or abuse within approximately the previous 2
             years

          -  Reports habitually consuming more than 14 drinks containing alcohol per week (females)
             or more than 21 drinks containing alcohol per week (males), or unwilling to limit
             alcohol intake to no more than 2 drinks per day or forego having alcohol within the 3
             hours before bedtime for the duration of his/her participation in the study

          -  A prolonged QT/QT interval corrected by Fridericia's formula (QTcF >450 ms) as
             demonstrated by a repeated electro cardiogram(ECG) at Screening (repeated only if
             initial ECG indicates a QTcF interval >450 ms)

          -  Current evidence of clinically significant disease (e.g., cardiac, respiratory,
             gastrointestinal, renal, neurological [including participants who lack capacity and/or
             whose cognitive decline indicates disorientation to person/place/time and/or
             situation], or psychiatric disease or malignancy other than basal cell carcinoma) or
             chronic pain that in the opinion of the investigator(s) could affect the participant's
             safety or interfere with the study assessments

          -  Comorbid nocturia resulting in frequent need to get out of bed to use the bathroom
             during the night

          -  Scheduled for major surgery during the study

          -  Used any prohibited prescription or over-the-counter concomitant medications within 1
             week before the first dose of study medication

          -  Used any modality of treatment for insomnia, including cognitive behavioral therapy or
             marijuana within 2 weeks before Screening

          -  Failed treatment with suvorexant (Belsomra®) (efficacy and/or safety) following
             treatment with an appropriate dose and of adequate duration in the opinion of the
             investigator

          -  Transmeridian travel across more than 3 time zones in the 2 weeks before Screening, or
             between Screening and Study Baseline

          -  Previously participated in any clinical trial of lemborexant
      "
NCT02956486,terminated,"
    due to an unfavorable risk-benefit ratio including no evidence of potential efficacy, and the
    adverse event profile of e2609 being worse than placebo.
  ",0,phase 3,"[""alzheimer's disease""]","[""['G30.8', 'G30.9', 'G30.0', 'G30.1']""]","['elenbecestat', 'placebo']",['CC1C2CSC(=NC2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(N=C4)C(F)F)F)N'],"
        Inclusion Criteria:

        Core Study

          -  Mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia
             including

               1. Mini Mental State Examination score equal to or greater than 24

               2. Clinical Dementia Rating (CDR) global score of 0.5

               3. CDR Memory Box score of 0.5 or greater

          -  Impaired episodic memory confirmed by a list learning task

          -  Positive biomarker for brain amyloid pathology as indicated by either amyloid positron
             emission tomography or cerebrospinal fluid AD assessment or both

        Extension Phase

        • Participants who complete the Core Study

        Exclusion Criteria:

        Core Study

          -  Females who are breastfeeding or pregnant at Screening or Baseline. Females of
             child-bearing potential must use a highly effective method of contraception throughout
             the entire study period and for 28 days after study drug discontinuation

          -  Any condition that may be contributing to cognitive impairment above and beyond that
             caused by the participant's AD

          -  Participants with a history of seizures within 5 years of Screening

          -  History of transient ischemic attacks or stroke within 12 months of Screening

          -  Psychiatric diagnosis or symptoms (example, hallucinations, major depression,
             delusions etc.)

          -  Suicidal ideation or any suicidal behavior within 6 months before Screening or has
             been hospitalized or treated for suicidal behavior in the past 5 years

          -  Have any contraindications to magnetic resonance imaging (MRI) scanning or

               1. Have lesions that could indicate a dementia diagnosis other than AD on brain MRI

               2. Exhibit other significant pathological findings on brain MRI.

          -  Participants who have a history of moderate to severe hepatic impairment (example,
             Child-Pugh Class B or C)

          -  Results of laboratory tests conducted during Screening that are outside the following
             limits:

               1. Absolute lymphocyte count below the lower limit of normal (LLN)

               2. Thyroid stimulating hormone above normal range

               3. Abnormally low Vitamin B12 levels

          -  Participants at increased risk of infection

          -  Have received any live vaccine/live attenuated vaccine in the 3 months before
             randomization

          -  Any chronic inflammatory disease that is not adequately controlled or that requires
             systemic immunosuppressive or immunomodulatory therapy

          -  Any other clinically significant abnormalities

          -  Severe visual or hearing impairment

          -  A prolonged corrected QT (QTc) interval (QT interval with Fridericia's correction
             [QTcF] greater than 450 milliseconds [ms])

          -  Malignant neoplasms within 5 years of Screening

          -  Known or suspected history of drug or alcohol abuse

          -  Taking prohibited medications, which must be reviewed with the Investigator

          -  Have participated in a recent clinical study

        Note: Other protocol-defined Inclusion/Exclusion Criteria may apply.
      "
NCT02954354,completed,,1,phase 3,['influenza'],"[""['J11.81', 'J11.82', 'J10.01', 'J10.81', 'J10.82', 'J11.08', 'J11.2']""]","['baloxavir marboxil', 'placebo to baloxavir marboxil', 'oseltamivir', 'placebo to oseltamivir']","['COC(=O)OCOC1=C2C(=O)N3CCOCC3N(N2C=CC1=O)C4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F', 'CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)OCC']","
        Inclusion Criteria:

          1. Patients who are able to understand the study and comply with all study procedures,
             and willing to provide written informed consent/assent prior to the predose
             examinations appropriately. As for adolescent patients, informed consent/assent of
             voluntary participation should be obtained in accordance with local requirements

          2. Male or female patients aged ≥ 12 to ≤ 64 years at the time of signing the informed
             consent/assent form.

          3. Patients with a diagnosis of influenza virus infection confirmed by all of the
             following:

               1. Fever ≥ 38ºC (axillary) in the predose examinations or > 4 hours after dosing of
                  antipyretics if they were taken

               2. At least one of the following general systemic symptoms associated with influenza
                  are present with a severity of moderate or greater

                    -  Headache

                    -  Feverishness or chills

                    -  Muscle or joint pain

                    -  Fatigue

               3. At least one of the following respiratory symptoms associated with influenza are
                  present with a severity of moderate or greater

                    -  Cough

                    -  Sore throat

                    -  Nasal congestion

          4. The time interval between the onset of symptoms and the predose examinations is 48
             hours or less. The onset of symptoms is defined as either:

               1. Time of the first increase in body temperature (an increase of at least 1ºC from
                  normal body temperature)

               2. Time when the patient experiences at least one general or respiratory symptom

          5. Women of childbearing potential who agree to use a highly effective method of
             contraception for 3 months after the first dose of study drug

        Exclusion Criteria:

          1. Patients with severe influenza virus infection requiring inpatient treatment.

          2. Patients aged ≥ 20 years with known allergy to oseltamivir (Tamiflu®).

          3. Patients with any of the following risk factors

               1. Women who are pregnant or within 2 weeks post-partum

               2. Residents of long-term care facilities (eg, welfare facilities for the elderly,
                  nursing homes)

               3. Chronic respiratory diseases including bronchial asthma

               4. Neurological and neurodevelopmental disorders including disorders of the brain,
                  spinal cord, peripheral nerve, and muscle (eg, cerebral palsy, epilepsy [seizure
                  disorders], stroke, intellectual disability, moderate to severe developmental
                  delay, muscular dystrophy, or spinal cord injury)

               5. Heart disease (such as congenital heart disease, congestive heart failure, or
                  coronary artery disease), excluding hypertension without any other heart-related
                  symptoms)

               6. American Indians and Alaskan natives

               7. Blood disorders (such as sickle cell disease)

               8. Endocrine disorders (including diabetes mellitus)

               9. Kidney disorders

              10. Liver disorders

              11. Metabolic disorders

              12. Compromised immune system (including patients receiving immunosuppressant
                  therapy, or those with cancer or human immunodeficiency virus [HIV] infection)

              13. Morbid obesity (body mass index [BMI] ≥ 40)

          4. Patients unable to swallow tablets or capsules.

          5. Patients who have previously received Baloxavir Marboxil.

          6. Patients weighing < 40 kg

          7. Patients who have been exposed to an investigational drug within 30 days prior to the
             predose examinations.

          8. Women who are breastfeeding or have a positive pregnancy test in the predose
             examinations. The following female patients who have documentation of either a or b
             below do not need to undergo a pregnancy test in the predose examinations:

               1. Postmenopausal (defined as cessation of regular menstrual periods for 2 years or
                  more and confirmed by a follicle-stimulating hormone test) women

               2. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or
                  tubal ligation

          9. Patients with concurrent infections requiring systemic antimicrobial and/or antiviral
             therapy at the predose examinations.

         10. Patients who have received peramivir, laninamivir, oseltamivir, zanamivir,
             rimantadine, umifenovir, or amantadine within 30 days prior to the predose
             examinations.

         11. Patients who have received an investigational monoclonal antibody for a viral disease
             in the last year.

         12. Patients with severe underlying diseases.

         13. Patients with known creatinine clearance ≤ 60 mL/min.

         14. Patients who, in the opinion of the investigator, would be unlikely to comply with
             required study visits, self-assessments, and interventions
      "
NCT02469090,completed,,1,phase 3,"['parkinson disease, off episodes']","[""['G20', 'G21.11', 'G21.19', 'G21.2', 'G21.3', 'G21.4', 'G21.8']""]","['apl-130277', 'placebo']",['CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O'],"
        Inclusion Criteria:

          -  Male or female ≥ 18 years of age.

          -  Clinical diagnosis of Idiopathic PD, consistent with UK Brain Bank Criteria.

          -  Clinically meaningful response to L-Dopa with well-defined early morning ""OFF""
             episodes, as determined by the Investigator.

          -  Receiving stable doses of L-Dopa/carbidopa (immediate or CR) administered at least 4
             times per day OR Rytary™ administered 3 times per day, for at least 4 weeks before the
             initial Screening Visit

          -  No planned medication change(s) or surgical intervention anticipated during the course
             of study.

          -  Patients must experience at least one well defined ""OFF"" episode per day with a total
             daily ""OFF"" time duration of ≥ 2 hours during the waking day, based on patient
             self-assessment.

          -  Stage III or less on the modified Hoehn and Yahr scale in the ""ON"" state.

          -  MMSE score > 25.

        Exclusion Criteria:

        A patient will not be eligible for study entry if any of the following exclusion criteria
        are met:

          -  Atypical or secondary parkinsonism.

          -  Previous treatment with any of the following: a neurosurgical procedure for PD;
             continuous s.c. apomorphine infusion; or Duodopa/Duopa.

          -  Treatment with any form of s.c. apomorphine within 7 days prior to the initial
             Screening Visit (SV1). Patients that stopped s.c. apomorphine for any reason other
             than systemic safety concerns or lack of efficacy may be considered.

          -  Contraindications to APOKYN®, or hypersensitivity to apomorphine hydrochloride or any
             of the ingredients of APOKYN® (notably sodium metabisulfite); Tigan®
             (trimethobenzamide hydrochloride; patients from US sites only); or domperidone
             (patients from non-US sites only).

          -  Participation in a clinical trial within 30 days prior to the initial Screening Visit
             (SV1).

          -  Currently taking selective 5HT3 antagonists (i.e., ondansetron, granisetron,
             dolasetron, palonosetron, alosetron), dopamine antagonists (excluding quetiapine or
             clozapine) or dopamine depleting agents.

          -  Drug or alcohol dependency in the past 12 months.

          -  History of malignant melanoma.

          -  Clinically significant medical, surgical, or laboratory abnormality in the opinion of
             the Investigator.

          -  Major psychiatric disorder including, but not limited to, dementia, bipolar disorder,
             psychosis, or any disorder that, in the opinion of the Investigator, requires ongoing
             treatment that would make study participation unsafe or make treatment compliance
             difficult.

          -  History of clinically significant hallucinations during the past 6 months.

          -  History of clinically significant impulse control disorder(s).

          -  Dementia that precludes providing informed consent or would interfere with
             participation in the study.
      "
NCT02108366,completed,,1,phase 3,"['influenza, human']","[""['J11.81', 'J11.82', 'J10.01', 'J10.81', 'J10.82', 'J11.08', 'J11.2']""]","['celecoxib', 'oseltamivir', 'placebo']","['CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F', 'CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)OCC']","
        Inclusion Criteria:

        1) Male or female patients ≥18 years 2) Written informed consent by patient or next-of kin
        (if patient is too ill to consent) 3) Presumptive diagnosis of influenza A satisfying both
        clinical and laboratory criteria. The laboratory criteria are defined as at least one
        RT-PCR positive for influenza A (H1N1, H3N2, H5N1 and H7N9) from respiratory clinical
        specimens including nasopharyngeal samples and endotracheal aspirates. The clinical
        criteria are defined as hospitalization with fever or one of the symptoms suggestive of
        influenza infection including sore throat, rhinorrhea, cough or shortness of breath 2)
        Desaturation to <90% in room air by pulse oximetry and required oxygen supplement 3) Within
        7 days of onset of symptoms. Patients have to fulfil all the aforementioned criteria.

        Exclusion Criteria:

        1) Age <18 years. 2) A known hypersensitivity to celecoxib, oseltamivir or zanamivir 3)
        Unable to obtain informed consents 4) Influenza A infection diagnosed beyond 7 days from
        symptom onset 5) Patients receiving other antiviral treatment (apart from oseltamivir or
        zanamivir), N-acetylcystiene, statins and tradition Chinese medicine during the current
        admission 6) Patients with renal impairment of creatinine clearance < 30mL/min
      "
NCT02873221,completed,,1,phase 3,"['migraine, with or without aura']","[""['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']""]","['ubrogepant', 'placebo-matching ubrogepant', 'usual care']",['CC1C(CC(C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(CC4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6'],"
        Inclusion Criteria:

        -Completed study UBR-MD-01(NCT02828020) or UBR-MD-02(NCT02867709).

        Exclusion Criteria:

          -  Patients with clinically significant electrocardiogram (ECG), vital sign, physical
             exam, or laboratory abnormalities

          -  Requirement for a medication during the study that is on the list of prohibited
             medications.
      "
NCT02219932,completed,,1,phase 3,['multiple sclerosis'],"[""['G35', 'C81.18']""]","['fampridine', 'placebo']",['C1=CN=CC=C1N'],"
        Key Inclusion Criteria:

          -  Must have a diagnosis of primary-progressive, secondary-progressive,
             progressive-relapsing, or relapsing-remitting MS per revised McDonald Committee
             criteria [McDonald 2001; Polman 2005] as defined by Lublin and Reingold [Lublin and
             Reingold 1996] of at least 3 months duration

          -  Must have an Expanded Disability Status Scale (EDSS) score of 4 to 7, inclusive

          -  Must have walking impairment, as deemed by the Investigator

        Key Exclusion Criteria:

          -  History of human immunodeficiency virus (HIV)

          -  Presence of acute or chronic hepatitis. Subjects who have evidence of prior hepatitis
             infection that has been serologically confirmed as resolved are not excluded from
             study participation

          -  Known allergy to fampridine, pyridine-containing substances, or any of the inactive
             ingredients in the prolonged-release fampridine tablet

          -  Creatinine clearance (CrCl) of <80 mL/min

          -  History of malignant disease

          -  Presence of pulmonary disease

          -  A body mass index (BMI) ≥40 (BMI formula: BMI = mass [kg]/[height(m)]2)

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      "
NCT02217267,completed,,0,phase 3,['peripheral neuropathy'],"[""['G90.09']""]","['lidocaine', 'placebo']",['CCN(CC)CC(=O)NC1=C(C=CC=C1C)C'],"
        Inclusion Criteria:

          -  Peripheral neuropathic pain from peripheral nerve injury within 6 months after injury

          -  Well understand to Thai language in writing or listening

        Exclusion Criteria:

          -  Underlying Heart disease or Arrhythmia

          -  Allergy to lidocaine, Gabapentin, Carbamazepine, tramadol

          -  History of epilepsy

          -  History of lidocaine used

          -  Underlying Psychiatric disease

          -  History of drug abuse

          -  Pregnancy and nursing
      "
NCT02211209,completed,,1,phase 3,['familial chylomicronemia syndrome'],"[""['D75.0', 'E78.01', 'E83.31', 'A81.83', 'M11.18', 'G12.24', 'G90.1']""]","['volanesorsen', 'placebo']",['CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5C(OC(C5OCCOC)N6C=C(C(=O)NC6=O)C)COP(=S)(O)OC7C(OC(C7OCCOC)N8C=C(C(=O)NC8=O)C)COP(=S)(O)OC9C(OC(C9OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=NC2=C(N=CN=C21)N)CO)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)O'],"
        Inclusion Criteria:

          -  History of chylomicronemia

          -  A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia)

          -  Fasting triglycerides (TG) ≥ 750 mg/dL (8.4 mmol/L) at Screening

        Exclusion Criteria:

          -  Diabetes mellitus if newly diagnosed or if HbA1c ≥ 9.0%

          -  Other types of severe hypertriglyceridemia

          -  Active pancreatitis within 4 weeks of screening

          -  Acute Coronary Syndrome within 6 months of screening

          -  Major surgery within 3 months of screening

          -  Treatment with Glybera therapy within 2 years of screening

          -  Previous treatment with IONIS-APOCIIIRx

          -  Have any other conditions in the opinion of the investigator which could interfere
             with the participant participating in or completing the study
      "
NCT02240030,completed,,1,phase 3,"[""idiopathic parkinson's disease""]","[""['G20']""]","['cvt-301 low dose', 'cvt-301 high dose']",['Status: 503'],"
        Inclusion Criteria:

          -  Idiopathic Parkinson's Disease (PD) diagnosed between the ages of 30 and 85 years;

          -  Hoehn and Yahr Stage 1-3 in an ""on"" state;

          -  Require levodopa-containing medication regimen at least 3 times during the waking day;

          -  Experience motor fluctuations with a minimum of 2 hours of average daily ""off"" time
             per waking day (excluding early morning ""off"" time) and demonstrate levodopa
             responsiveness;

          -  Are on stable PD medication regimen;

          -  Total daily LD dose <1600 mg/day;

          -  Able to perform a spirometry maneuver in the ON and OFF states;

          -  Normal cognition confirmed by MMSE score ≥25

        Exclusion Criteria:

          -  Pregnant or lactating females;

          -  Previous surgery for PD or plan to have stereotactic surgery during the study period;

          -  History of psychotic symptoms requiring treatment, or suicide ideation or attempt
             within last year;

          -  Known contraindication to the use of levodopa;

          -  Any significant condition, severe concurrent disease, abnormality or finding that
             would make patients unsuitable or may compromise patient safety;

          -  Any contraindication to performing routine spirometry.
      "
NCT02496767,completed,,0,phase 3,['amyotrophic lateral sclerosis'],"[""['G12.21']""]","['tirasemtiv', 'placebo tablets']",['CCC(CC)N1C2=NC(=CN=C2NC1=O)C#C'],"
        Inclusion Criteria:

          -  A diagnosis of familial or sporadic ALS (defined as meeting the possible,
             laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS
             according to the World Federation of Neurology El Escorial criteria) ≤ 24 months prior
             to screening

          -  Upright SVC ≥ 70 % of predicted for age, height and sex

          -  Able to swallow tablets without crushing, and in the opinion of the Investigator, is
             expected to continue to be able to do so during the trial

          -  A caregiver if one is needed

          -  Clinical laboratory findings within the normal range or, if outside the normal range,
             deemed not clinically significant by the Investigator

          -  Male patients must agree for the duration of the study and 10 weeks after the end of
             the study to use a condom during sexual intercourse with female partners who are of
             childbearing potential (i.e., following menarche until post-menopausal if not
             anatomically and physiologically incapable of becoming pregnant) and to have female
             partners use an additional effective means of contraception (e.g., diaphragm plus
             spermicide, or oral contraceptives) or the male patient must agree to abstain from
             sexual intercourse during and for 10 weeks after the end of the study, unless the male
             patient has had a vasectomy and confirmed sperm count is zero

          -  Female patients must be post-menopausal (≥ 1 year) or sterilized, or, if of
             childbearing potential, not be breastfeeding, have a negative pregnancy test, have no
             intention to become pregnant during the course of the study, and use effective
             contraceptive drugs or devices while requiring male partner to use a condom for the
             duration of the study and for 10 weeks after the end of the study

          -  Patients must be either on a stable dose of riluzole 50 mg twice daily for at least 30
             days prior to screening or have not taken riluzole for at least 30 days prior to
             screening and are willing not to begin riluzole use until they complete study drug
             dosing

        Exclusion Criteria:

          -  At the time of screening, any use of non-invasive positive pressure ventilation
             (NIPPV, e.g. continuous positive airway pressure [CPAP] or bi-level positive airway
             pressure [BiPAP]) for any portion of the day, or mechanical ventilation via
             tracheostomy, or on any form of oxygen supplementation

          -  Patients with a diaphragm pacing system (DPS) at study entry or who anticipate DPS
             placement during the course of the study

          -  BMI of 20.0 kg/m2 or lower

          -  Unwilling or unable to discontinue tizanidine and theophylline-containing medications
             during study participation

          -  Serum chloride outside the normal reference range

          -  Neurological impairment due to a condition other than ALS, including history of
             transient ischemic attack within the past year

          -  Presence at screening of any medically significant cardiac, pulmonary, GI,
             musculoskeletal, or psychiatric illness that might interfere with the patient's
             ability to comply with study procedures or that might confound the interpretation of
             clinical safety or efficacy data, including, but not limited to:

               1. Poorly controlled hypertension

               2. NYHA Class II or greater congestive heart failure

               3. Chronic obstructive pulmonary disease or asthma requiring daily use
                  bronchodilator medications

               4. GI disorder that might impair absorption of study drug

               5. History of significant liver disease defined by bilirubin > 2 times the upper
                  limit of normal (ULN) or ALT or AST > 3 times the ULN on repeat testing

               6. Poorly controlled diabetes mellitus

               7. History of vertigo within three months of study entry

               8. History of syncope without an explainable or treated cause

               9. History of untreated intracranial aneurysm or poorly controlled seizure disorder

              10. Amputation of a limb

              11. Cognitive impairment, related to ALS or otherwise, sufficient to impair the
                  patient's ability to give informed consent and to understand and/or comply with
                  study procedures

              12. Cancer with metastatic potential (other than basal cell carcinoma, carcinoma in
                  situ of the cervix, or squamous cell carcinoma of the skin excised with clean
                  margins) diagnosed and treated within the last two years

              13. Any other condition, impairment or social circumstance that, in the opinion of
                  the Investigator, would render the patient not suitable to participate in the
                  study

              14. Patient judged to be actively suicidal or a suicide risk by the Investigator

          -  Has taken any investigational study drug within 30 days or five half-lives of the
             prior agent, whichever is greater, prior to dosing

          -  Prior participation in any form of stem cell therapy for the treatment of ALS

          -  Previously received tirasemtiv in any previous clinical trial
      "
NCT03642145,withdrawn,"
    study is no longer necessary given the safety and efficacy of emflaza in this age range has
    already been established after review of already available data.
  ",0,phase 3,['duchenne muscular dystrophy'],"[""['G71.01']""]",['deflazacort'],['CC1=NC2(C(O1)CC3C2(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)C(=O)COC(=O)C'],"
        Inclusion Criteria:

          -  In the opinion of the Investigator, the participant and parent(s)/caregiver are
             capable of complying with protocol requirements.

          -  The participant's legally acceptable representative signs and dates a written informed
             consent form and any required privacy authorization prior to the initiation of any
             study procedures.

          -  The participant must have a diagnosis of DMD defined by genetic or biopsy confirmation
             of DMD or have documented, increased serum creatine kinase more than 40 times the
             upper limit of normal (ULN) and shown phenotypic signs of DMD.

          -  The participant weighs between 11 kilograms (kg) and 50 kg at screening visit.

          -  Ability to comply with scheduled visits, oral drug administration, and study
             procedures.

          -  The participant is current on childhood vaccinations according to the Center for
             Disease Control (CDC) recommended immunizations for children from birth through 6
             years old. Note: The investigator should discuss timing of receipt of the varicella
             vaccine with the caregiver prior to initiation of chronic steroid treatment.
             Administration of live or live attenuated vaccines is not recommended in participants
             receiving immunosuppressive doses of corticosteroids. Participants whose caregivers
             decline vaccinations as a matter of personal belief may be included.

          -  Baseline health is judged to be stable based on medical history, physical examination,
             laboratory profiles, and vital signs at screening, as deemed by the Investigator.

          -  The participant is able to ingest the oral tablets either whole or crushed.

        Exclusion Criteria:

          -  The participant has received 4 weeks or more of continuous corticosteroid therapy
             within 3 months of study screening visit.

          -  The participant has, in the judgment of the Investigator, clinically significant
             abnormal clinical laboratory parameters at screening or baseline that may affect
             safety.

          -  The participant has, in the judgment of the Investigator, a history or current medical
             condition that could affect safety including, but not limited to:

               1. Major renal or hepatic impairment

               2. Immunosuppression or other contraindications for corticosteroid treatment

               3. History of chronic systemic fungal or viral infections

               4. Diabetes mellitus or significant glucose intolerance

               5. Idiopathic hypercalciuria

               6. Symptomatic cardiomyopathy Note: Elective surgeries can be discussed with medical
                  monitor.

          -  The participant has a history of hypersensitivity or allergic reaction to steroids or
             their formulations including, but not limited to lactose, sucrose, etc.

          -  The participant has received any drug, including prescription and non-prescription
             medications, and herbal remedies known to be significant inhibitors and/or inducers of
             cytochrome P3A4 (CYP3A4) enzymes and/or P glycoprotein (P-gp) 14 days prior to the
             first dose of study drug.

          -  The participant has an indication that requires long-term use of strong CYP3A4
             inhibitors and/or inducers that would interfere with the pharmacokinetics of
             deflazacort.

          -  The participant has received any investigational compound and/or has participated in
             another clinical study within 30 days prior to study treatment with the exception of
             observational cohort studies or non-interventional studies.
      "
NCT02545868,completed,,1,phase 3,"['multiple sclerosis, relapsing-remitting']","[""['G35', 'G93.81', 'K74.1', 'Q85.1', 'G12.21', 'G12.23', 'M34.0']""]",['ocr'],['CCCCCC(=O)CC(C=CCC=CCC=CCCCC(=O)O)S'],"
        Inclusion Criteria:

          -  Diagnosis of RMS in accordance with the revised McDonald criteria

          -  Received at least one previous immunization against TT or tetanus and diphtheria
             (DT/Td) or tetanus, diphtheria, and acellular pertussis (DTaP/Tdap)

          -  Expanded Disability Status Scale (EDSS) at Screening from 0 to 5.5 points, inclusive

          -  For sexually active female participants of reproductive potential, use of reliable
             means of contraception

        Exclusion Criteria:

          -  Contraindications for or intolerance to oral or IV corticosteroids, including IV
             methylprednisolone, according to the country label

          -  Known presence of other neurologic disorders

          -  Treatment with any investigational agent within 24 weeks of screening or 5 half-lives
             of the investigational drug, whichever is longer, or treatment with any experimental
             procedure for multiple sclerosis
      "
NCT02544763,completed,,1,phase 3,"['tuberous sclerosis complex', 'seizures']","[""['G35', 'G93.81', 'K74.1', 'Q85.1', 'G12.21', 'G12.23', 'M34.0']"", ""['G40.89', 'R56.1', 'F44.5', 'G40.501', 'G40.509', 'G40.111', 'G40.119']""]","['gwp42003-p', 'placebo']",['CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O'],"
        Key Inclusion Criteria:

          -  Participant has a well-documented clinical history of epilepsy.

          -  Participant has a clinical diagnosis of Tuberous Sclerosis Complex (TSC) according to
             the criteria agreed by the 2012 International TSC Consensus Conference.

          -  All medications or interventions for epilepsy (including ketogenic diet and any
             neurostimulation devices for epilepsy) must have been stable for 1 month prior to
             screening and the participant is willing to maintain a stable regimen throughout the
             trial.

        Key Exclusion Criteria:

          -  Participant has a history of pseudo-seizures.

          -  Participant has clinically significant unstable medical conditions other than
             epilepsy.

          -  Participant has an illness in the 4 weeks prior to screening or randomization, other
             than epilepsy, which in the opinion of the investigator could affect seizure
             frequency.

          -  Participant has undergone general anesthetic in the 4 weeks prior to screening or
             randomization.

          -  Participant has undergone surgery for epilepsy in the 6 months prior to screening.

          -  Participant is being considered for epilepsy surgery or any procedure involving
             general anesthesia.

          -  Participant has been taking felbamate for less than 1 year prior to screening.

          -  Participant is taking an oral mTOR inhibitor.

          -  Participant has any known or suspected hypersensitivity to cannabinoids or any of the
             excipients of the Investigational Medicinal Product (IMP), such as sesame oil.

          -  Participant has any history of suicidal behavior or any suicidal ideation of type 4 or
             5 on the C-SSRS in the last month or at screening.

          -  Participant is currently using or has in the past used recreational or medicinal
             cannabis, or cannabinoid-based medications, within the 3 months prior to screening and
             is unwilling to abstain for the duration for the study.

          -  Participant has tumor growth which, in the opinion of the Investigator, could affect
             the primary endpoint.

          -  Participant has significantly impaired hepatic function at the screening or
             randomization visit

          -  Participant has received an IMP within the 12 weeks prior to the screening visit.
      "
NCT02203916,completed,,1,phase 3,['hypertension'],"[""['I15.0', 'I97.3', 'K76.6', 'P29.2', 'G93.2', 'H40.053', 'I10']""]","['azilsartan medoxomil', 'azilsartan medoxomil placebo']",['CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)OCC6=C(OC(=O)O6)C'],"
        Inclusion Criteria:

          1. In the opinion of the investigator, the participant is capable of understanding and
             complying with protocol requirements.

          2. The participant or, when applicable, the participant's legally acceptable
             representative, signs and dates a written informed consent form and any required
             privacy authorization prior to the initiation of any study procedures.

          3. Is treated with antihypertensive therapy and has a post-washout mean sitting clinic
             systolic blood pressure (SBP) ≥150 and ≤180 mm Hg on Day 1; or the patient has not
             received antihypertensive treatment within 28 days prior to Screening and has a mean
             sitting clinic SBP ≥150 and ≤180 mm Hg at the Screening Visit and on Day 1.

          4. Is male or female aged ≥19 years.

          5. A female of childbearing potential who is sexually active with a nonsterilized male
             partner agrees to routinely use adequate contraception from signing of the informed
             consent through 30 days after last study drug dose.

          6. Is willing to discontinue current antihypertensive medications on Day -21. If on
             amlodipine or chlorthalidone prior to Screening, the participant is willing to
             discontinue this medication on Day -28.

        Exclusion Criteria:

          1. Has received any investigational compound within 30 days prior to the first dose of
             study medication.

          2. Has received TAK-491 in a previous clinical study or as a therapeutic agent.

          3. Is an immediate family member, study site employee, or is in a dependent relationship
             with a study site employee who is involved in conduct of this study (eg, spouse,
             parent, child, sibling) or may consent under duress.

          4. Has sitting trough clinic diastolic blood pressure (DBP) greater than 114 mm Hg at Day
             1 (after placebo run-in).

          5. Has a history of hypersensitivity to TAK-491 (azilsartan medoxomil), any of its
             excipients, or other angiotensin-converting enzyme (ARBs).

          6. Has a history of myocardial infarction, heart failure, unstable angina, coronary
             artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy,
             cerebrovascular accident, or transient ischemic attack.

          7. Has clinically significant cardiac conduction defects (e.g., 3rd degree
             atrioventricular block, left bundle branch block, sick sinus syndrome, atrial
             fibrillation, or flutter).

          8. Has hemodynamically significant left ventricular outflow obstruction due to aortic
             valvular disease and hypertrophic obstructive cardiomyopathy (HOCM).

          9. Has secondary hypertension of any etiology (e.g., renovascular disease,
             pheochromocytoma, Cushing syndrome).

         10. Is noncompliant (less than 70% or greater than 130%) with study medication during
             placebo run-in period.

         11. Has severe renal dysfunction or disease (confirmed by calculated creatinine clearance
             <30 mL/min/1.73m^2) at Screening.

         12. Has known or suspected unilateral or bilateral renal artery stenosis.

         13. Has a history of drug or alcohol abuse within the past 2 years.

         14. Has a history of cancer that has not been in remission for at least 5 years prior to
             the first dose of study drug. (This criterion does not apply to those patients with
             basal cell or stage I squamous cell carcinoma of the skin.)

         15. Has type 1 or poorly controlled type 2 diabetes mellitus (hemoglobin A1c [HbA1c]>8.0%)
             at Screening.

         16. Has an alanine aminotransferase (ALT) level greater than 2.5 times the upper limit of
             normal, active liver disease, or jaundice at Screening.

         17. Has hyperkalemia (defined as serum potassium greater than the upper limit of normal
             per the central laboratory) at Screening.

         18. Has any other serious disease or condition at screening or randomization that would
             compromise participant safety, might affect life expectancy, or make it difficult to
             successfully manage and follow the participant according to the protocol.

         19. Is required to take excluded medications.

         20. If female, is pregnant or lactating or intending to become pregnant before, during, or
             within 30 days after participating in this study; or intending to donate ova during
             such time period.
      "
NCT02327182,terminated,"
    this study was terminated due to the benefit-risk balance of mt-4666.
  ",0,phase 3,"[""alzheimer's disease""]","[""['G30.8', 'G30.9', 'G30.0', 'G30.1']""]",['mt-4666'],['C1CN2CCC1C(C2)NC(=O)C3=CC4=C(S3)C(=CC=C4)Cl'],"
        Inclusion Criteria:

          -  Probable Alzheimer's disease consistent with the National Institute on Aging and the
             Alzheimer's Association Criteria for Diagnosis of Alzheimer's Disease (McKhann et al.
             2011).

          -  MMSE score of ≥ 14 and ≤ 24 at the screening and ≥ 12 and ≤ 26 at the baseline.

          -  Modified Hachinski Ischemic Score (mHIS) ≤ 4 at the screening

          -  Appropriate caregiver available

          -  Subject living at home or in facilities who do not require continuous (24-hour)
             nursing care.

        Exclusion Criteria:

          -  Diagnosis of any other disease which may cause dementia

          -  Diagnosis of major depressive disorder as defined by Diagnostic and Statistical Manual
             of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) within last five years

          -  History of or current diagnosis of any psychosis

          -  History of myocardial infarction or unstable angina within six months before screening

          -  History of cerebrovascular disorder within 18 months before screening

          -  complication of hepatic disorder or renal dysfunction
      "
NCT02779959,unknown status,,1,phase 3,['migraine disorders'],"[""['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']""]",['prochlorperazine'],['CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl'],"
        Inclusion Criteria:

          -  Patients between 18-65 years of age evaluated in the emergency department at
             Harbor-UCLA with migraine headache as defined by the Headache Classification Committee
             of the International Headache Society. (Patients must have had at least one prior
             similar headache, with or without nausea, vomiting, aura, photophobia, or
             phonophobia).

          -  Only subjects able to consent to treatment will be included.

        Exclusion Criteria:

        Patients with the following conditions:

          -  pregnancy

          -  breastfeeding

          -  fever greater or equal to 100.4 degrees

          -  diastolic blood pressure of 105 or higher

          -  altered mental status

          -  meningeal signs

          -  suspicion for intracranial process requiring further investigation

          -  known allergy to prochlorperazine

          -  the use of ergotamines, antiemetics, antipsychotics or sedatives in the previous 24
             hours of study entry.
      "
NCT03629184,completed,,1,phase 3,['influenza'],"[""['J11.81', 'J11.82', 'J10.01', 'J10.81', 'J10.82', 'J11.08', 'J11.2']""]","['baloxavir marboxil', 'oseltamivir']","['COC(=O)OCOC1=C2C(=O)N3CCOCC3N(N2C=CC1=O)C4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F', 'CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)OCC']","
        Inclusion Criteria:

          -  Aged 1 to < 12 years at randomization (Day 1).

          -  Written informed consent/assent for study participation obtained from participant's
             parents or legal guardian, with assent as appropriate by the participant, depending on
             the patient's level of understanding

          -  Participant able to comply with study requirements, depending on the patient's level
             of understanding

          -  Participant with a diagnosis of influenza virus infection confirmed by the presence of
             all of the following:

          -  Fever ≥ 38 degree celsius (tympanic temperature) at screening

          -  At least one respiratory symptom (either cough or nasal congestion)

          -  The time interval between the onset of symptoms and screening is ≤ 48 hours

        Exclusion Criteria:

          -  Severe symptoms of influenza virus infection requiring inpatient treatment

          -  Concurrent infections requiring systemic antiviral therapy at screening

          -  Require, in the opinion of the investigator, any of the prohibited medication during
             the study

          -  Previous treatment with peramivir, laninamivir, oseltamivir, zanamivir, or amantadine
             within 2 weeks prior to screening

          -  Immunization with a live/attenuated influenza vaccine in the 2 weeks prior to
             randomization

          -  Concomitant treatment with steroids or other immuno-suppressant therapy

          -  Known HIV infection or other immunosuppressive disorder

          -  Uncontrolled renal, vascular, neurologic, or metabolic disease (e.g., diabetes,
             thyroid disorders, adrenal disease), hepatitis, cirrhosis, or pulmonary disease or
             participants with known chronic renal failure.

          -  Active cancer at any site

          -  History of organ transplantation

          -  Known allergy to either study drug (i.e., baloxavir marboxil and oseltamivir) or to
             acetaminophen

          -  Females with child-bearing potential

          -  Participation in a clinical trial within 4 weeks or five half-lives of exposure to an
             investigational drug prior to screening, whichever is longer
      "
NCT02080364,terminated,"
    not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose.
  ",0,phase 3,"[""alzheimer's disease""]","[""['G30.8', 'G30.9', 'G30.0', 'G30.1']""]","['azeliragon', 'placebo']",['CCCCC1=NC(=CN1C2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)C4=CC=C(C=C4)OCCCN(CC)CC'],"
        Inclusion Criteria:

          -  Diagnosis of probable Alzheimer Disease (AD) with documented evidence of progression
             of disease

          -  Mini Mental State Examination (MMSE) score of 21-26, inclusive

          -  Clinical Dementia Rating global score of 0.5 or 1

          -  Rosen-Modified Hachinski Ischemia Score less than or equal to 4

          -  Brain magnetic resonance imaging (MRI) consistent with the diagnosis of probable AD

          -  Concurrent use of cholinesterase inhibitor or memantine with stable dose for at least
             3 months prior to randomization

          -  Caregiver willing to participate and be able to attend clinic visits with patient

          -  Ability to ingest oral medications

        Exclusion Criteria:

          -  Significant neurological or psychiatric disease other than Alzheimer's disease

          -  Participants with evidence or history of severe drug allergies (resulting in dyspnea
             or severe rash).

          -  Any contraindications to MRI (e.g., clinically significant claustrophobia,
             non-removable ferromagnetic implants). Patients with contraindications to MRI may
             undergo computed tomography (CT) on approval by sponsor.

          -  Any contraindications to the FDG-PET study (e.g. allergy to any component of the FDG
             dose) in the cohort undergoing a PET scan.

          -  Previous exposure to investigational or non-investigational therapies for Alzheimer's
             disease within 6 months of screening

          -  History of cancer within the last 5 years except adequately treated cervical carcinoma
             in-situ, cutaneous basal cell or squamous cell cancer, or non-progressive prostate
             cancer not requiring treatment

          -  Women of childbearing potential

          -  Uncontrolled blood pressure and/or blood pressure above 160/100

          -  Prescription medical food intended for dietary management of the metabolic processes
             associated with Alzheimer's disease.

          -  Diagnosis or history of cerebrovascular stroke, severe carotid stenosis, cerebral
             hemorrhage, intracranial tumor, subarachnoid hemorrhage.

          -  Patients with unstable, uncontrolled diabetes (HbA1c > 7.7%) and those requiring
             insulin.
      "
NCT03290053,terminated,"
    poor inclusion rate & lack of funding
  ",0,phase 3,['ischemic stroke'],"[""['I25.5', 'H47.013', 'H93.013', 'G45.9', 'H47.011', 'H47.012', 'H47.019']""]","['sonovue', 'sodium chloride']","['FS(F)(F)(F)(F)F', '[Na+].[Cl-]']","
        Inclusion Criteria:

          -  Male or female patients ≥18 years with acute ischaemic stroke in the anterior
             circulation, who has given written consent for his/her participation to the study.

          -  Remaining neurological deficit that is ≥1 NIHSS points, sufficient to warrant
             treatment with tPA (not taking possible contraindications into account) and is severe
             enough that possible improvement is clearly analysable

          -  Treatment <4½ hours of symptom onset or of waking up in the morning with symptoms

          -  Sufficient bone window for acceptable or better acquisition of flow information with
             ultrasound with TIBI ≤ 4 in the symptomatic artery

          -  In cases with women of Childbearing Capacity (WOCBC): Only if willing to comply with
             effective contraception methods during the course of the trial. Acceptable methods are
             such as oral contraceptives, contraceptive patches, contraceptive implant, vaginal
             contraceptive, double-barrier methods (for example, condom and spermicide),
             intrauterine device (IUD), hormonal IUD

        Exclusion Criteria:

          -  Patients with premorbid modified Rankin Scale (mRS) score ≥3;

          -  Patients for whom a complete NIHSS cannot be obtained;

          -  Hemiplegic migraine with no arterial occlusion on baseline Computed Tomography of
             brain (CT);

          -  Seizure at stroke onset and no visible occlusion on baseline CT;

          -  Intracranial haemorrhage on baseline CT;

          -  Clinical presentation suggesting subarachnoid haemorrhage even if baseline CT is
             normal;

          -  Large areas of hypodense ischaemic changes on baseline CT;

          -  Pregnancy or breast-feeding, pericarditis; sepsis; any other serious medical illness
             likely to interact with treatment; confounding pre-existent neurological or
             psychiatric disease; unlikely to complete follow-up; any investigational drug <14
             days;

          -  Inability to provide informed consent sufficiently clearly that the study physician
             can be convinced that informed consent has been given by the patient - such as severe
             aphasia or coma.

        Specific sonothrombolysis exclusion criteria

          -  known hypersensitivity/allergy to SonoVue;

          -  recent or unstable coronary ischemia or resting angina <7 days;

          -  acute cardiac insufficiency, cardiac insufficiency class III/IV; serious cardiac
             arrhythmias;

          -  any right-left-shunt; severe pulmonary hypertension; uncontrolled hypertension;

          -  moderate to severe Chronic Obstructive Pulmonary Disease (COPD; baseline O2 saturation
             <80%);

          -  acute respiratory distress syndrome (ARDS);
      "
NCT03714672,completed,,1,phase 3,['acute pain'],"[""['G89.12', 'G89.18', 'G89.11', 'G89.3']""]","['tramadol/diclofenac 50/50', 'tramadol/diclofenac 25/25', 'tramadol 50', 'diclofenac 50']","['Status: 400', 'Status: 400']","
        Inclusion Criteria:

          1. The participant has read the informed consent form, has understood the relevant
             aspects of the clinical study, and grants his/her authorization to participate by
             signing the informed consent form prior to the inclusion in the clinical study and the
             performance of any procedure.

          2. Male and female participants above 18 years up to 60 years.

          3. Female participants of childbearing potential must be practicing an acceptable method
             of birth control and must have a negative urine pregnancy test at enrollment with
             confirmation at the Allocation Visit.

          4. Participants are in good health, i.e., the medical record, vital signs, physical
             examination, and laboratory parameter assessments do not show any abnormal deviations
             impeding the participation in the clinical study.

          5. Participants requiring extraction of 3 or more third molars with 2 mandibular impacted
             third molars.

          6. Clinical and radiological diagnosis of impacted lower third molars.

          7. Class I and Class II molars according to Pell and Gregory's classification (Gay Escoda
             et al. 2004).

          8. Participants must be able to swallow the IMPs.

        Exclusion Criteria at Enrollment:

          1. Findings in the medical record, vital signs, and/or physical examination demonstrating
             abnormal conditions of participant's general state of health preventing his/her
             participation in the clinical study according to the investigator's opinion.

          2. Participant unable to speak, read, or write in Spanish language.

          3. Clinical laboratory parameters exceed the pre-defined alert ranges (i.e., 1 standard
             deviation above or below the upper/lower limit of the normal ranges).

          4. Known hypersensitivity to the IMPs, the anesthetic to be used during surgery, or to
             the rescue medication (ibuprofen, ketorolac).

          5. Known alcohol or drug abuse in the last 6 months or any history of seizures. Alcohol
             abuse is defined as the consumption of more than 3 ounces (about 90 milliliters) of
             liquor or spirits or 18 ounces (about 530 milliliters) of beer per day, for 5
             consecutive days during the 6-month period. Drug abuse is defined as the use of any
             recreational drug for 5 consecutive days during the 6 month period.

          6. Participants who take analgesic medication for chronic pain, monoamine oxidase
             inhibitors, tricyclic antidepressants, neuroleptics, or other drugs that reduce the
             seizure threshold within 4 weeks of enrollment.

          7. Pregnant or lactating women.

          8. Participants who received systemic corticosteroids or opioid analgesics less than 2
             weeks before surgery.

          9. Participants with molars linked to the mandibular canal.

         10. Participants requiring immediate dental procedures other than third and fourth molars
             extraction,

             Exclusion Criteria at the Allocation Visit:

         11. Participant received a long-acting non-steroidal anti-inflammatory drug within 24
             hours or 5 times the elimination half-life of that drug prior to surgery, whatever the
             longer.

         12. Participant received any analgesic medication other than short-acting pre-operative or
             intra-operative anesthetic agents within 24 hours before taking IMPs.

         13. Participant received more than 300 mg of lidocaine in total.

         14. Participant received any analgesic medication other than the IMPs immediately after
             the oral surgical procedure was completed.

         15. Baseline pain intensity of the participant after oral surgical procedure remains below
             5 points on the 11-point NRS.
      "
NCT03051607,terminated,"
    new safety information
  ",0,phase 3,['idiopathic parkinson disease'],"[""['E20.0', 'I95.0', 'L50.1', 'D61.3', 'G24.2', 'G24.4', 'G60.3']""]",['tozadenant'],['CC1(CCN(CC1)C(=O)NC2=NC3=C(C=CC(=C3S2)N4CCOCC4)OC)O'],"
        Inclusion Criteria:

          -  Patient understands study requirements and has given his/her written informed consent
             on an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved
             consent form.

          -  Parkinson's disease diagnosis consistent with UK Parkinson's Disease Society Brain
             Bank Diagnostic criteria

          -  Minimum of 3 years since diagnosis.

          -  Meet Hoehn and Yahr PD stage

          -  Good response to levodopa

          -  Stable regimen of anti-PD medications

          -  Patients must have been taking a levodopa-containing anti-PD medication continuously
             for at least the previous 12 months

          -  Patient has documented a minimum amount of Off time.

          -  If of childbearing potential (male and female) must use an acceptable method of
             contraception

        Exclusion Criteria:

          -  Previous tozadenant study participation

          -  Current or recent participation in another study.

          -  Secondary or atypical parkinsonism

          -  Neurosurgical intervention for PD (except DBS if electrode placement has been
             performed over 12 months prior to screening)

          -  Patient is taking apomorphine, budipine, istradefylline, tolcapone, or DUOPA™/Duodopa®

          -  Treatment with excluded medications

          -  Untreated or uncontrolled hyperthyroidism or hypothyroidism

          -  Clinically significant out-of-range laboratory

          -  MMSE out of range

          -  Current episode of major depression (stable treatment for depression is permitted).

          -  Recent suicide attempt or suicidal ideation type 4 or type 5 of the Columbia-Suicide
             Severity Rating Scale (C-SSRS)

          -  Women lactating or pregnant

          -  Hypersensitivity to any components of tozadenant or excipients

          -  Abnormal findings on the physical or neurological examination, or medical history that
             would make the patient unsuitable for the study

          -  History of hepatitis or cholangitis
      "
NCT02737501,completed,,1,phase 3,"['non-small cell lung cancer', 'lung cancer', 'advanced malignancies', 'carcinoma']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['K74.02', 'G47.22', 'H35.3133', 'H35.3134', 'H35.3113', 'H35.3114', 'H35.3123']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['brigatinib', 'crizotinib']","['CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC', 'CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N']","
        Inclusion Criteria:

          1. Have histologically or cytologically confirmed stage IIIB (and not a candidate for
             definitive multimodality therapy) or stage four (IV) NSCLC.

          2. Must have documented ALK rearrangement.

          3. Have sufficient tumor tissue available for central analysis.

          4. Have at least 1 measurable (that is, target) lesion per RECIST v1.1.

          5. Recovered from toxicities related to prior anticancer therapy to National Cancer
             Institute (of the United States) (NCI) Common Terminology Criteria for Adverse Events
             (version 4.0) (CTCAE v 4.0) grade be less than or equal to (<=) 1.

          6. Are a male or female participants greater than or equal to (>=)18 years old.

          7. Have adequate organ function, as defined by the study protocol.

          8. Have Eastern Cooperative Oncology Group (ECOG) performance status <=2.

          9. Have normal QT interval on screening ECG evaluation, defined as QT interval corrected
             (Fridericia) (QTcF) of <= 450 millisecond (msec) in males or <=470 msec in females.

         10. For female participants of childbearing potential, have a negative pregnancy test
             documented prior to randomization.

         11. For female and male participants who are fertile, agree to use a highly effective form
             of contraception, as defined by the study protocol.

         12. Provide signed and dated informed consent indicating that the participants has been
             informed of all pertinent aspects of the study, including the potential risks, and is
             willingly participating.

         13. Have the willingness and ability to comply with scheduled visit and study procedures.

        Exclusion Criteria:

          1. Previously received an investigational antineoplastic agent for NSCLC.

          2. Previously received any prior tyrosine kinase inhibitor (TKI), including ALK-targeted
             TKIs.

          3. Previously received more than 1 regimen of systemic anticancer therapy for locally
             advanced or metastatic disease.

          4. Received chemotherapy or radiation within 14 days of first dose of study drug, except
             stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT).

          5. Received anti-neoplastic monoclonal antibodies within 30 days of the first dose of
             study drug.

          6. Had major surgery within 30 days of the first dose of study drug, minor surgical
             procedures such as catheter placement or minimally invasive biopsies are allowed.

          7. Have been diagnosed with another primary malignancy other than NSCLC, except for
             adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively
             treated non-metastatic prostate cancer; or participants with another primary
             malignancy who are definitively relapse-free with at least 3 years elapsed since the
             diagnosis of the other primary malignancy.

          8. Have symptomatic CNS metastases (parenchymal or leptomeningeal) at screening or
             asymptomatic disease requiring an increasing dose of corticosteroids to control
             symptoms within 7 days prior to randomization.

          9. Have current spinal cord compression (symptomatic or asymptomatic and detected by
             radiographic imaging). Participants with leptomeningeal disease and without cord
             compression are allowed.

         10. Be pregnant, planning a pregnancy, or breastfeeding.

         11. Have significant, uncontrolled, or active cardiovascular disease, as defined by the
             study protocol.

         12. Have uncontrolled hypertension.

         13. Have a history or the presence at baseline of pulmonary interstitial disease,
             drug-related pneumonitis, or radiation pneumonitis.

         14. Have an ongoing or active infection.

         15. Have a known history of human immunodeficiency virus (HIV) infection.

         16. Have a known or suspected hypersensitivity to brigatinib or its excipients and/or
             crizotinib or its excipients.

         17. Have malabsorption syndrome or other gastrointestinal (GI) illness or condition.

         18. Have any condition or illness that, in the opinion of the investigator, would
             compromise participant's safety or interfere with the evaluation of the study drug.
      "
NCT02622958,completed,,1,phase 3,['social anxiety disorder'],"[""['F20.81', 'F21', 'F34.0', 'F34.1', 'F42.3', 'F45.0', 'F51.5']""]",['ph94b'],['CC12CCC3C(C1CC=C2)CCC4=CC(CCC34C)O'],"
        Inclusion Criteria:

          -  Written informed consent provided prior to conducting any study-specific assessment.

          -  Male and female adults, 18 through 65 years of age, inclusive.

          -  Current diagnosis of Social Anxiety Disorder as defined in the DSM IV of Mental
             Disorders, which is not secondary to another pre-existing psychiatric condition or to
             a medical condition.

          -  Confirmation of diagnosis of Social Anxiety Disorder according to the MINI, 5.0.0

          -  Clinician-rated Liebowitz Social Anxiety Scale total score ≥60 at both Screening and
             Baseline visits.

          -  Clinician-rated HAM-D17 total score <18 at both Screening and Baseline visits.

          -  CGI-Severity score ≥4 at both Screening and Baseline visits.

          -  Subject must have:

               -  experienced and documented a minimum total of six social interaction or
                  performance events during the two week Screening Period prior to the Baseline
                  Visit, and

               -  for at least three of these events, must have achieved a peak score of ≥60 on the
                  Subjective Units of Distress Scales (SUDS), as rated in the Patient Diary.

          -  Women of child-bearing potential must be able to commit to the consistent and correct
             use of an effective method of birth control throughout the study and have a negative
             urine pregnancy test result prior to study medication administration.

        Exclusion Criteria:

          -  History of bipolar disorder (I or II), schizophrenia, schizoaffective disorder,
             psychosis, eating disorder, obsessive-compulsive disorder. Any other current Axis I
             disorder other than SAD which is the primary focus of treatment. Note that subjects
             with concurrent Generalized Anxiety Disorder (GAD) are eligible for the study provided
             that GAD is not the primary diagnosis.

          -  Subjects who meet criteria for substance abuse within the year prior to entry.

          -  Clinically significant nasal pathology or history of significant nasal trauma, nasal
             surgery, or nasal-septal perforation that may have damaged the nasal chemosensory
             epithelium.

          -  An acute or chronic condition, including an infectious illness, uncontrolled seasonal
             allergies at the time of the study, or significant nasal congestion that potentially
             could affect drug delivery to the nasal chemosensory epithelium.

          -  Two or more documented failed treatment trials with a registered medication approved
             for SAD during the previous six months, whereby a treatment trial is defined as a
             period of at least six (6) weeks (or longer as documented in package insert for a
             particular drug) during which the patient received an adequate dosage (defined as the
             treatment dose indicated in the package insert to obtain efficacy for that particular
             drug) of the medication.

          -  Use of any psychotropic medication within 30 days prior to study entry (other than
             eszopiclone, ramelteon, zaleplon, or zolpidem for insomnia as described in Section
             3.3).

          -  Concomitant use of non-study anxiolytics such as benzodiazepines or beta blockers
             during the study and within 30 days prior to study entry.

          -  Concomitant use of any over-the-counter, prescription product, or herbal preparation
             for treatment of the symptoms of social anxiety during the study and within 30 days
             prior to study entry.

          -  Prior exposure to PH94B.

          -  Improvement of more than 20% in the LSAS score at Baseline relative to Screening.

          -  Women who have a positive urine human chorionic gonadotropin pregnancy test prior to
             study medication administration.

          -  Subjects with clinically significant abnormalities in hematology, blood chemistry,
             urinalysis, ECG, or physical examination identified at the Screening or Baseline
             visit.

          -  Subjects with a positive urine drug screen at either the Screening or Baseline visit.

          -  Presence of any clinical condition or disease, or use of a concomitant medication,
             that in the clinical judgment of the Investigator could place the patient at undue
             risk, interfere with study participation, or confound the results of the study.
      "
NCT03235479,completed,,1,phase 3,"['migraine, with or without aura']","[""['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']""]","['rimegepant', 'placebo']",['C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6'],"
        Key Inclusion Criteria:

          1. Patient has at least 1 year history of migraines (with or without aura), consistent
             with a diagnosis according to the International Classification of Headache Disorder,
             3rd Edition, Beta version[1] including the following:

               -  Not more than 8 attacks of moderate or severe intensity per month within last 3
                  months

               -  Consistent migraine headaches of at least 2 migraine headache attacks of moderate
                  or severe intensity in each of the 3 months prior to the Screening Visit and
                  maintains this requirement during the Screening Period

          2. Less than 15 days with headache (migraine or non-migraine) per month in each of the 3
             months prior to the Screening Visit and maintains this requirement during the
             Screening Period

          3. Patients on prophylactic migraine medication are permitted to remain on therapy
             provided they have been on a stable dose for at least 3 months prior to study entry.

          4. Patients with contraindications for use of triptans may be included provided they meet
             all other study entry criteria.

        Key Exclusion Criteria:

          1. Patient history of HIV disease

          2. Patient history with current evidence of uncontrolled, unstable or recently diagnosed
             cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and
             cerebral ischemia. Patients with Myocardial Infarction (MI), Acute Coronary Syndrome
             (ACS),Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient
             ischemic attack (TIA) during the 6 months prior to screening.

          3. Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however
             patients can be included who have stable hypertension and/or diabetes for 3 months
             prior to being enrolled)

          4. Patient has a current diagnosis of major depression, other pain syndromes, psychiatric
             conditions (eg, schizophrenia), dementia, or significant neurological disorders (other
             than migraine) that, in the Investigator's opinion, might interfere with study
             assessments

          5. Patient has a history of gastric, or small intestinal surgery, or has a disease that
             causes mal-absorption

          6. The patient has a history or current evidence of any significant and/or unstable
             medical conditions (eg, history of congenital heart disease or arrhythmia, known
             suspected infection, hepatitis B or C, or cancer) that, in the investigator's opinion,
             would expose them to undue risk of a significant adverse event (AE) or interfere with
             assessments of safety or efficacy during the course of the trial

          7. History of, treatment for, or evidence of, alcohol or drug abuse within the past 12
             months or patients who have met DSM-V criteria for any significant substance use
             disorder within the past 12 months from the date of the screening visit.
      "
NCT03237845,completed,,1,phase 3,"['migraine, with or without aura']","[""['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']""]","['rimegepant', 'placebo']",['C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6'],"
        Key Inclusion Criteria:

          1. Patient has at least 1 year history of migraines (with or without aura), consistent
             with a diagnosis according to the International Classification of Headache Disorder,
             3rd Edition, Beta version[1] including the following:

               -  Not more than 8 attacks of moderate or severe intensity per month within last 3
                  months

               -  Consistent migraine headaches of at least 2 migraine headache attacks of moderate
                  or severe intensity in each of the 3 months prior to the Screening Visit and
                  maintains this requirement during the Screening Period

          2. Less than 15 days with headache (migraine or non-migraine) per month in each of the 3
             months prior to the Screening Visit and maintains this requirement during the
             Screening Period

          3. Patients on prophylactic migraine medication are permitted to remain on therapy
             provided they have been on a stable dose for at least 3 months prior to study entry.

          4. Patients with contraindications for use of triptans may be included provided they meet
             all other study entry criteria.

        Key Exclusion Criteria:

          1. Patient history of HIV disease

          2. Patient history with current evidence of uncontrolled, unstable or recently diagnosed
             cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and
             cerebral ischemia. Patients with Myocardial Infarction (MI), Acute Coronary Syndrome
             (ACS),Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient
             ischemic attack (TIA) during the 6 months prior to screening.

          3. Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however
             patients can be included who have stable hypertension and/or diabetes for 3 months
             prior to being enrolled)

          4. Patient has a current diagnosis of major depression, other pain syndromes, psychiatric
             conditions (eg, schizophrenia), dementia, or significant neurological disorders (other
             than migraine) that, in the Investigator's opinion, might interfere with study
             assessments

          5. Patient has a history of gastric, or small intestinal surgery, or has a disease that
             causes malabsorption.

          6. The patient has a history or current evidence of any significant and/or unstable
             medical conditions (eg, history of congenital heart disease or arrhythmia, known
             suspected infection, hepatitisB or C, or cancer) that, in the investigator's opinion,
             would expose them to undue risk of a significant adverse event (AE) or interfere with
             assessments of safety or efficacy during the course ofthe trial

          7. History of, treatment for, or evidence of, alcohol or drug abuse within the past 12
             months or patients who have met DSM-V criteria for any significant substance use
             disorder within thepast 12 months from the date of the screening visit.
      "
NCT02585934,completed,,0,phase 3,"[""alzheimer's disease""]","[""['G30.8', 'G30.9', 'G30.0', 'G30.1']""]","['rvt-101', 'placebo']",['Status: 503'],"
        Inclusion Criteria:

          -  Male or female subject with AD

          -  Ongoing donepezil therapy for AD

          -  An MMSE score 12 to 24 inclusive at Screening; MMSE score 10-26 inclusive at Baseline

          -  Hachinski Ischaemia score less than or equal to 4 at Screening.

          -  If female, subject must be: a. of non-childbearing potential or surgically sterile;
             or, b. willing to use an adequate methods of birth control. Male subjects who are
             sexually active will also be required to use an adequate form of birth control.

          -  Subject has the ability to comply with procedures for cognitive and other testing in
             the opinion of the investigator.

          -  Subject has a reliable caregiver who is willing to report on subject's status
             throughout the study.

        Exclusion Criteria:

        Other Causes for Dementia

          -  Diagnosis of vascular dementia

          -  Atypical clinical features or clinical course of dementia that would lead the
             investigator to conclude symptoms are more likely due to an alternate dementia
             diagnosis including, but not limited to, frontotemporal dementia, Lewy body dementia,
             or others.

        Confounding Medical Conditions

          -  History of significant psychiatric illness such as schizophrenia or bipolar affective
             disorder or any other significant psychiatric illness that in the opinion of the
             investigator would interfere with participation in the study;

          -  Any clinically relevant concomitant disease, which, in the opinion of the
             investigator, makes the subject unsuitable for inclusion in the study.
      "
NCT02425644,completed,,1,phase 3,['multiple sclerosis'],"[""['G35', 'C81.18']""]","['ponesimod', 'teriflunomide']","['CCCN=C1N(C(=O)C(=CC2=CC(=C(C=C2)OCC(CO)O)Cl)S1)C3=CC=CC=C3C', 'CC(=C(C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F)O']","
        Inclusion Criteria:

        Male and female subjects aged 18 to 55 years with established diagnosis of MS McDonald 2010
        with relapsing course from onset (i.e., RRMS and SPMS with superimposed relapses).

        Subjects must have active disease evidenced by one or more MS attacks with onset within the
        period of 12 to 1 months prior to randomization, or by two or more MS attacks with onset
        within the 24 to 1 months prior to randomization, or with one or more gadolinium-enhancing
        (Gd+) lesion(s) of the brain on an MRI performed within 6 months prior to randomization.

        Enrolled subjects must be ambulatory (EDSS score of up to 5.5 inclusive) and may be
        treatment-naïve or previously treated with MS disease modifying therapy.

        Exclusion Criteria:

        Subjects with significant medical conditions or therapies for such conditions (e.g.,
        cardiovascular, pulmonary, immunological, hepatic,ophthalmological conditions) or lactating
        or pregnant women are not eligible to enter the study.

        Subjects with contraindications to MRI or with clinically relevant medical or surgical
        conditions that, in the opinion of the investigator, would put the subject at risk by
        participating in the study are not eligible to enter the study.
      "
NCT02294058,completed,,1,phase 3,['multiple sclerosis'],"[""['G35', 'C81.18']""]","['ozanimod', 'interferon beta-1a', 'placebo to ozanimod', 'placebo to interferon beta-1a']",['CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)C#N'],"
        Inclusion Criteria:

          -  Multiple sclerosis as diagnosed by the revised 2010 McDonald criteria

          -  EDSS score between 0 and 5.0 at baseline

        Exclusion Criteria:

        • Primary progressive multiple sclerosis
      "
NCT02828020,completed,,1,phase 3,"['migraine, with or without aura']","[""['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']""]","['ubrogepant', 'placebo-matching ubrogepant']",['CC1C(CC(C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(CC4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6'],"
        Inclusion Criteria:

          -  At least a 1-year history of migraine with or without aura consistent with a diagnosis
             according to the International Classification of Headache Disorders, 3rd edition, beta
             version

          -  Migraine onset before age 50

          -  History of migraines typically lasting between 4 and 72 hours if untreated or treated
             unsuccessfully and migraine episodes are separated by at least 48 hours of headache
             pain freedom

          -  History of 2 to 8 migraine attacks per month with moderate to severe headache pain in
             each of the previous 3 months.

        Exclusion Criteria:

          -  Difficulty distinguishing migraine headache from other headaches

          -  Has taken medication for acute treatment of headache (including acetaminophen,
             nonsteroidal anti-inflammatory drugs [NSAIDs], triptans, ergotamine, opioids, or
             combination analgesics) on 10 or more days per month in the previous 3 months

          -  Has a history of migraine aura with diplopia or impairment of level of consciousness,
             hemiplegic migraine, or retinal migraine

          -  Has a current diagnosis of new persistent daily headache, trigeminal autonomic
             cephalgia (eg, cluster headache), or painful cranial neuropathy

          -  Required hospital treatment of a migraine attack 3 or more times in the previous 6
             months

          -  Has a chronic non-headache pain condition requiring daily pain medication

          -  Has a history of malignancy in the prior 5 years, except for adequately treated basal
             cell or squamous cell skin cancer, or in situ cervical cancer

          -  Has a history of any prior gastrointestinal conditions (eg, diarrhea syndromes,
             inflammatory bowel disease) that may affect the absorption or metabolism of
             investigational product; participants with prior gastric bariatric interventions which
             have been reversed are not excluded

          -  Has a history of hepatitis within previous 6 months.
      "
NCT02820324,completed,,1,phase 3,['acute pain'],"[""['G89.12', 'G89.18', 'G89.11', 'G89.3']""]","['oliceridine', 'placebo', 'morphine']","['COC1=C(SC=C1)CNCCC2(CCOC3(C2)CCCC3)C4=CC=CC=N4', 'CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O']","
        Inclusion Criteria:

          -  Has undergone abdominoplasty with no additional collateral procedures.

          -  Experiences a pain intensity rating of moderate to severe acute pain.

          -  Able to provide written informed consent before any study procedure.

        Exclusion Criteria:

          -  ASA Physical Status Classification System classification of P3 or worse.

          -  Has surgical or post-surgical complications.

          -  Has clinically significant medical conditions or history of such conditions that may
             interfere with the interpretation of efficacy, safety, or tolerability data obtained
             in the trial, or may interfere with the absorption, distribution, metabolism, or
             excretion of drugs.

          -  Has previously participated in another TRV130 clinical study.
      "
NCT02550665,completed,,1,phase 3,"[""alzheimer's disease""]","[""['G30.8', 'G30.9', 'G30.0', 'G30.1']""]",['donepezil'],['COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC'],"
        Inclusion Criteria:

          -  dementia according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV
             criteria

          -  probable Alzheimer's disease dementia according to National Institute on
             Aging-Alzheimer's Association (NIAAA) criteria

          -  Mini-Mental State Examination (MMSE) score of 20 or less

          -  General Deterioration Scale (GDS) score of 4 or more / Clinical Dementia Rating (CDR)
             score of 2 or more

          -  stable dose of 10mg donepezil at least 3 months before screening

          -  caregiver who can come together at every visit and give informations about side
             effects profiles should exist

          -  patients and caregivers accepted the study

        Exclusion Criteria:

          -  patients receiving other concomitant acetylcholinesterase inhibitor

          -  uncontrolled psychiatric disorders

          -  drug overuse or alcohol abuse history within 5 years

          -  significant uncontrolled or active medical conditions

          -  uncontrolled epilepsy

          -  patients who cannot come at scheduled visits
      "
NCT02555215,completed,,1,phase 3,"['multiple sclerosis, relapsing-remitting']","[""['G35', 'G93.81', 'K74.1', 'Q85.1', 'G12.21', 'G12.23', 'M34.0']""]",['dimethyl fumarate'],['COC(=O)C=CC(=O)OC'],"
        Key Inclusion Criteria:

          -  Ability of parents, legal guardians, and/or subjects to understand the purpose and
             risks of the study and provide signed and dated informed consent and authorization to
             use confidential health information in accordance with national and local subject
             privacy regulations. Subjects will provide assent in addition to the parental or
             guardian consent, as appropriate, per local regulations.

          -  Subjects who completed, as per protocol, the previous BG00012 clinical study 109MS202
             (NCT02410200) and remain on BG00012 treatment.

        Key Exclusion Criteria:

          -  Unwillingness or inability to comply with study requirements, including the presence
             of any condition (physical, mental, or social) that is likely to affect the subject's
             ability to comply with the protocol.

          -  Any significant changes in medical history occurring after enrollment in the parent
             Study 109MS202 (NCT02410200), including laboratory test abnormalities or current
             clinically significant conditions that in the opinion of the Investigator would have
             excluded the subject's participation from the parent study. The Investigator must
             re-review the subject's medical fitness for participation and consider any factors
             that would preclude treatment.

          -  Subjects from Study 109MS202 (NCT02410200) who could not tolerate study treatment.

        NOTE: Other protocol defined inclusion/exclusion criteria may apply.
      "
NCT03948178,terminated,"
    this was an open label extension for patients completing the refals study (3119002;
    nct03505021). study 3119002 showed lack of efficacy of odm109 so the sponsor decided to
    terminate this study
  ",0,phase 3,['amyotrophic lateral sclerosis'],"[""['G12.21']""]",['levosimendan'],['CC1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N'],"
        Inclusion Criteria:

          -  Written or verbal informed consent (IC) for participation in the study

          -  Subjects who completed 48 weeks of treatment according to the REFALS study protocol

          -  Able to swallow study treatment capsules at the time of completing 48 weeks dosing in
             the REFALS study

        Exclusion Criteria:

          -  Development (or significant worsening from baseline of the REFALS study) of serious
             cardiovascular disease (e.g.: myocardial infarction, heart failure, arrhythmia,
             stroke, or second or third degree atrioventricular (AV) block)

          -  Pulse/heart rate repeatedly >100 bpm after 5-minute rest at baseline. If the
             pulse/heart rate is >100 bpm in the first recording, then a second recording must be
             done after another 5 min rest to confirm pulse/heart rate >100 bpm

          -  Systolic blood pressure (SBP) <90 mmHg

          -  Severe renal impairment (creatinine clearance < 30ml/min or creatine >170 µmol/l at 48
             week visit of the REFALS study, or on dialysis

          -  Severe hepatic impairment at the discretion of the investigator

          -  Women of reproductive age without a negative pregnancy test and without a commitment
             to using a highly effective method of contraception (e.g.: oral hormonal contraceptive
             associated with inhibition of ovulation, intrauterine devices and long acting
             progestin agent), if sexually active during the study, and for 1 month after the last
             dose of the study treatment. Women who are postmenopausal (1 year since last menstrual
             cycle), surgically sterilised or who have undergone a hysterectomy are considered not
             to be reproductive and can be included

          -  Subject judged to be actively suicidal by the investigator

          -  Any other clinical significant cardiovascular, gastrointestinal, hepatic, renal,
             neurological or psychiatric disorder or any other major concurrent illness that in the
             opinion of the investigator could interfere with the interpretation of the study
             results or constitute a health risk for the subject if he/she took part in the study
      "
NCT02229851,completed,,1,phase 3,"['growth hormone disorder', 'adult growth hormone deficiency']","[""['F20.81', 'F21', 'F34.0', 'F34.1', 'F42.3', 'F45.0', 'F51.5']"", ""['D81.810', 'E53.0', 'E53.1', 'E61.0', 'E61.1', 'E61.2', 'E61.3']""]","['somapacitan', 'somatropin', 'placebo']",['C(CCCCCCCC1=NNN=N1)CCCCCCCC(=O)NS(=O)(=O)CCCC(=O)NCCOCCOCC(=O)NC(CCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NC(CCCCNC(=O)CSCC(C(=O)O)N)C(=O)N)C(=O)O)C(=O)O'],"
        Inclusion Criteria:

          -  Male or female of at least 23 years of age and not more than 79 years of age at the
             time of signing informed consent

          -  Human growth hormone (hGH) treatment naïve or no exposure to hGH or growth hormone
             (GH) secretagogues for at least 180 days prior to randomisation with any registered or
             investigational hGH or GH secretagogue product (if only used in connection with
             stimulation tests for diagnosis of growth hormone deficiency (GHD), subjects can be
             included)

          -  If applicable, hormone replacement therapies for any other hormone deficiencies,
             adequate and stable for at least 90 days prior to randomisation as judged by the
             investigator

          -  FOR ALL COUNTRIES EXCEPT JAPAN:

        Confirmed diagnosis of adult growth hormone deficiency (Subjects must satisfy one of the
        following criterion and documentation of test results must be available before
        randomisation (either from subjects' file or new test):

          1. Insulin tolerance test (ITT) or glucagon test: a peak GH response of less than 3 ng/mL
             (3 mcg/L)

          2. Growth hormone releasing hormone (GHRH) + arginine test according to body mass index
             (BMI): i) BMI less than 25 kg/m^2, a peak GH less than 11 ng/mL (11 mcg/L), ii) BMI
             25-30 kg/m^2, a peak GH less than 8 ng/mL (8 mcg/L), iii) BMI greater than 30 kg/m^2,
             a peak GH less than 4 ng/mL (4 mcg/L)

          3. Three or more pituitary hormone deficiencies and insulin like growth factor - I
             standard deviation score (IGF-I SDS) less than -2.0 - FOR JAPAN ONLY: Confirmed
             diagnosis of adult growth hormone deficiency (subjects with adult onset adult growth
             hormone deficiency (AGHD) need to satisfy at least one of the following criteria,
             subjects with a history of childhood GHD need to satisfy at least 2 of the following
             criteria):

        a. ITT test: a peak GH of less than or equal to 1.8 ng/mL (assay using recombinant GH
        standard) b. glucagon test: a peak GH of less than or equal to 1.8 ng/mL (assay using
        recombinant GH standard) c. growth hormone releasing peptide 2 (GHRP-2) tolerance test: a
        peak GH of less than or equal to 9 ng/mL (assay using recombinant GH standard)

        Exclusion Criteria:

          -  Active malignant disease or history of malignancy. Exceptions to this exclusion
             criterion: - Resection in situ carcinoma of the cervix uteri. Complete eradication of
             squamous cell or basal cell carcinoma of the skin

          -  Subjects with GHD attributed to treatment of intracranial malignant tumours or
             leukaemia, provided that a recurrence-free survival period of at least 5 years is
             documented in the subject's file
      "
NCT02221869,completed,,1,phase 3,['narcolepsy with cataplexy'],"[""['G47.411', 'G47.421', 'G47.419', 'G47.429']""]",['xyrem'],['C(CC(=O)O)CO'],"
        Inclusion Criteria:

          1. Male or female subjects aged 7-16 years at Visit 2 for subjects on Xyrem at study
             entry and at Visit 1.1 for Xyrem-naïve subjects (to ensure subjects are <18 years of
             age at the end of the study)

          2. Have a primary diagnosis of narcolepsy with cataplexy that meets International
             Classification of Sleep Disorders (ICSD)-2 or ICSD-3 criteria, whichever was in effect
             at the time of the diagnosis or, with the permission of the Medical Monitor, completes
             a Multiple Sleep Latency Test (MSLT) during Screening to confirm the diagnosis of Type
             1 narcolepsy by ICSD-3 criteria (i.e., the subject meets all other ICSD-3 criteria for
             Type 1 narcolepsy)

          3. Have given documented assent indicating that he/she was aware of the investigational
             nature of the study and the required procedures and restrictions before participation
             in any protocol-related activities

          4. Have parent(s)/guardian(s) who have given informed consent for his/her/their child's
             participation in the study

          5. Be willing to spend the required number of nights (2 to 3) in a sleep laboratory for
             PSG evaluations

          6. If currently treated with Xyrem, must have been taking unchanged doses (twice nightly
             dosing no higher than 9 g/night) of Xyrem, and stimulants, if applicable, for the
             treatment of narcolepsy symptoms for at least 2 months prior to screening

        In addition to the above inclusion criteria, subjects participating in the PK evaluation
        must meet the following inclusion criteria:

        7. Be willing to spend 2 additional nights in the clinic for PK evaluation

        -

        Exclusion Criteria:

          1. Inability to understand assent or follow study instructions for any reason, in the
             opinion of the Investigator

          2. Parent(s) or guardian(s) unable to comply with the requirements of the study for any
             reason, in the opinion of the Investigator

          3. Other documented clinically significant condition (including an unstable medical
             condition, chronic disease other than narcolepsy with cataplexy, or history or
             presence of another neurological disorder) that might affect the subject's safety
             and/or interfere with the conduct of the study in the opinion of the Investigator

          4. Treatment with benzodiazepines, non-benzodiazepine anxiolytics/ hypnotics/sedatives,
             neuroleptics, opioids, barbiturates, diclofenac, valproate, phenytoin, ethosuximide
             within 2 weeks prior to enrollment (discontinuation for the purpose of study
             enrollment is permitted only if considered safe by the Investigator and approved by
             the Medical Monitor)

          5. Treatment with any other medications that have anticataplectic effect (e.g.,
             serotonin-norepinephrine reuptake inhibitors [SNRIs], selective serotonin reuptake
             inhibitors [SSRIs], or tricyclic antidepressants [TCAs]) within 1 month before
             Screening

          6. Unsafe for the subject to receive placebo treatment for 2 weeks, in the opinion of the
             Investigator

        In addition to the above exclusion criteria, subjects participating in the PK evaluation
        must not demonstrate the following:

        -
      "
NCT02224703,completed,,1,phase 3,"['epilepsy', 'dravet syndrome']","[""['G40.803', 'G40.804', 'G40.911', 'G40.919', 'G40.B11', 'G40.B19', 'G40.801']"", ""['G40.833', 'G40.834']""]","['gwp42003-p', 'placebo control']",['CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O'],"
        Key Inclusion Criteria:

          -  Participant must have been male or female, aged between 2 and 18 years (inclusive).

          -  Participant must have had a documented history of Dravet syndrome that was not
             completely controlled by current antiepileptic drugs.

          -  Participant must have been taking 1 or more antiepileptic drugs at a dose that had
             been stable for at least 4 weeks.

          -  All medications or interventions for epilepsy (including ketogenic diet and vagus
             nerve stimulation) must have been stable for 4 weeks prior to screening and
             participant was willing to maintain a stable regimen throughout the study.

        Key Exclusion Criteria:

          -  Participant had clinically significant unstable medical conditions other than
             epilepsy.

          -  Participant had clinically relevant symptoms or a clinically significant illness in
             the 4 weeks prior to screening or randomization, other than epilepsy.

          -  Participant was currently using or had in the past used recreational cannabis,
             medicinal cannabis, or synthetic cannabinoid-based medications (including Sativex®)
             within the 3 months prior to study entry and was unwilling to abstain for the duration
             for the study.

          -  Participant had any known or suspected hypersensitivity to cannabinoids or any of the
             excipients of the investigational medicinal products.

          -  There were plans for the participant to travel outside their country of residence
             during the study.

          -  Any history of suicidal behavior or any suicidal ideation of type four or five on the
             Columbia-Suicide Severity Rating Scale (Children's) at screening.
      "
NCT02224560,completed,,1,phase 3,"['epilepsy', 'lennox gastaut syndrome']","[""['G40.803', 'G40.804', 'G40.911', 'G40.919', 'G40.B11', 'G40.B19', 'G40.801']"", ""['G40.813', 'G40.814', 'G40.811', 'G40.812']""]","['gwp42003-p', 'placebo control']",['CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O'],"
        Key Inclusion Criteria:

          -  Participant and/or parent(s)/legal representatives were willing and able to give
             informed assent/consent for participation in the study.

          -  Participant and his or her caregivers were willing and able (in the investigator's
             opinion) to comply with all study requirements.

          -  Participant was male or female aged between 2 and 55 years (inclusive).

          -  Participant had a documented history of LGS. This included written documentation of
             having met electroencephalogram (EEG) diagnostic criteria during the participant's
             history and evidence of at least 1 type of generalized seizure, including drop
             seizures (atonic, tonic, tonic-clonic or myoclonic) for at least 6 months.

          -  Participant had a history of slow (<3.0 hertz [Hz]) spike-and-wave pattern in an EEG
             prior to the enrollment into the baseline period.

          -  Participant had at least 2 drop seizures each week during the first 28 days of the
             baseline period.

          -  Participant was refractory; that is having documented failures on more than 1
             antiepileptic drug (AED).

          -  Participant was taking 1 or more AEDs at a dose which had been stable for at least 4
             weeks prior to screening.

          -  All medications or interventions for epilepsy (including ketogenic diet and vagus
             nerve stimulation [VNS]) were stable for 4 weeks prior to screening and the
             participant was willing to maintain a stable regimen throughout the study. The
             ketogenic diet and VNS treatments were not counted as an AED.

          -  Participant and/or parent(s)/legal representatives were willing to allow his or her
             primary care practitioner and consultant to be notified of participation in the study.

          -  Participant completed his or her interactive voice response (IVRS) telephone diary on
             at least 25 days of the baseline period.

        Key Exclusion Criteria:

          -  Etiology of participant's seizures was a progressive neurologic disease. Participants
             with tuberous sclerosis were not excluded from study participation, unless there was a
             progressive tumor.

          -  Participant had an anoxic episode requiring resuscitation within 6 months of
             screening.

          -  Participant had clinically significant unstable medical conditions other than
             epilepsy.

          -  Participant had clinically relevant symptoms or a clinically significant illness in
             the 4 weeks prior to screening or randomization, other than epilepsy.

          -  Participant had a history or presence of alcohol or substance abuse within the last 2
             years prior to the study or daily consumption of 5 or more alcohol-containing
             beverages.

          -  Participant was currently using or had in the past used recreational or medicinal
             cannabis, or synthetic cannabinoid-based medications (including Sativex®) within the 3
             months prior to study entry and was unwilling to abstain for the duration of the
             study.

          -  Participant had a history of symptoms (for example, dizziness, light-headedness,
             blurred vision, palpitations, weakness, syncope) related to a drop in blood pressure
             due to postural changes.

          -  Participant had any known or suspected hypersensitivity to cannabinoids or any of the
             excipients of the IMP, such as sesame oil.

          -  Female participant was of child bearing potential or male participant's partner was of
             child bearing potential; unless willing to ensure that they or their partner used a
             highly effective method of contraception for the duration of the study and for 3
             months thereafter.

          -  Female participant was pregnant (positive pregnancy test), lactating or planning
             pregnancy during the course of the study and for 3 months thereafter.

          -  Participant had been part of a clinical study involving another IMP in the previous 6
             months.

          -  Patient had significantly impaired hepatic function at screening (Day -28) or
             randomization (Day 1), defined as any of the following: alanine aminotransferase (ALT)
             or aspartate aminotransferase (AST) > 5 × upper limit of normal (ULN); ALT or AST > 3
             × ULN and total bilirubin > 2 × ULN or international normalized ratio (INR) > 1.5; ALT
             or AST > 3 × ULN with the presence of fatigue, nausea, vomiting, right upper quadrant
             pain or tenderness, fever, rash, and/or eosinophilia (>5%). This criterion could only
             be confirmed once the laboratory results were available; participants randomized into
             the study who were later found not to meet this criterion were withdrawn from the
             study.

          -  Any history of suicidal behavior or any suicidal ideation of type 4 or 5 on the
             Columbia Suicide Severity Rating Scale in the last month or at screening.

          -  Participant was unwilling to abstain from donation of blood during the study.

          -  Participant planned to travel outside his or her country of residence during the
             study.

          -  Participant had previously randomized into the study.

          -  Participant was taking more than 4 concurrent AEDs.

          -  Participant had taken corticotropins in the 6 months prior to screening.

          -  Participant was currently taking long-term systemic steroids (excluding inhaled
             medication for asthma treatment) or any other daily medication known to exacerbate
             epilepsy. An exception was made of prophylactic medication, for example, idiopathic
             nephrotic syndrome or asthma.

          -  Participant was taking felbamate, and he or she had been taking it for less than 1
             year prior to screening.
      "
NCT02605434,unknown status,,0,phase 3,"[""parkinson's disease""]","[""['G20']""]","['accordion pill™ carbidopa/levodopa', 'sinemet®', 'placebo -ap-cd/ld', 'placebo- sinemet']",['Status: 503'],"
        Main Inclusion Criteria:

          1. Subjects must be approved for suitability by an Enrollment Approval Committee

          2. Able and willing to give written (signed and dated) informed consent and adhere to
             visit schedule and available to complete the study

          3. Men or women 30 years of age and higher at initial screening assessment. (For the 100
             subjects who enter the Gastroscopy sub study, the age limits are 30-80 years of age,
             inclusive, at initial screening assessment)

          4. Diagnosed with Parkinson's disease, consistent with UK brain bank criteria

          5. Has a good response to Levodopa and is taking at least 4 doses of a Levodopa
             containing medication (or 3 doses of Rytary) per day during waking hours (not
             including nighttime long acting levodopa) at a stable dose for at least 28 days prior
             to initial screening assessment

          6. Other Anti-PD treatment (such as dopamine agonists, selective MAO-B inhibitors,
             anticholinergic agents or Amantadine) are permitted if stable for at least 28 days
             prior to study entry and provided they are not anticipated to be changed during the
             course of the study

          7. Total LD immediate release daily dose of 400 mg to 1300 mg or equivalent prior to
             initial screening assessment. Specifically for Rytary, doses up to 1755 mg daily are
             acceptable.

          8. Able to complete a Hauser Home Diary and can tell the difference between ""On"" and
             ""Off"" time

               1. Achieved at least 75% diary concordance with an approved site rater in a 4-hour
                  training session including at least one ""Off time"" assessment

               2. Returned a valid 2-day practice diary after training has been completed.

          9. At least 2.5 hours ""Off time"" per day during waking hours on Screening 2-day Practice
             Hauser Home Diary (morning akinesia should be incorporated into the total ""Off time""
             assessment).

         10. Other than PD, the subject is in satisfactory health, as assessed by physical
             examination and screening tests. No clinically significant medical, psychiatric or
             laboratory abnormality that could compromise safety or interfere with study procedures
             in the opinion of either the investigator or the Enrollment Approval
             Committee/Sponsor.

         11. Living in an area that is within 3 hours driving distance from the study site or is
             willing to stay in such a place the night before each study visit

        Main Exclusion Criteria:

          1. Participation in another drug clinical trial within 28 days prior to initial screening
             assessment (calculated from the previous study's last dosing date)

          2. Atypical Parkinsonism (subjects with Parkinsonian features caused by disorder such as
             multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies or
             multiple brain infarcts)

          3. Clinically significant cardiac, pulmonary, hepatic or renal disease or other condition
             or any major complication/illness which contraindicates his/her participation in the
             opinion of either the investigator or the Enrollment Approval Committee/Sponsor.

          4. Severe dyskinesia in the opinion of either the investigator or the Enrollment Approval
             Committee.

          5. Treatment with non-selective monoamine oxidase (MAO) inhibitors during the last 28
             days prior to initial screening assessment or planning to take during study
             participation

          6. Previous or planned neurosurgical treatment for Parkinson's Disease (e.g., procedures
             including ablation or deep brain stimulation) during the course of the study

          7. Significant cognitive impairment as defined by the Mini-Mental State Examination
             (MMSE) score < 26.

          8. Clinically significant psychiatric illness, including major depression (Hamilton
             Depression Rating Scale-17 ≥14). Subjects with a lifetime history of suicidal attempt
             (including an active attempt, interrupted attempt or aborted attempt)

          9. Current or previous treatment for more than 1 month within the past 2 years with any
             neuroleptic drug (antipsychotic) or any other drug with anti-dopaminergic properties
             (e.g. metoclopramide, domperidone)

         10. Currently experiencing or any known history of psychosis or delusions within 2 years
             prior to Screening.

         11. Known history of substance abuse within the past 2 years

         12. Moderate or greater level of alcohol consumption

         13. Unable to swallow large pills (e.g., large vitamin pills)

         14. History of Melanoma or suspicious skin lesion which could be a Melanoma

         15. Narrow-angle Glaucoma

         16. History of small bowel or gastric surgery (Including PEG-J placement for
             Duopa/Duodopa) or bowel obstruction, diagnosis of small bowel narrowing, diagnosis of
             Crohn's disease, or frequent nausea or emesis, regardless of etiology, (Previous
             appendectomy or hernioplasty will not be exclusionary).

         17. Active peptic ulcer disease or a history of peptic ulcer or upper GI bleeding

         18. Regular use of opioids (Intermittent opioid use is not exclusionary)

         19. Symptomatic gastroparesis with frequent vomiting (at least once a week)

         20. Concomitant use of NSAIDs and oral steroids within the past 28 days

         21. Allergy to the study drug or any of its excipients, or to Yellow Dye #5 (tartrazine)

         22. Women who are pregnant or nursing. Women of childbearing potential who are not willing
             to use a medically acceptable method of contraception.
      "
NCT02569853,completed,,1,phase 3,['episodic migraine'],"[""['G44.011', 'G44.031', 'F41.0', 'G44.019', 'G44.039', 'G44.211', 'G44.219']""]",['dfn-11'],['CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C'],"
        Inclusion Criteria:

          1. If female, a subject must have a negative serum pregnancy test at screening, does not
             plan to become pregnant during the study, and is not lactating

          2. If female, a subject also must have a negative urine pregnancy test at all subsequent
             study visits after the Screening Visit, and agree to practice a reliable form of
             contraception or abstinence during the study. Acceptable forms of contraception
             include implants, injectables, combined oral contraceptives, an intrauterine device, a
             vasectomized partner, an exclusively female partner, and double-barrier methods.

          3. If male (with female partner), a subject must agree to practice a reliable form of
             contraception or abstinence during the study.

          4. A history of episodic migraine who experience 2 to 6 migraine attacks a month for at
             least the past 12 months with no more than 14 migraine headache days per month, and
             with 48 hours of headache free time between migraine headaches

          5. Have migraine with or without aura; if with aura, the aura cannot last longer than 60
             minutes

        Exclusion Criteria:

          1. Minors, even if they are in specified study age range

          2. Medication overuse headache as defined by ICHD II:

               -  Opioids ≥ 10 days a month during the 90 days prior to screening

               -  Combination medications (e.g., Fiorinal®) ≥ 10 days a month during the 90 days
                  prior to screening

               -  Nonsteroidal anti-inflammatory drugs (NSAIDs) or other simple medications > 14
                  days a month during the 90 days prior to screening

               -  Triptans or ergots ≥ 10 days a month during the 90 days prior to screening

          3. Subjects treated with onabotulinumtoxin A (Botox®) or other botulinum toxin treatment;
             or history of receiving such treatment during the 180 days prior to screening

          4. On unstable dosages of migraine prophylactic medications during the 30 days prior to
             and through screening

          5. Taking mini-prophylaxis for menstrual migraine

          6. Subjects with hemiplegic or basilar migraine or other forms of neurologically
             complicated migraine

          7. Subjects who have prolonged aura (i.e., more than 1 hour)

          8. Cerebrovascular disease including but not limited to a history of stroke or transient
             ischemic attack (TIA)

          9. A history of migralepsy (seizure following a migraine) or a concurrent diagnosis of
             seizure disorder

         10. Subjects who cannot differentiate between a migraine headache and tension-type or
             cluster headache or other types of headache

         11. Subjects with a history of more than occasional (based on Investigator's judgment)
             tension-type headache (distinct from migraine headache days count).

         12. Subjects with a history of cluster headaches

         13. Subjects with the diagnosis of ""probable migraine"" (ICHD II)

         14. Ischemic coronary artery disease (CAD): including but not limited to angina pectoris,
             history of myocardial infarction or documented silent ischemia or coronary artery
             vasospasm, including Prinzmetal's angina

         15. Subjects with Wolff-Parkinson-White syndrome or arrhythmias associated with other
             cardiac accessory conduction pathway disorders

         16. Subjects with a history of congenital heart disease

         17. A history of uncontrolled hypertension or screening systolic/diastolic > 140/90 mmHg

         18. Have peripheral vascular disease including but not limited to ischemic bowel disease
             (IBD) and Raynaud's disease.

         19. Any abnormal physiology and/or pathology which, in the opinion of the Investigator or
             Sponsor, which would be contraindicated for study participation and would not allow
             the objectives of the study to be met

         20. Subjects who show any clinical laboratory or electrocardiogram (ECG) abnormality that
             in the opinion of the Investigator would endanger the subject or interfere with the
             study conduct. If the results of the clinical laboratory or ECG are outside of normal
             reference range the subject may still be enrolled but only if these findings are
             determined to be not clinically significant by the Investigator. This determination
             must be recorded in the subject's source document prior to enrolment.

         21. Fridericia's corrected QT (QTcF) interval greater than 450 msec

         22. Severe renal impairment (creatinine > 2 mg/dl)

         23. Serum total bilirubin > 2.0 mg/dL

         24. Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline
             phosphatase > 2.5 times the upper limit of normal

         25. Subjects with uncontrolled diabetes mellitus, or a glycosylated hemoglobin (HbA1c) >
             7.0%, or with diabetes mellitus requiring insulin

         26. A history of alcohol or substance use disorder according to the Diagnostic and
             Statistical Manual of Mental Disorders, Edition V (DSM-V) (including marijuana) within
             1 year prior to screening

         27. Current treatment with antipsychotics or use of antipsychotics within 30 days of
             screening

         28. A history of or current neurological or psychiatric impairment, including but not
             limited to psychosis, current major depression, bipolar disorder or cognitive
             dysfunction that, in the opinion of the Investigator, would compromise data collection

         29. Subjects who have received treatment with an investigational drug or device within 30
             days of the screening visit or participated in a central nervous system clinical trial
             in the 3 months prior to screening

         30. Subjects with any other medical condition that, in the judgment of the Investigator
             and/or Medical Monitor, would confound the objectives of the study (e.g., positive
             screening test for human immunodeficiency virus [HIV], hepatitis B surface antigen
             positive or hepatitis C positive, a known history of systemic lupus erythematosis)

         31. Subjects who plan to donate blood, sperm, or oocytes during the study and for 30 days
             after the last dose of study medication

         32. Subjects who are employees or immediate relatives of the employees of the Sponsor, any
             of its affiliates or partners, or of the study center
      "
NCT02348593,completed,,1,phase 3,['narcolepsy'],"[""['G47.411', 'G47.419', 'G47.421', 'G47.429']""]","['jzp-110', 'placebo oral tablet']",['C1=CC=C(C=C1)CC(COC(=O)N)N'],"
        Major Inclusion Criteria:

          1. Males and females between 18 and 75 years of age, inclusive

          2. Diagnosis of narcolepsy according to ICSD-3 or DSM-5 criteria

          3. Body mass index from 18 to <45 kg/m2

          4. Consent to use a medically acceptable method of contraception

          5. Willing and able to provide written informed consent

        Major Exclusion Criteria:

          1. Female subjects who are pregnant, nursing, or lactating

          2. Moderate or severe sleep apnea on the baseline PSG.

          3. Any other clinically relevant medical, behavioral, or psychiatric disorder other than
             narcolepsy that is associated with excessive sleepiness

          4. History or presence of bipolar disorder, bipolar related disorders, schizophrenia,
             schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5
             criteria

          5. History or presence of any acutely unstable medical condition, behavioral or
             psychiatric disorder (including active suicidal ideation), or surgical history that
             could affect the safety of the subject or interfere with study efficacy, safety, PK
             assessments, or the ability of the subject to complete the trial per the judgment of
             the Investigator

          6. History of bariatric surgery within the past year or a history of any gastic bypass
             procedure

          7. Presence or history of significant cardiovascular disease

          8. Use of any over-the-counter (OTC) or prescription medications that could affect the
             evaluation of excessive sleepiness

          9. Use of any medications that could affect the evaluation of cataplexy

         10. Received an investigational drug in the past 30 days or five half-lives (whichever is
             longer)

         11. Previous exposure to or participation in a previous clinical trial of JZP-110
             (ADX-N05, R228060, YKP10A)

         12. History of phenylketonuria (PKU) or history of hypersensitivity to
             phenylalanine-derived products
      "
NCT02348632,completed,,1,phase 3,"['narcolepsy', 'obstructive sleep apnea']","[""['G47.411', 'G47.419', 'G47.421', 'G47.429']"", ""['G47.33', 'P28.32']""]",['jzp-110'],['C1=CC=C(C=C1)CC(COC(=O)N)N'],"
        Major Inclusion Criteria:

          1. Subject meets one of the following:

               1. Completed Study 14-002 or 14-003 (Group A)

               2. Completed Study 14-004, 15-004, 15-005, ADX-N05 201 or ADX-N05 202 (Group B)

          2. Body mass index from 18 to <45 kg/m2

          3. Consent to use a medically acceptable method of contraception

          4. Willing and able to provide written informed consent

        Major Exclusion Criteria:

          1. Female subjects who are pregnant, nursing, or lactating

          2. Any other clinically relevant medical, behavioral, or psychiatric disorder other than
             narcolepsy or OSA that is associated with excessive sleepiness

          3. History or presence of bipolar disorder, bipolar related disorders, schizophrenia,
             schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5
             criteria

          4. Presence of any acutely unstable medical condition, behavioral or psychiatric disorder
             (including active suicidal ideation), or surgical history that could affect the safety
             of the subject or interfere with study efficacy or safety assessments, or the ability
             of the subject to complete the trial per the judgment of the Investigator

          5. History of bariatric surgery within the past year or a history of roux-en-y procedure

          6. Presence or history of significant cardiovascular disease

          7. Use of any over the counter (OTC) or prescription medications that could affect the
             evaluation of excessive sleepiness

          8. Received an investigational drug other than JZP-110 in the past 30 days or five
             half-lives (whichever is longer)

          9. History of phenylketonuria (PKU) or history of hypersensitivity to
             phenylalanine-derived products
      "
NCT02274766,completed,,1,phase 3,"['dyskinesia', 'levodopa-induced dyskinesia (lid)', ""parkinson's disease (pd)""]","[""['K22.4', 'G24.01']"", ""['K22.4', 'G24.01']"", ""['G20']""]",['ads-5102'],['C1C2CC3CC1CC(C2)(C3)N.Cl'],"
        Inclusion Criteria:

          -  Signed a current IRB/REB/IEC-approved informed consent form;

          -  Parkinson's disease, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical
             Diagnostic Criteria;

          -  On a stable regimen of antiparkinson's medications for at least 30 days prior to
             screening, including a levodopa preparation administered not less than three times
             daily, and willing to continue the same doses and regimens during study participation;

          -  Following diary training, the subject is willing and able to understand and complete
             the 24-hour PD home diary (trained caregiver/study partner assistance allowed);

          -  Any other current and allowed prescription/non-prescription medications and/or
             nutritional supplements taken regularly must have been at a stable dose and regimen
             for at least 30 days prior to screening, and subject must be willing to continue the
             same doses and regimens during study participation (this criterion does not apply to
             medications that are being taken pre-study only on an as-needed basis);

        Exclusion Criteria:

          -  History of neurosurgical intervention related to Parkinson's disease (e.g. deep brain
             stimulation);

          -  History of seizures within 2 years prior to screening;

          -  History of stroke or TIA within 2 years prior to screening;

          -  History of cancer within 5 years prior to screening, with the following exceptions:
             adequately treated non-melanomatous skin cancers, localized bladder cancer,
             non-metastatic prostate cancer, in situ cervical cancer, or other definitively treated
             cancer that is considered cured;

          -  Presence of cognitive impairment, as evidenced by a Mini-Mental Status Examination
             (MMSE) score of less than 24 during screening;

          -  If female, is pregnant or lactating;

          -  If a sexually active female, is not surgically sterile or at least 2 years
             post-menopausal, or does not agree to utilize an effective method of contraception
             from screening through at least 4 weeks after the completion of study treatment, using
             one of the following: barrier methods (diaphragm or partner using condoms plus use of
             spermicidal jelly or foam, preferably double-barrier methods); oral or implanted
             hormonal contraceptive; intrauterine device (IUD); or vasectomized male partner;

          -  Treatment with an investigational drug or device within 30 days prior to screening;

          -  Treatment with an investigational biologic within 6 months prior to screening;

          -  Current participation in another clinical trial;
      "
NCT02946073,completed,,1,phase 3,"['chronic lower back pain', 'chronic pain']","[""['G89.29', 'G89.4', 'R39.82', 'G89.22', 'G89.28', 'G89.21', 'G89.3']""]",['buprenorphine'],['CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O'],"
        Inclusion Criteria:

          1. Written informed consent provided prior to the conduct of any study-related
             procedures.

          2. Male or non-pregnant, non-lactating female subject, greater than or equal to 18 years
             old.

          3. Body mass index (BMI) between 18 and 38 kg/m2, inclusive.

          4. Treated with daily opioids for moderate to severe CLBP for a minimum of 3 months prior
             to Screening.

          5. On a stable dose of ≥40 mg/day of oral morphine or MED during the 14 days prior to
             Screening.

          6. Systolic blood pressure ≥100 mmHg and diastolic blood pressure ≥60 mmHg.

          7. Female subject of childbearing potential who is willing to use a reliable method of
             contraception during the entire study (Screening Visit to final Follow-up). To be
             considered not of childbearing potential, female subjects must be surgically sterile
             (hysterectomy or bilateral oophorectomy, or bilateral tubal ligation with surgery at
             least 6 weeks before Screening).

          8. Male subject who is willing to use reliable contraception

          9. Willing and able to comply with all study procedures and requirements.

        Exclusion Criteria:

          1. Positive for hepatitis B surface antigen, hepatitis C viral RNA, or antibodies to
             human immunodeficiency virus (HIV).

          2. Clinically significant symptoms, medical conditions, or other circumstances which, in
             the opinion of the investigator, would preclude compliance with the protocol, adequate
             cooperation in the study, or obtaining informed consent, or may prevent the subject
             from safely participating in the study, including the following:

               1. Severe respiratory insufficiency, respiratory depression, airway obstruction,
                  gastrointestinal motility disorders, biliary tract disease, severe hepatic
                  insufficiency, or planned surgery.

               2. Bipolar disorder

          3. Current diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fifth
             Edition-defined moderate to severe substance use disorder (including alcohol), other
             than caffeine or nicotine.

          4. Female subject planning to become pregnant during the study.

          5. Surgical procedure(s) for CLBP within 6 months prior to Screening.

          6. Concomitant disease(s) that could prolong the QTcF interval, such as autonomic
             neuropathy (caused by diabetes or Parkinson's disease), HIV, cirrhosis, Long QT
             Syndrome, or family history of Long QT Syndrome.

          7. QTcF >450 ms for males and >470 ms for females, or clinically significant
             electrocardiogram (ECG) abnormality at Screening, at the investigator's discretion.

          8. Currently taking medications that have the potential to prolong the QTcF interval or
             may require such medications during the course of the study (Appendix 1) and has
             clinically significant abnormalities on screening ECG readings, as determined by the
             investigator.

          9. A nerve or plexus block, including epidural steroid injections or facet blocks, within
             1 month prior to Screening or botulinum toxin injection in the lower back region
             within 3 months of Screening.

         10. History of chemotherapy or confirmed malignancy (except basal cell carcinoma) within
             the past 2 years.

         11. Any other acute or chronic pain condition that could interfere with the subject's
             ability to report their CLBP accurately and consistently and/or interfere with the
             study staff's ability to assess the subjects CLBP.

         12. An active or pending workman's compensation, insurance claim, or litigation related to
             back pain (i.e., primary claim is back pain).

         13. Clinically significant history, in the opinion of the investigator, of suicidal
             ideation or current evidence that the subject is actively suicidal.

         14. Clinically significant history of major depressive disorder that is poorly controlled
             with medication, per investigator judgment.

         15. Hypersensitivity or allergy to BPN, other opioids, or excipients of CAM2038.

         16. Hypersensitivity or allergy to acetaminophen.

         17. Use of strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4), such as some
             azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., clarithromycin),
             or protease inhibitors (e.g., ritonavir, indinavir, and saquinavir) within the 30 days
             prior to Screening,

         18. Use or planned use of natural supplements that can affect CYP3A4, such as St. John's
             Wort, throughout the study.

         19. Has a major bleeding disorder, such as hemophilia, or treated with high levels of
             anticoagulants per the investigator's discretion.

         20. Current or confirmed past diagnosis of Sphincter of Oddi dysfunction.

         21. Has a significant hepatic disease, as indicated by Screening clinical laboratory
             assessment results (aspartate aminotransferase, alanine aminotransferase, or lactate
             dehydrogenase values ≥3 × the upper limit of normal [ULN]) or has a creatinine value
             ≥1.5 × ULN).

         22. Is an employee of the investigator or the trial site, with direct involvement in the
             proposed trial or other studies under the direction of the investigator or trial site
             or is a family member of the investigator or of an employee of the investigator.

         23. Has any pending legal action that could prohibit participation or compliance in the
             study.

        Criteria for Entry into the Titration Phase:

          1. After at least a 12-hour washout from the last IR morphine dose, subject must have a
             COWS ≥5 and an API pain score over the past 24 hours ≥5 in order to receive a test
             dose of Buprenex.

          2. Passed all baseline criteria, including a normal QTcF, had no change in QTcF >30 ms at
             1 hour after the test dose with Buprenex, and had a COWS score <5 after the test dose
             with Buprenex.

        Note:

          -  Subjects on BPN at Screening are required to participate in the down titration and
             will undergo a washout period prior to the test dose and first on-study treatment.
             Subjects entering the study on BPN will not transition to IR Morphine, but will
             refrain from taking their BPN for 12 -24 hours prior to the test dose to achieve the
             desired washout period.

          -  Subjects on BPN at Screening are still required to follow the same Day 1 procedures
             (e.g., confirmation of pain scores, COWS assessment and Buprenex test dose) as non-BPN
             subjects.

        Criteria for Randomization into the Double-Blind Phase:

          1. Been on a stable dose of CAM2038 q1w for at least 2 consecutive weeks.

          2. CAM2038 titrated to a dose that provides analgesia (i.e., 7-day API score of ≤4 and at
             least 2 points below the value at the start of Titration Phase) and is well tolerated
             for 7 days before randomization.

          3. Requires no more than an average of one hydrocodone/acetaminophen 5 mg/325 mg/day
             during the last 7 days prior to randomization.

          4. Demonstrated study medication (CAM2038) compliance ≥80% during the previous 14 days.

          5. Demonstrated daily compliance with pain intensity scoring for ≥11 of the previous 14
             days, including the last 3 days prior to randomization.

        Inclusion Criteria for Open Label Extension For Subjects Continuing from The Randomized
        Double-Blind Phase.

        Subjects must have:

          1. Completed Double Blind Phase of the study

          2. Signed Informed Consent for Safety Extension

        Subjects completing the double-blind phase will be enrolled directly into the open label
        extension at their respective dose level of CAM2038. They will not be required to
        participate in a Buprenex treatment test dosing or participate in a titration phase.

        For De Novo Subjects (New Subjects Recruited Directly into The Open Label Extension)

        Subjects who are not participating in the Double-Blind Phase of the Study must meet all of
        the following inclusion criteria in order to be eligible for participation in the study:

          1. Written informed consent provided prior to the conduct of any study-related
             procedures.

          2. Male or non-pregnant and non-lactating female subject, greater than or equal to 18
             years old.

          3. BMI between 18 and 38 kg/m2, inclusive.

          4. Treated with daily opioids for moderate to severe chronic pain disorder such as CLBP
             or osteoarthritis for a minimum of 3 months prior to Screening.

          5. On a stable dose of >40 mg/day of oral morphine or MED during the 14 days prior to
             Screening.

          6. Systolic blood pressure ≥100 mmHg and diastolic blood pressure ≥60 mmHg.

          7. Female subject of childbearing potential who is willing to use a reliable method of
             contraception during the entire study (Screening Visit to final Follow-up). To be
             considered not of childbearing potential, female subjects must be surgically sterile
             (hysterectomy or bilateral oophorectomy, or bilateral tubal ligation with surgery at
             least 6 weeks before Screening).

          8. Male subject who is willing to use reliable contraception

          9. Willing and able to comply with all study procedures and requirements.

        Exclusion Criteria for Subjects Continuing from The Randomized Double-Blind Phase

        1. Clinically significant symptoms, medical conditions, or other circumstances which, in
        the opinion of the investigator, would preclude compliance with the protocol, adequate
        cooperation in the study, or obtaining informed consent, or may prevent the subject from
        safely participating in the study.

        Exclusion Criteria for De Novo Subjects only:

        Same exclusion criteria as for subjects participating in the Randomized Double-Blind
        Treatment Phase.

        Criteria for Entry into the Titration Phase (for De novo subjects):

          1. After at least a 12-hour washout from the last IR morphine dose, subject should have a
             COWS ≥5 and an API pain score over the past 24 hours ≥5 in order to receive a test
             dose of Buprenex.

          2. Passed all baseline criteria, including a normal QTcF, had no change in QTcF >30 ms at
             1 hour after the test dose with Buprenex, and had a COWS score <5 after the test dose
             with Buprenex.

        Note:

          -  Subjects on BPN at Screening are required to participate in the down titration and
             will undergo a washout period prior to the test dose and first on-study treatment.
             Subjects entering the study on BPN will not transition to IR Morphine, but will
             refrain from taking their BPN for 12 -24 hours prior to the test dose to achieve the
             desired washout period.

          -  However, subjects on BPN at Screening are still required to follow the same Day 1
             procedures (e.g., confirmation of pain scores, COWS assessment and Buprenex test dose)
             as non-BPN subjects.

        Criteria for Enrolment into the Open Label Treatment Phase (for de Novo subjects):

          1. Been on a stable dose of CAM2038 q1w for at least 2 consecutive weeks.

          2. CAM2038 titrated to a dose that provides analgesia (i.e., 7-day API score of ≤4 and at
             least 2 points below the value at the start of Titration Phase) and is well tolerated
             for 7 days before randomization.

          3. Requires no more than an average of one hydrocodone/acetaminophen 5 mg/325 mg/day
             during the last 7 days prior to randomization
      "
NCT02949011,completed,,1,phase 3,['influenza'],"[""['J11.81', 'J11.82', 'J10.01', 'J10.81', 'J10.82', 'J11.08', 'J11.2']""]","['baloxavir marboxil', 'placebo to baloxavir marboxil', 'oseltamivir', 'placebo to oseltamivir']","['COC(=O)OCOC1=C2C(=O)N3CCOCC3N(N2C=CC1=O)C4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F', 'CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)OCC']","
        Inclusion Criteria:

          1. Patients or their legal guardians who provide written informed consent to participate
             in the study on a voluntary basis. For adolescent patients, informed consent/assent of
             voluntary participation should be obtained in accordance with local requirements.

          2. Male or female patients ≥ 12 years at the time of signing the informed consent/assent
             form.

          3. Patients with a diagnosis of influenza confirmed by all of the following:

               1. Fever ≥ 38ºC (axillary) during the predose examinations or within the 4 hours
                  prior if antipyretics were taken

               2. A positive rapid influenza diagnostic test (RIDT) result OR A patient with a
                  negative RIDT may be enrolled if the patient reports contact with a known case of
                  influenza within the prior 7 days and all other inclusion criteria are met.

               3. At least 1 each of the following general and respiratory symptoms associated with
                  influenza is present with a severity of moderate or greater:

             i. General symptoms (headache, feverishness or chills, muscle or joint pain, or
             fatigue) ii. Respiratory symptoms (cough, sore throat, or nasal congestion)

          4. The time interval between the onset of symptoms and the predose examinations is 48
             hours or less. The onset of symptoms is defined as either:

               1. Time of the first increase in body temperature (an increase of at least 1ºC from
                  normal body temperature)

               2. Time when the patient experiences at least 1 new general or respiratory symptom

          5. If a women of childbearing potential, agrees to use a highly effective method of
             contraception for 3 months after the first dose of study drug

          6. Patients will be considered at high risk* of influenza complications due to the
             presence of at least 1 of the following inclusion criteria:

               1. Asthma or chronic lung disease (such as chronic obstructive pulmonary disease or
                  cystic fibrosis)

               2. Endocrine disorders (including diabetes mellitus)

               3. Residents of long-term care facilities (eg, nursing homes)

               4. Compromised immune system (including patients receiving corticosteroids not
                  exceeding 20 mg of prednisolone or equivalent, and patients being treated for
                  human immunodeficiency virus [HIV] infection with a CD4 count > 350 cells/mm³
                  within the last 6 months)

               5. Neurological and neurodevelopmental disorders (including disorders of the brain,
                  spinal cord, peripheral nerve, and muscle, eg, cerebral palsy, epilepsy [seizure
                  disorders], stroke, muscular dystrophy, or spinal cord injury)

               6. Heart disease (such as congenital heart disease, congestive heart failure, or
                  coronary artery disease), excluding hypertension without any other heart-related
                  symptoms

               7. Adults aged ≥ 65 years

               8. American Indians and Alaskan Natives

               9. Blood disorders (such as sickle cell disease)

              10. Metabolic disorders (such as inherited metabolic disorders and mitochondrial
                  disorders)

              11. Morbid obesity (body mass index ≥ 40 kg/m²)

              12. Women who are within 2 weeks postpartum and are not breastfeeding

        Exclusion Criteria:

          1. Patients with severe influenza virus infection requiring inpatient treatment.

          2. Patients with known allergy to oseltamivir (Tamiflu®).

          3. Patients unable to swallow tablets or capsules.

          4. Patients who have previously received baloxavir marboxil.

          5. Patients weighing ≤ 40 kg.

          6. Patients who have been exposed to an investigational drug within 30 days prior to the
             predose examinations.

          7. Women who are pregnant, breastfeeding, or have a positive pregnancy test at the
             predose examinations. The following female patients who have documentation of either a
             or b below do not need to undergo a pregnancy test at the predose examinations:

               1. Postmenopausal women (defined as cessation of regular menstrual periods for 2
                  years or more and confirmed by a follicle-stimulating hormone test)

               2. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or
                  tubal ligation

          8. Patients with concurrent infections at the predose examinations requiring systemic
             antimicrobial therapy.

          9. Patients with liver disease associated with hepatic impairment.

         10. Patients with cancer within the last 5 years (unless nonmelanoma skin cancer).

         11. Patients with untreated HIV infection or treated HIV infection with a CD4 count below
             350 cells/mm3 in the last 6 months.

         12. Patients with immunosuppression following organ or bone marrow transplants.

         13. Patients exceeding 20 mg of prednisolone or equivalent dose of chronic systemic
             corticosteroids.

         14. Patients who have received peramivir, laninamivir, oseltamivir, zanamivir,
             rimantadine, umifenovir or amantadine within 30 days prior to the predose
             examinations.

         15. Patients who have received an investigational monoclonal antibody for a viral disease
             in the last year.

         16. Patients with known creatinine clearance ≤ 60 mL/min.

         17. Patients who, in the opinion of the investigator, would be unlikely to comply with
             required study visits, self-assessments, and interventions
      "
NCT03495921,terminated,"
    slow accrual and as a result, a strategic business decision was made to terminate enrollment.
  ",0,phase 3,"['ewing sarcoma', 'ewing family of tumors', ""ewing's tumor metastatic"", ""ewing's sarcoma metastatic"", ""ewing's tumor recurrent"", 'rare diseases', 'sarcoma', 'neoplasms, connective and soft tissue', 'neoplasms by histologic type', 'neoplasms, bone tissue', 'neoplasms, connective tissue', 'sarcoma, ewing', 'neoplasms']","[""['C49.A1', 'C49.A2', 'C49.A5', 'C49.A3', 'C49.A4', 'C49.A9', 'C7A.00']"", ""['G47.13', 'J01.41', 'K11.22', 'K12.0', 'N96', 'F33.8', 'G03.2']"", ""['C96.A', 'C46.9', 'C96.22', 'C46.0', 'C46.2', 'C92.31', 'C92.32']"", ""['C49.9', 'C49.3', 'C49.4', 'C49.5', 'D21.9', 'C49.6', 'C49.8']"", ""['R82.89', 'R84.7', 'R85.7', 'R86.7', 'R87.7', 'R89.7']"", ""['D49.2']"", ""['C49.9', 'C49.3', 'C49.4', 'C49.5', 'D21.9', 'C49.6', 'C49.8']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['irinotecan', 'temozolomide']","['CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7', 'CN1C(=O)N2C=NC(=C2N=N1)C(=O)N']","
        Tissue Procurement Inclusion Criteria:

          1. Histologically confirmed Ewing's Sarcoma Family of Tumors (ESFT).

          2. Age greater than or equal to 2 years.

          3. Estimated survival greater than or equal to 6 months.

          4. Evidence of EWS translocation by FISH or RT-PCR or Next Generation Sequencing (NGS).
             If available, NGS sequencing report should be submitted to Gradalis.

          5. Recurrence or refractory to 1 line of systemic chemotherapy, including but not limited
             to doxorubicin, vincristine, and ifosfamide.

          6. Planned standard of care surgical procedure (e.g., tumor biopsy or palliative
             resection or thoracentesis) and expected availability of a cumulative soft-tissue mass
             of ~10-30 grams tissue (""grape"" to ""golf-ball"" size / approximately 2 cm total
             diameter on imaging) or pleural fluid estimated volume ≥ 500mL (from a primary or
             secondary thoracentesis, yielding in a high volume of tumor cells) for immunotherapy
             manufacture.

          7. Tumor intended for immunotherapy manufacture is not embedded in bone and does not
             contain luminal tissue (e.g. bowel, ureter, bile duct).

          8. Ability to understand and the willingness to sign a written protocol specific informed
             consent for tissue harvest or a parental/guardian informed consent and pediatric
             assent when appropriate.

        Tissue Procurement Exclusion Criteria:

          1. Medical condition requiring any form of chronic systemic immunosuppressive therapy
             (steroid or other) except physiologic replacement doses of hydrocortisone or
             equivalent (no more than 30 mg hydrocortisone or 10 mg prednisone equivalent daily)
             for < 30 days duration.

          2. Known history of other malignancy unless having undergone curative intent therapy
             without evidence of that disease for ≥ 3 years except cutaneous squamous cell and
             basal cell skin cancer, superficial bladder cancer, in situ cervical cancer or other
             in situ cancers are allowed if definitively resected.

          3. Brain metastases unless treated with curative intent (gamma knife or surgical
             resection) and without evidence of progression for ≥ 2 months.

          4. Any documented history of autoimmune disease with exception of Type 1 diabetes on
             stable insulin regimen, hypothyroidism on stable dose of replacement thyroid
             medication, vitiligo, or asthma not requiring systemic steroids.

          5. Known HIV or chronic Hepatitis B or C infection.

          6. Known hypersensitivity to any temozolomide component or to dacarbazine (DTIC).

          7. Known hypersensitivity to irinotecan or its excipients.

          8. Known history of allergies or sensitivities to gentamicin.

          9. History of or current evidence of any condition (including medical, psychiatric or
             substance abuse disorder), therapy, or laboratory abnormality that might confound the
             results of the study, interfere with the patient's participation for the full duration
             of the study, or is not in the best interest of the patient to participate, in the
             opinion of the treating Investigator.

        Study Enrollment Inclusion Criteria:

          1. Completed manufacture of at least 4 vials of Vigil.

          2. Karnofsky performance status (KPS) / Lansky performance status (LS) ≥80 percent.

          3. Normal organ and marrow function as defined below:

             Absolute granulocyte count ≥1,000/mm3, Absolute lymphocyte count ≥400/mm3, Platelets
             ≥75,000/mm3, Hemoglobin ≥ 8.0 mg/dL, Total bilirubin ≤ institutional upper limit of
             normal*, AST(SGOT)/ALT(SGPT) ≤2x institutional upper limit of normal, Creatinine <1.5
             mg/dL

             * documented Gilbert's syndrome may be considered after medical monitor review

          4. Subject has recovered to CTCAE Grade 1 (except for parameters noted in Item 3, above)
             or better from all adverse events associated with prior therapy or surgery.
             Pre-existing motor or sensory neurologic pathology or symptoms, or dermatologic must
             be recovered to CTCAE Grade 2 or better.

          5. If female of childbearing potential, has a negative urine or serum pregnancy test. If
             the urine test is positive or cannot be confirmed as negative, a negative serum test
             will be required for study entry.

          6. Ability to understand and the willingness to sign a written informed protocol specific
             consent or a parental/guardian informed consent and pediatric assent when appropriate.

        Study Enrollment Exclusion Criteria:

        In addition to the procurement exclusion criteria, subjects will NOT be eligible for study
        registration and randomization if meeting any of the following additional criteria:

          1. Any anti-neoplastic therapy between tissue procurement for Vigil manufacture and start
             of study therapy.

          2. Live vaccine used for the prevention of infectious disease administered < 30 days
             prior to the start of study therapy.

          3. Post-surgery complication that in the opinion of the treating investigator would
             interfere with the patient's study participation or make it not in the best interest
             of the patient to participate.

        Inclusion Criteria for Cross-Over:

        Group B subjects will be eligible for cross-over, if they meet all of the following
        criteria:

          1. Evidence of radiologic disease progression by RECIST 1.1 after enrollment into Group
             B.

          2. Successful manufacturing of at least 4 vials of Vigil.

          3. Karnofsky performance status (KPS) / Lansky performance status (LS) ≥70%.

          4. Normal organ and marrow function as defined below:

             Absolute granulocyte count ≥1,000/mm3 Absolute lymphocyte count ≥400/mm3 Platelets
             ≥75,000/mm3 Total bilirubin ≤ institutional upper limit of normal AST(SGOT)/ALT(SGPT)
             ≤2x institutional upper limit of normal Creatinine <1.5 mg/dL

             *documented Gilbert's syndrome may be considered after medical monitor review.

          5. Subject has recovered to CTCAE Grade 1 (except for parameters noted in Item 4, above)
             or better from all adverse events associated with prior therapy or surgery.
             Preexisting motor, sensory neurologic pathology or symptoms, or dermatologic
             toxicities must be recovered to CTCAE Grade 2 or better.

          6. If female of childbearing potential, has a negative urine or serum pregnancy test. If
             the urine test is positive or cannot be confirmed as negative, a negative serum test
             will be required for study entry.

          7. Ability to understand and the willingness to sign a written informed protocol specific
             consent or a parental/guardian informed consent and pediatric assent when appropriate.

        Exclusion Criteria for Cross-Over:

        In addition to the Procurement and Study Enrollment exclusion criteria, Subjects will not
        be eligible for cross-over if meeting any of the following criteria:

          1. With the exception of irinotecan and temozolomide while on study, any anti-neoplastic
             therapy between tissue procurement for Vigil manufacture and start of study therapy.

          2. Live vaccine used for the prevention of infectious disease administered < 30 days
             prior to the start of study therapy.
      "
NCT02700815,completed,,1,phase 3,['acute pain'],"[""['G89.12', 'G89.18', 'G89.11', 'G89.3']""]","['diclofenac', 'capsaicin', 'placebo']","['C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl', 'CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC']","
        Inclusion criteria:

          -  Signed and dated written informed consent at Visit 1 in accordance with Good Clinical
             Practice and local legislation

          -  Male or female patients >=18 years with current diagnosis of acute back pain or of
             neck pain for at least 24 hours, but less than 21 days

          -  Acute back pain or acute neck pain resulting in pain on movement (POM) >= 50 mm
             (Visual Analogue Scale 0-100) for at least one POM procedure out of 5 standardized
             procedures.

          -  Sensitivity to algometric pressure on the painful trigger point <= 25 N/cm2

          -  Women of childbearing potential must be ready and able to use highly effective methods
             of birth control

        Exclusion criteria:

          -  History of 3 or more episodes of back or neck pain in the last 6 months excluding the
             current episode

          -  Surgery due to back or neck pain or rehabilitation due to back or neck pain in the
             last 12 months

          -  Back or neck pain that is attributable to any specific identifiable cause (e.g. disc
             prolapse, spondylolisthesis, osteomalacia, inflammatory arthritis, metabolic,
             neurological diseases or tumour)

          -  Trauma or strains of the back or neck muscles within the last 3 months

          -  Prior use within the last 3 days before Visit 1 or concomitant use of any
             anti-inflammatory drugs, heparinoids, muscle relaxants or analgesics. Long-acting
             glucocorticoids must have been discontinued 10 days before study entry. Spinal
             injections should have been discontinued in due time (investigator's judgement) before
             patient enrolment to allow complete wash-out of the active ingredient based on
             investigator's judgment

          -  Non-pharmacological treatment (physiotherapy, heat treatment (e.g. heat patch, hot
             water bottle), or massage, acupuncture, transcutaneous electrical nerve stimulation)
             or locally applied pharmacological product to the back or neck area 24 hours prior
             study entry and during the study period

          -  Known severe hepatocellular insufficiency, severe renal insufficiency or Gilbert's
             syndrome (Morbus Meulengracht)

          -  Any other medical condition that would interfere with efficacy and safety assessments
             based on investigator's judgement or any on-going clinical condition that would
             jeopardize patient's or site personnel's safety or study compliance based on
             investigator judgement.

          -  Known intolerance or hypersensitivity to the active ingredients or any excipient(s).

          -  Patients in whom attacks of asthma, bronchospasm, rhinitis or urticaria were
             precipitated by the intake of Acetyl salicylic acid (ASS) or other NSAIDs

          -  Irritated skin (based on investigator's judgement), skin wounds, eczema or open
             injuries at application site

          -  Negative experience in the past with heat treatments for muscle complaints

          -  Patient not able to understand and comply with trial requirements based on
             investigators judgement

          -  Alcohol or drug abuse

          -  Participation in a clinical trial within the previous 30 days or simultaneous
             participation in another clinical trial

          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial
      "
NCT02193074,terminated,"
    after a positive interim analysis, the decision was made to terminate the study early to allow
    for participants to enroll into an open label study
  ",1,phase 3,['spinal muscular atrophy'],"[""['G12.9', 'G12.1', 'G12.0']""]",['nusinersen'],['CC1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)OP(=S)(O)OCC3C(C(C(O3)N4C=C(C(=NC4=O)N)C)OCCOC)OP(=S)(O)OCC5C(C(C(O5)N6C=NC7=C(N=CN=C76)N)OCCOC)OP(=S)(O)OCC8C(C(C(O8)N9C=C(C(=NC9=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)O)OCCOC'],"
        Key Inclusion Criteria:

          -  Be born (gestational age) between 37 and 42 weeks

          -  Be medically diagnosed with spinal muscular atrophy (SMA)

          -  Have Survival Motor Neuron2 (SMN2) Copy number = 2

          -  Body weight equal to or greater than 3rd percentile for age using appropriate
             country-specific guidelines

          -  Be able to follow all study procedures

          -  Reside within approximately 9 hours ground-travel distance from a participating study
             center, for the duration of the study

        Key Exclusion Criteria:

          -  Hypoxemia (oxygen [O2] saturation awake less than 96% or O2 saturation asleep less
             than 96%, without ventilation support) during screening evaluation

          -  Clinically significant abnormalities in hematology or clinical chemistry parameters or
             Electrocardiogram (ECG), as assessed by the Site Investigator, at the Screening visit
             that would render the participant unsuitable for participation in the study

          -  Participant's parent or legal guardian is not willing to meet standard of care
             guidelines (including vaccinations and respiratory syncytial virus prophylaxis if
             available), nor provide nutritional and respiratory support throughout the study

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      "
NCT03017508,completed,,1,phase 2/phase 3,"['social anxiety disorder', 'performance anxiety']","[""['F20.81', 'F21', 'F34.0', 'F34.1', 'F42.3', 'F45.0', 'F51.5']"", ""['Y65.51', 'Y65.52', 'Y65.53']""]","['bhv-0223', 'placebo']",['C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N'],"
        Inclusion Criteria:

          1. Male or female (post-menopausal, surgically sterile, or negative pregnancy test at
             screening and agreement to utilize an established birth control, including complete
             abstinence, during the testing period) between the age of 18 and 65 yrs.

          2. Meet DSM-5 criteria for social anxiety disorder by structured clinical interview
             (SCID) and have a LSAS public speaking subscale score >6.

          3. Stable psychiatric medications. Participants must have had stable doses of all
             psychiatric medications for the month prior to treatment and have been on stable doses
             of SSRI and antidepressants for at least 1 month prior to study enrollment. As needed
             benzodiazepine use will be permitted as long as subjects refrain from using
             benzodiazepines for the 48 hours prior to the study.

          4. Medically and neurologically healthy on the basis of physical examination, SMAC-20
             (including LFT's, TFT's), VDRL, CBC w/ diff, urinalysis, urine toxicology, EKG, and
             medical history. Individuals with stable medical problems that do not have CNS effects
             or interfere with medications administered (e.g., oral hypoglycemics) may be included
             if their medications have not been adjusted in the month prior to entry;

          5. Urine toxicology screen negative for drug of abuse.

          6. Able to provide written informed consent according to the Yale Human Investigation
             Committee (HIC) guidelines.

        Exclusion Criteria:

          1. Positive pregnancy test

          2. Breastfeeding females

          3. History of substance abuse disorder (ETOH, cocaine, opiates, PCP) within the last 6
             months or positive urine toxicology on screening (within the previous 6 months).

          4. History of pervasive developmental disorder or psychotic disorder by DSM-IV-TR
             criteria.

          5. Presence of dentures, braces, piercings at the time of dosing, or any physical
             findings in the mouth or tongue that, in the opinion of the Principal Investigator,
             would be likely to interfere with successful completion of the dosing procedure.

          6. Participants with a medical condition that might interfere with the physiological
             absorption and motility (ie, gastric bypass, duodenectomy) or gastric bands.

          7. Participants with any clinically significant abnormality or abnormal laboratory test
             results.

          8. Participant has a current diagnosis of viral hepatitis (HBsAG or HVC) or a history of
             liver disease.

          9. Participant has significant history of seizure disorder other than a single childhood
             febrile seizure (eg. Epilepsy)

         10. Participant using any drugs known to induce or inhibit CYP 1A2 metabolism (examples of
             inducers: rifampin, carbamazepine, etc.; examples of inhibitors: fluvoxamine,
             ciprofloxacin, fluoroquinolones, etc.) within 30 days prior to the first study drug
             administration.

         11. Participants with a history of allergic reactions to riluzole or other related drugs.

         12. Participant has a history of anaphylaxis, a documented hypersensitivity reaction, or a
             clinically important reaction to any drug.

         13. Participant has received another investigational drug or device within the 30 days (90
             days for biologics) prior to the first dosing or is currently participating in an
             investigational study involving no drug administration.

         14. Participant with clinically significant electrocardiogram (ECG) abnormalities (QTcF
             >450 msec) or vital sign abnormalities (systolic blood pressure lower than 90 or over
             140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less
             than 50 or over 100 bpm) at Screening or Baseline (Day -1).

         15. Any reason which, in the opinion of the Principal Investigator, would prevent the
             participant from being in the study.
      "
NCT02351882,completed,,1,phase 2/phase 3,"['alzheimer disease', 'agitation', 'weight loss', 'pain', 'oxidative stress']","[""['G30.8', 'G30.9', 'G30.0', 'G30.1']"", ""['R45.1', 'F01.A11', 'F01.B11', 'F01.C11', 'F03.A11', 'F03.B11', 'F03.C11']"", ""['R63.4']"", ""['N50.82', 'R07.2', 'R07.82', 'R10.13', 'R10.33', 'R14.1', 'R52']""]","['nabilone', 'placebo']",['CCCCCCC(C)(C)C1=CC(=C2C3CC(=O)CCC3C(OC2=C1)(C)C)O'],"
        Inclusion Criteria:

          -  Males or females ≥55 years of age

          -  Diagnostic and Statistical Manual (DSM) -V criteria for Major Neurocognitive Disorder
             due to AD. Patients with both Major Neurocognitive Disorder due to AD and Major
             Vascular Neurocognitive Disorder (i.e., mixed AD and cerebrovascular disease) will
             also be included.

          -  Currently in moderate-to-severe stage of dementia (Mini-Mental Status Examination
             (MMSE) ≤24)

          -  Presence of clinically significant agitation (Neuropsychiatric Inventory (NPI)
             agitation subscale ≥3)

          -  If treated with cognitive-enhancing medications (cholinesterase inhibitors and/or
             memantine), dosage must be stable for at least 3 months. If the ChEI and/or memantine
             has been discontinued, they may enroll after 1 month.

        Exclusion Criteria:

          -  Change in psychotropic medications less than 1 month prior to study randomization
             (e.g., concomitant antidepressants)

          -  Contraindications to nabilone (history of hypersensitivity to any cannabinoid)

          -  Current or past significant cardiovascular disease (e.g. uncontrolled hypertension,
             ischemic heart disease, arrhythmia and severe heart failure)

          -  Presence or history of other psychiatric disorders or neurological conditions (e.g.
             psychotic disorders, schizophrenia, stroke, epilepsy), previous or current abuse
             of/dependence on marijuana
      "
NCT02352363,completed,,1,phase 3,"[""idiopathic parkinson's disease""]","[""['G20']""]",['cvt-301'],['C1=CC(=C(C=C1CC(C(=O)O)N)O)O'],"
        Inclusion Criteria:

          -  Has signed and dated an Internal Review Board/Independent Ethics Committee
             (IRB/IEC)-approved informed consent form before any protocol-specific screening
             procedures are performed.

          -  Women of child-bearing potential must use protocol-defined contraceptive measures and
             must have a negative serum human chorionic gonadotropin (hCG) test at screening. These
             patients must be willing to remain on their current form of contraception for the
             duration of the study.

          -  Patients who have idiopathic PD (i.e., not induced by drugs or other diseases) as
             defined by fulfilling Steps 1 and 2 of the United Kingdom (UK) Brain Bank criteria,
             diagnosed after the age of 30 years.

          -  Patients who are classified as Stage 1 to 3 (in the ON state) on the modified Hoehn
             and Yahr scale for staging of PD severity.

          -  Patients who have experienced motor fluctuations for a minimum of 2 hours of average
             daily OFF time per waking day (excluding early morning OFF time) by self-report and
             confirmed by the PD Diary (on 3 consecutive days) during the screening period.

        Exclusion Criteria:

          -  Patients who have dyskinesia of a severity that would significantly interfere with
             their ability to participate or perform study procedures.

          -  Pregnant or lactating females or females wishing to become pregnant.

          -  Patients who have any known contraindication to the use of levodopa (LD), including a
             history of malignant melanoma or a history of narrow-angle glaucoma.

          -  Patients who have had previous surgery for PD (including but not limited to deep brain
             stimulation [DBS] or cell transplantation).

          -  Patients with a history of psychotic symptoms requiring treatment, or suicide ideation
             or attempt within the prior 12 months.
      "
NCT02357901,completed,,1,phase 3,"['opioid dependence', 'opioid related disorders']","[""['F11.20', 'F11.24', 'F11.281', 'F11.282', 'F11.288', 'F11.29', 'F11.21']"", ""['F20.81', 'F21', 'F34.0', 'F34.1', 'F42.3', 'F45.0', 'F51.5']""]","['suboxone', 'rbp-6000', 'placebo']",['CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O'],"
        Inclusion Criteria:

          -  Currently meets Diagnostic and Statistical Manual of Mental Disorders, 5th Edition
             (DSM-5) criteria for moderate or severe opioid use disorder

          -  By medical history has met DSM-5 criteria for moderate or severe opioid use disorder
             for the 3 months immediately prior to signing the informed consent form

          -  Is seeking medication-assisted treatment for opioid use disorder

          -  Is an appropriate candidate for opioid partial-agonist medication-assisted treatment
             in the opinion of the investigator or medically responsible physician

          -  Body mass index (BMI) of ≥ 18.0 to ≤ 35.0 kg/m^2

        Exclusion Criteria:

          -  Current diagnosis other than opioid use disorder requiring chronic opioid treatment

          -  Current substance use disorder as defined by DSM-5 criteria with regard to any
             substances other than opioids, cocaine, cannabis, tobacco, or alcohol.

          -  Positive urine drug screen (UDS) result at screening for cocaine or cannabis AND meets
             DSM-5 criteria for either moderate or severe cocaine or cannabis use disorder,
             respectively

          -  Meets DSM-5 criteria for moderate or severe alcohol use disorder

          -  Received medication-assisted treatment for opioid use disorder (e.g., methadone,
             buprenorphine) in the 90 days prior to providing written informed consent
      "
NCT02354352,completed,,1,phase 3,['duchenne muscular dystrophy'],"[""['G71.01']""]","['eplerenone', 'spironolactone']","['CC12CCC(=O)C=C1CC(C3C24C(O4)CC5(C3CCC56CCC(=O)O6)C)C(=O)OC', 'CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C']","
        Inclusion Criteria:

          -  Boys age ≥7 years with DMD confirmed clinically and by mutation analysis able to
             undergo cardiac magnetic resonance (CMR) without sedation

          -  LV EF ≥45% (+/-5%) by clinically-acquired echocardiography, nuclear scan or cardiac
             MRI done within 2 weeks of enrollment

        Exclusion Criteria:

          -  Non-MR compatible implants

          -  Severe claustrophobia

          -  Gadolinium contrast allergy

          -  Kidney disease

          -  Prior use of or allergy to aldosterone antagonist

          -  Use of other investigational therapy.
      "
NCT03022838,terminated,"
    the study was terminated prematurely due to poor recruitment.
  ",0,phase 2/phase 3,"['migraine', 'caffeine withdrawal']","[""['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']""]",['caffeine'],['CN1C=NC2=C1C(=O)N(C(=O)N2C)C'],"
        Inclusion Criteria:

          -  migraine present for at least 1 year and fulfilling diagnostic criteria (ICHD-3 beta)

          -  =/> 3 migraine attacks per month

          -  no migraine prophylaxis the last month

          -  consumption =/> 300 mg and </= 800 mg caffeine per day the last month

          -  signed consent

        Exclusion Criteria:

          -  suspicion of medication-overuse headache

          -  pregnancy and breast feeding

          -  serious co-morbidity or conditions requiring Medical treatment or caution

          -  working night shift

          -  use of drugs with moderate or major interactions with caffeine
      "
NCT01994720,completed,,0,phase 3,"['acute ischaemic stroke', 'transient ischaemic attack']","[""['R29.5', 'F95.0', 'G45.4', 'P61.0', 'P61.5', 'D80.7', 'H53.123']""]","['ticagrelor', 'acetylsalicylic acid (asa)']",['CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F'],"
        Inclusion Criteria:

          -  Men or women equal or elder 40 years of age

          -  Either acute ischaemic stroke or high-risk TIA as defined here and randomisation
             occurring within 24 hours after onset of symptoms

        Key Exclusion Criteria:

          -  Planned use of antithrombotic therapy in addition to study medication including
             antiplatelets (eg, open label ASA, GPIIb/IIIa inhibitors, clopidogrel, ticlopidine,
             prasugrel, dipyridamole, ozagrel, cilostazol) and anticoagulants (eg, warfarin, oral
             thrombin and factor Xa inhibitors, bivalirudin, hirudin, argatroban, unfractionated
             and low molecular weight heparins). - Any history of atrial fibrillation, ventricular
             aneurysm or suspicion of cardioembolic pathology for TIA or stroke. - Planned carotid,
             cerebrovascular, or coronary revascularisation that requires halting study medication
             within 7 days of randomisation. - Receipt of any intravenous or intra-arterial
             thrombolysis or mechanical thrombectomy within 24 hours prior to randomisation -
             History of previous symptomatic non-traumatic intracerebral bleed at any time
             (asymptomatic microbleeds do not qualify), gastrointestinal (GI) bleed within the past
             6 months, or major surgery within 30 days.
      "
NCT02477618,completed,,0,phase 3,['super-refractory status epilepticus'],"[""['G40.803', 'G40.804', 'G40.823', 'G40.824', 'G40.833', 'G40.834', 'G40.911']""]","['sage-547', 'placebo']",['Status: 503'],"
        Inclusion Criteria:

          -  Subjects two (2) years of age and older

          -  Subjects who have:

               -  Failed to respond to the administration of at least one first-line agent (e.g.,
                  benzodiazepine or other emergent initial anti-epileptic drug [AED] treatment),
                  according to institution standard of care, and;

               -  Failed to respond to at least one second-line agent (e.g., phenytoin,
                  fosphenytoin, valproate, phenobarbital, levetiracetam or other urgent control
                  AED), according to institution standard of care, and;

               -  Not previously been administered a third-line agent but have been admitted to an
                  intensive care unit with the intent of administering at least one third-line
                  agent for at least 24 hours; or who have previously failed zero, one or more wean
                  attempts from third-line agents and are now on continuous intravenous infusions
                  of one or more third-line agent and in an EEG burst or seizure suppression
                  pattern; or who have previously failed one or more wean attempts from third-line
                  agents and are now either not on a continuous intravenous infusion of at least
                  one third-line agent or are on a continuous intravenous infusion of one or more
                  third-line agent but not in an EEG burst or seizure suppression pattern

        Exclusion Criteria:

          -  Subjects with SRSE due to anoxic/hypoxic encephalopathy with highly malignant/
             malignant EEG features

          -  Children (subjects aged less than 17 years) with an encephalopathy due to a rapidly
             progressing underlying neurological disorder

          -  Subjects who have any of the following:

               1. a glomerular filtration rate (GFR) low enough to warrant dialysis but for
                  whatever reason, dialysis is not planned or non-continuous dialysis planned (that
                  would not adequately remove Captisol®);

               2. severe cardiogenic or vasodilatory shock requiring two or more pressors that is
                  not related to third-line agent use;

               3. fulminant hepatic failure;

               4. no reasonable expectation of recovery (for instance, a likely outcome is
                  persistent vegetative state) or life-expectancy, in the experience of the
                  investigator, is less than 30 days.

          -  Subjects who are being administered more than three third-line agents concomitantly or
             in whom the qualifying wean cannot be completed per protocol
      "
NCT02815709,completed,,1,phase 3,['acute pain'],"[""['G89.12', 'G89.18', 'G89.11', 'G89.3']""]","['oliceridine', 'placebo', 'morphine']","['COC1=C(SC=C1)CNCCC2(CCOC3(C2)CCCC3)C4=CC=CC=N4', 'CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O']","
        Inclusion Criteria:

          -  Has undergone primary, unilateral, first metatarsal bunionectomy (osteotomy and
             internal fixation) with no additional collateral procedures.

          -  Experiences a pain intensity rating of moderate to severe acute pain.

          -  Able to provide written informed consent before any study procedure.

        Exclusion Criteria:

          -  ASA Physical Status Classification System classification of P3 or worse.

          -  Has surgical or post-surgical complications.

          -  Has clinically significant medical conditions or history of such conditions that may
             interfere with the interpretation of efficacy, safety, or tolerability data obtained
             in the trial, or may interfere with the absorption, distribution, metabolism, or
             excretion of drugs.

          -  Has previously participated in another TRV130 clinical study.
      "
NCT02337725,completed,,1,phase 3,"[""parkinson's disease""]","[""['G20']""]","['tvp-1012', 'placebo']",['CS(=O)(=O)O.C#CCNC1CCC2=CC=CC=C12'],"
        Inclusion Criteria:

        Run-in period

          -  In the opinion of the investigator or sub-investigator, the participant is capable of
             understanding and complying with protocol requirements.

          -  The participant signs and dates a written, informed consent form and any required
             privacy authorization prior to the initiation of any study procedures.

          -  The participant has a diagnosis of Parkinson's disease with at least two of the
             following signs: resting tremor, akinesia/bradykinesia, and muscle rigidity.

          -  The participant has a Movement Disorder Society-Unified Parkinson's Disease Rating
             Scale (MDS-UPDRS) Part II + Part III total score of >=14 at the start of the run-in
             period.

          -  The participant has Modified Hoehn & Yahr stage 1 to 3 at the start of the run-in
             period.

          -  The participant has the Parkinson's disease diagnosed within 5 years prior to the
             start of the run-in period.

          -  The participant is an outpatient of either sex aged >= 30 and < 80 years.

          -  A female participant of childbearing potential who is sexually active with a
             nonsterilized male partner agrees to use routinely adequate contraception from signing
             of informed consent to 1 month after the last dose of the investigational drug.

        Treatment period

        - The participant has a MDS-UPDRS Part II + Part III total score of >= 14 at baseline.

        Exclusion Criteria:

        Run-in period

          -  The participant has received any investigational medication within 90 days prior to
             the start of the run-in period.

          -  The participant has received TVP-1012 in the past.

          -  The participant is study site employee, an immediate family member, or in a dependent
             relationship with a study site employee who is involved in the conduct of this study
             (e.g., spouse, parent, child, sibling) or may consent under duress.

          -  Participant has donated 400 mL or more of his or her blood volume within 90 days prior
             to the start of the run-in period.

          -  The participant has unstable systemic disease.

          -  The participant has Mini-Mental State Examination (MMSE) score of <= 24 at the start
             of the run-in period.

          -  The participant has known or a history of schizophrenia, major or severe depression,
             or any other clinically significant psychiatric disease.

          -  The participant has a history of hypersensitivity or allergies to TVP-1012 (including
             any associated excipients) or selegiline.

          -  The participant has a history of clinically significant hypertension or other
             reactions associated with ingestion of tyramine-rich food (e.g., cheese, lever,
             herring, yeast, horsebean, banana, beer or wine).

          -  The participant has a history or concurrent of drug abuse or alcohol dependence.

          -  The participant has received neurosurgical intervention for Parkinson's disease (e.g.,
             pallidotomy, thalamotomy, deep brain stimulation).

          -  The participant has received transcranial magnetic stimulation within 6 months prior
             to the start of the run-in period

          -  The participant has received amantadine or anticholinergic medication for >= 180 days.

          -  The participant has received selegiline, a levodopa-containing product or dopamine
             agonist for >= 90 days.

          -  The participant has received selegiline, pethidine, tramadol, reserpine or methyldopa
             within 90 days prior to the start of the run-in period.

          -  The participant has received a levodopa-containing product, dopamine agonist,
             amantadine or anticholinergic drug within 30 days prior to the start of the run-in
             period.

          -  The participant has received any psychoneurotic agent or antiemetic medication of
             dopamine antagonist within 14 days prior to the start of the run-in period. However,
             the participant has been receiving quetiapine or domperidone with a stable dose
             regimen for >= 14 days prior to the start of the run-in period may be included in the
             study.

          -  The participant has previously received a catechol-O-methyltransferase (COMT)
             inhibitor, droxidopa, zonisamide or istradefylline.

          -  The participant is required to take any of the prohibited concomitant medications or
             treatments.

          -  If female, the participant is pregnant or lactating or intending to become pregnant
             during this study, or within 1 month after the last dose of the investigational drug;
             or intending to donate ova during such time period.

          -  The participant has clinically significant neurologic, cardiovascular, pulmonary,
             hepatic (including mild cirrhosis), renal, metabolic, gastrointestinal, urological,
             endocrine, or hematological disease.

          -  The participant has clinically significant or unstable brain or cardiovascular
             disease, such as:

               -  clinically significant arrhythmia or cardiac valvulopathy,

               -  cardiac arrest of NYHA Class II or higher,

               -  concurrent or a history of ischemic cardiac disease within 6 months prior to the
                  start of the run-in period,

               -  concurrent or a history of clinically significant cerebrovascular disease within
                  6 months prior to the start of the run-in period,

               -  sever hypertension (systolic blood pressure of 180 mmHg or higher, or diastolic
                  blood pressure of 110 mmHg or higher),

               -  clinically significant orthostatic hypotension (including those with systolic
                  pressure decrease of 30 mmHg or more following postural change from
                  supine/sitting position to standing position),

               -  a history of syncope due to hypotension within 2 years prior to the start of the
                  run-in period.

          -  The participant is required surgery or hospitalization for surgery during the study
             period

          -  Participant has a history of cancer within 5 years prior to the start of the run-in
             period, except cervix carcinoma in situ which has completely cured.

          -  The participant has acquired immunodeficiency syndrome (AIDS) [including human
             immunodeficiency virus (HIV) carrier], or hepatitis [including viral hepatitis carrier
             such as hepatitis B surface (HBs) antigen or hepatitis C antibody (HCV) positive].
             However, the participant who has a negative result for HCV antigen or HCV-RNA can be
             included in the study.

          -  The participant who, in the opinion of the investigator or sub-investigator, is
             unsuitable for any other reason.

        Treatment period

          -  The participant whose diagonosis of Parkinson's disease is ruled out by dopamine
             transporter scintigraphy performed during the run-in period if conducted.

          -  The participant has laboratory data meeting any of the following at the start of the
             run-in period:

               -  Creatinine >= 2 x upper limit of normal (ULN)

               -  Total bilirubin >= 2 x ULN

               -  ALT or AST >= 1.5 x ULN

               -  ALP >= 3 x ULN

          -  The participant has received any of the prohibited concomitant medications or
             treatments during the run-in period.
      "
NCT03095456,completed,,1,phase 3,"['chronic obstructive pulmonary disease, copd', 'low peak inspiratory flow rate (pifr)']","[""['G91.1', 'I42.1', 'N11.1', 'J05.0', 'P28.42', 'G47.33', 'J44.9']""]","['revefenacin', 'placebo for revefenacin', 'placebo for spiriva handihaler®']",['CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N'],"
        Inclusion Criteria:

          -  Subject is a male or female subject 40 years of age or older with a diagnosis of COPD.

          -  Subject has a current or past cigarette smoking history (or equivalent for cigar or
             pipe smoking history) of at least 10 pack-years.

          -  Subject is willing and able to provide signed and dated written informed consent to
             participate prior to initiation of any study related procedures.

        Exclusion Criteria:

          -  Subject has a concurrent disease or condition that, in the opinion of the
             investigator, would interfere with continued study participation or confound the
             evaluation of safety and tolerability of the study drug.

          -  Subject has a history of reactions or hypersensitivity to inhaled or nebulized
             anticholinergics.

          -  Subject suffers from any medical condition that would preclude the use of inhaled
             anticholinergics, including narrow-angle glaucoma, symptomatic benign prostatic
             hyperplasia, bladder neck obstruction, or urinary retention.
      "
NCT02284906,terminated,"
    lack of efficacy of the drug; no safety concern
  ",0,phase 3,"[""mild cognitive impairment due to alzheimer's disease""]","[""['G30.8', 'G30.9', 'G30.0', 'G30.1']""]","['pioglitazone', 'placebo']",['CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3'],"
        Inclusion Criteria:

          1. Completed the pivotal AD-4833/TOMM40_301 study with an adjudicated diagnosis of mild
             cognitive impairment (MCI) due to Alzheimer's Disease (AD) without ongoing serious
             adverse events (SAEs) from AD-4833/TOMM40_301.

          2. Is male or female and is at least 65 years of age at the time of the Baseline Visit.

          3. In the opinion of the investigator, is capable of understanding and complying with the
             protocol requirements.

          4. The participant or, when applicable, the participant's legally acceptable
             representative signs and dates a written, informed consent form and any required
             privacy authorization prior to the initiation of any study procedures.

          5. Must be living independently or in nonmedical residential care.

          6. Has a project partner able to separately consent on his/her own behalf and take part
             in the study (with the intent to do so as long as the participant is enrolled),
             providing information on the cognitive, functional, and behavioral status of the
             participant and assisting with observation of adverse events (AEs) and monitoring of
             study medication, if needed. Project partners participating in the pivotal
             AD-4833/TOMM40_301 study are encouraged to participate in this extension study in this
             capacity.

        Exclusion Criteria:

          1. Completed the pivotal AD-4833/TOMM40_301 study with an adjudicated diagnosis of AD
             dementia.

          2. Has a current diagnosis of significant psychiatric illness, per Diagnostic and
             Statistical Manual of Mental Disorders, 4th Edition (including but not limited to
             major depressive disorder, anxiety disorders) and is in an acute phase/episode, or the
             participant has a current diagnosis or history of schizophrenia or bipolar disorder.

          3. Has a glycosylated hemoglobin (HbA1c) >8% at the extension study Baseline Visit or
             requires treatment with insulin, triple oral antidiabetic therapy or a peroxisome
             proliferator-activated receptor gamma (PPAR-γ) agonist.

          4. Has a clinically significant unstable illness, for example, hepatic impairment or
             renal insufficiency, or cardiovascular, pulmonary, gastrointestinal (including s/p
             gastric bypass surgery), endocrine, neurological, rheumatologic, immunologic,
             infectious, skin and subcutaneous tissue disorders, or metabolic disturbance.

          5. Is an immediate family member, study site employee, or is in a dependent relationship
             with a study site employee who is involved in conduct of this study (eg, spouse,
             pivotal, child, sibling) or may consent under duress.

          6. Is required to take excluded medications.

          7. Has a history of hypersensitivity or allergies to pioglitazone or related compounds.

          8. Had any of the following values at the extension study Baseline Visit:

               1. A serum total bilirubin value >15 x upper limit of normal (ULN).

               2. A serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value
                  >2 x ULN.

               3. Unexplained microscopic/macroscopic hematuria on 2 repeat examinations within 2
                  weeks.

          9. Has a disease or takes medication that, in the opinion of the investigator, could
             interfere with the assessments of safety, tolerability, or efficacy, or prevent the
             participant from adequately participating in the study or continue for the anticipated
             duration of the study.

         10. Has received any investigational compound, with the exception of treatment during the
             AD-4833/TOMM40_301 study, within 30 days prior to Baseline or 5 half-lives prior to
             Baseline or is currently participating in another study that entails the
             administration of an investigational or marketed drug, supplement, or intervention
             including, but not limited to diet, exercise, lifestyle, or invasive procedure.

         11. Has any cancer that has been in remission for less than 2 years from the extension
             study Baseline Visit. Participants with basal cell or stage I squamous cell carcinoma
             of the skin will be eligible. Participants with current diagnosis of bladder cancer
             are not eligible irrespective of the remission status.

         12. Has a current diagnosis of macular edema, degeneration or any maculopathy.

         13. Has a history or current diagnosis of congestive heart failure (CHF), New York Heart
             Association class III-IV.
      "
NCT03049735,completed,,1,phase 3,"['heavy menstrual bleeding', 'uterine fibroid']","[""['G43.831', 'G43.839', 'G43.821', 'G43.829', 'N94.9', 'N94.89']""]","['relugolix', 'estradiol/norethindrone acetate', 'estradiol/norethindrone acetate placebo', 'relugolix placebo']","['CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC', 'Status: 400', 'Status: 400']","
        Key Inclusion Criteria:

          1. Premenopausal female aged 18 to 50 years old (inclusive) on the day of signing and
             dating the informed consent form.

          2. Has regularly occurring menstrual periods of ≤ 14 days duration with a cycle of 21 to
             38 days from the start of 1 menstrual period until the start of the next, by
             participant history for at least 3 months prior to the first screening visit.

          3. Has a diagnosis of uterine fibroids that is confirmed by a transvaginal and/or
             transabdominal ultrasound performed during the screening period.

          4. Has heavy menstrual bleeding associated with uterine fibroids as evidenced by an MBL
             of ≥ 160 milliliter (mL) during 1 cycle or ≥ 80 mL per cycle for 2 menstrual cycles as
             measured by the alkaline hematin method during the screening period.

        Key Exclusion Criteria:

          1. Has transvaginal and/or transabdominal ultrasound during the screening period
             demonstrating pathology other than uterine fibroids that could be responsible for or
             contributing to the patient's heavy menstrual bleeding.

          2. Has known rapidly enlarging uterine fibroids in the opinion of the investigator.

          3. Has a weight that exceeds the weight limit of the DXA scanner or has a condition that
             precludes an adequate DXA measurement at the lumbar spine and proximal femur.

          4. Has a history of or currently has osteoporosis, or other metabolic bone disease,
             hyperparathyroidism, hyperprolactinemia, hyperthyroidism, anorexia nervosa, or low
             traumatic (from the standing position) or atraumatic fracture (toe, finger, skull,
             face and ankle fractures are allowed). A history of successfully treated
             hyperparathyroidism, hyperprolactinemia, or hyperthyroidism is allowed if the
             participant's bone mineral density is within normal limits.

          5. Has a history of the use of bisphosphonates, calcitonin, calcitriol, ipriflavone,
             teriparatide, denosumab, or any medication other than calcium and vitamin D
             preparations to treat bone mineral density loss.

          6. Has been a participant in an investigational drug or device study within the 1 month
             prior to the first screening visit.
      "
NCT02972658,terminated,"
    as the feeder study (azes) was stopped for futility after an independent assessment, this trial
    was also stopped.
  ",0,phase 3,"[""alzheimer's disease""]","[""['G30.8', 'G30.9', 'G30.0', 'G30.1']""]",['lanabecestat'],['CC#CC1=CC(=CN=C1)C2=CC3=C(CC4(C35N=C(C(=N5)N)C)CCC(CC4)OC)C=C2'],"
        Inclusion Criteria:

          -  Participants previously enrolled in AMARANTH (NCT02245737) who meet eligibility
             criteria for delayed-start I8D-MC-AZFD.

        Exclusion Criteria:

          -  Participants who participate in AMARANTH (NCT02245737) who develop new conditions
             precluding them from enrolling into I8D-MC-AZFD.
      "
NCT02848326,completed,,1,phase 2/phase 3,"['migraine, with or without aura']","[""['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']""]","['atogepant', 'placebo-matching atogepant']",['CC1C(CC(C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(CC4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=C(C=CC(=C6F)F)F'],"
        Inclusion Criteria:

          -  Has at least a 1-year history of migraine with or without aura

          -  Age of the patient at the time of migraine onset < 50 years

          -  History of 4 to 14 migraine days (migraine/probable migraine headache days) per month
             on average in the 3 months prior to Visit 1 in the Investigator's judgment

          -  Demonstrated compliance with e-diary

        Exclusion Criteria:

          -  Has a history of migraine accompanied by diplopia or decreased level of consciousness
             and retinal migraine

          -  Has a current diagnosis of chronic migraine, new persistent daily headache, trigeminal
             autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy

          -  Difficulty distinguishing migraine headache from other headaches

          -  Has a history of malignancy in the prior 5 years, except for adequately treated basal
             cell or squamous cell skin cancer, or in situ cervical cancer

          -  Has a history of gastric or small intestinal surgery, or has a disease that causes
             malabsorption

          -  Has a history of hepatitis within previous 6 months

          -  Usage of opioids or barbiturates > 2 days/month, triptans or ergots ≥ 10 days/month,
             or simple analgesics (eg, aspirin, non-steroidal anti-inflammatory drugs [NSAIDs],
             acetaminophen) ≥ 15 days/month in the 3 months prior to Visit 1

          -  Pregnant or nursing females
      "
NCT03201900,completed,,1,phase 3,['partial onset seizures'],"[""['G40.011', 'G40.019', 'G40.001', 'G40.009']""]",['e2007'],['C1=CC=C(C=C1)N2C=C(C=C(C2=O)C3=CC=CC=C3C#N)C4=CC=CC=N4'],"
        Inclusion Criteria:

          -  Be considered reliable and willing to be available for the study period and are able
             to record seizures and report adverse events (AEs) himself/herself or have a caregiver
             who can record seizures and report AEs for them

          -  Participants who are newly diagnosed or recurrent epilepsy and have experienced at
             least 2 unprovoked seizures separated by a minimum of 24 hours in the 1 year prior to
             the Pretreatment Phase

          -  Participants who have excluded the progressive central nervous system (CNS)
             abnormality occurring seizures by computed tomography (CT) or magnetic resonance
             imaging (MRI)

          -  Participants who have had a diagnosis of epilepsy with partial seizures with or
             without secondarily generalized seizures according to the International League Against
             Epilepsy (ILAE) Classification of Epileptic Seizures (1981). Diagnosis should have
             been established by clinical history and an electroencephalogram (EEG) that is
             consistent with localization-related epilepsy; normal interictal EEGs will be allowed
             provided that the participant meets the other diagnosis criterion (ie, clinical
             history)

        Exclusion Criteria:

          -  Participants who present only simple partial seizures without motor signs

          -  Participants who have seizure clusters where individual seizures cannot be counted

          -  Participants who present or have a history of Lennox-Gastaut syndrome

          -  Participants who have a history of status epilepticus

          -  Participants who have a history of psychogenic non-epileptic seizures

          -  Participants who have a history of suicidal ideation/attempt

          -  Participants who present clinically problematic psychological or neurological
             disorder(s)

          -  Evidence of clinically significant disease

          -  Evidence of clinically significant active hepatic disease

          -  A prolonged time from the beginning of the QRS complex to the end of the T wave (QT)
             interval corrected for heart rate

          -  Participants who have a history of receiving any AEDs (except for AEDs used as rescue
             treatment), antipsychotics or anti-anxiety drugs within 12 weeks prior to the
             Pretreatment Phase

          -  Participants who have not used a stable dose of antidepressant in the 12 weeks

          -  Participants who have a history of any type of surgery for brain or central nervous
             system within 1 year

          -  Participants who have a history of receiving any AED (including AED used as rescue
             treatment) for more than 2 weeks

          -  Participants who have used intermittent rescue benzodiazepines on 2 or more occasions
             within 4 weeks

          -  Participants who have a history of receiving any AED polytherapy

          -  Participants who experienced treatment with perampanel

          -  Participants who have had non-constant ketogenic diet within 4 weeks

          -  Participants who have a history of drug or alcohol dependency or abuse

          -  Participants who have had multiple drug allergies or a severe drug reaction to an
             AED(s)

          -  Females who are breastfeeding or pregnant in the Pretreatment Phase (as documented by
             a positive beta-human chorionic gonadotropin [β-hCG] test)

          -  Females of childbearing potential who:

               -  Within 28 days before the start of the Pretreatment Phase, did not use a highly
                  effective method of contraception, which includes any of the following:

                    -  total abstinence (if it is their preferred and usual lifestyle);

                    -  an intrauterine device or intrauterine hormone-releasing system (IUS);

                    -  a contraceptive implant;

                    -  an oral contraceptive (with additional barrier method) (Participant must be
                       on a stable dose of the same oral contraceptive product for at least 28 days
                       before dosing and throughout the study and for 28 days after study drug
                       discontinuation);

                    -  have a vasectomized partner with confirmed azoospermia

               -  Do not agree to use a highly effective method of contraception (as described
                  above) throughout the entire study period and for 28 days after study drug
                  discontinuation

          -  Participants who have participated in a study involving administration of an
             investigational drug or device within 4 weeks before Visit 1, or within approximately
             5 half-lives of the previous investigational compound, whichever is longer
      "
NCT02459080,completed,,1,phase 3,['chronic obstructive pulmonary disease (copd)'],"[""['G91.1', 'I42.1', 'N11.1', 'J05.0', 'P28.42', 'G47.33', 'J44.9']""]","['td-4208', 'placebo']",['CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N'],"
        Inclusion Criteria:

          -  Subject is a male or female subject 40 years of age or older

        Exclusion Criteria:

          -  Females who are pregnant, lactating, breast-feeding or planning to become pregnant
             during the study
      "
NCT02453386,terminated,"
    new safety information
  ",0,phase 3,"[""idiopathic parkinson's disease""]","[""['G20']""]","['tozadenant', 'placebo']",['CC1(CCN(CC1)C(=O)NC2=NC3=C(C=CC(=C3S2)N4CCOCC4)OC)O'],"
        Inclusion Criteria:

          -  Patient understands study requirements and has given his/her written informed consent
             on an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved
             consent form.

          -  Parkinson's disease diagnosis consistent with UK Parkinson's Disease Society Brain
             Bank Diagnostic criteria

          -  Minimum of 3 years since diagnosis.

          -  Meet Hoehn and Yahr PD stage

          -  Good response to levodopa

          -  Stable regimen of anti-PD medications

          -  Patients must have been taking a levodopa-containing anti-PD medication continuously
             for at least the previous 12 months

          -  Patient has documented a minimum amount of Off time.

          -  If of childbearing potential (male and female) must use an acceptable method of
             contraception

        Exclusion Criteria:

          -  Previous tozadenant study participation

          -  Current or recent participation in another study.

          -  Secondary or atypical parkinsonism

          -  Neurosurgical intervention for PD

          -  Patient is taking apomorphine, budipine, istradefylline, tolcapone, or DUOPA™/Duodopa®

          -  Treatment with excluded medications

          -  Untreated or uncontrolled hyperthyroidism or hypothyroidism

          -  Clinically significant out-of-range laboratory

          -  MMSE out of range

          -  Current episode of major depression (stable treatment for depression is permitted).

          -  Recent suicide attempt or suicidal ideation type 4 or type 5 of the Columbia-Suicide
             Severity Rating Scale (C-SSRS)

          -  Women lactating or pregnant

          -  Hypersensitivity to any components of tozadenant or excipients

          -  Abnormal findings on the physical or neurological examination, or medical history that
             would make the patient unsuitable for the study

          -  History of hepatitis or cholangitis
      "
NCT01911975,completed,,1,phase 3,['small fiber neuropathy'],"[""['G58.0', 'G61.1', 'A52.15', 'G60.3', 'G61.82', 'H46.2', 'H46.3']""]","['lacosamide', 'placebo']",['CC(=O)NC(COC)C(=O)NCC1=CC=CC=C1'],"
        Inclusion Criteria:

          1. Male and/or female subjects between the ages of 18 and 80 years.

          2. Presence of a clinical diagnosis of Small Fiber Neuropathy (SFN), with at least 2 of
             the following clinical symptoms:

               -  Burning feet.

               -  Allodynia.

               -  Diminished pain and/or temperature sensation.

               -  Dry eyes or mouth.

               -  Orthostatic dizziness.

               -  Bowel disturbances (constipation, diarrhea, gastroparesis).

               -  Urinary disturbances.

               -  Sweat changes (hyper-/hypohidrosis).

               -  Visual accommodation problems and/or blurred vision.

               -  Hot flashes/palpitations.

               -  Impotence, diminished ejaculation or lubrication.

          3. In addition to the clinical diagnosis of SFN, presence of confirmed abnormality on
             intra-epidermal nerve fiber density evaluation (IENFD) and/or Quantitative Sensory
             Testing (QST) and a mutation in the SCN9A gene, confirmed by sequencing. Where
             possible, in vitro confirmation of the functionality of the mutation should have been
             performed and documented.

          4. Presence of pain due to SFN for at least 3 months prior to Screening and an average
             self-reported pain score of at least 3 during this time.

          5. If on analgesic medication to manage pain due to SFN, subject must have stable
             analgesic medication for a minimum of 30 days prior to the start of the study and
             should continue with the same regimen throughout the study.

          6. Evidence of a personally signed and dated informed consent document indicating that
             the subject (or a legal representative) has been informed of all pertinent aspects of
             the study.

          7. Subjects who are willing and able to comply with scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

        Exclusion Criteria:

          1. Subjects with predominantly signs of large nerve fiber involvement, clinically
             significant abnormal nerve conduction studies.

          2. History or presence of illnesses known to cause SFN (excluding diabetes mellitus).

          3. Subjects with other severe pain conditions which may impair the self-assessment of
             pain due to SFN.

          4. Any condition possibly affecting drug intake and absorption.

          5. History of known alcohol, analgesic or illicit drug abuse within 12 months of
             Screening.

          6. Subjects taking medications with activity at sodium channels. These medications are
             prohibited until the end of the study period and require a washout period of at least
             5 half lives (90 days for capsaicin patches) prior to the Screening visit.

          7. 12-lead ECG demonstrating QTcF (Fridericia's correction) >450 or a QRS interval >120
             msec at Screening. If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should
             be repeated two more times and the average of the three QTcF values should be used to
             determine the subject's eligibility.

          8. Severe renal impairment (creatinine clearance ≤ 30 mL/min).

          9. Treatment with an investigational drug within 30 days or 5 half-lives preceding the
             first dose of study medication.

         10. Participation in other studies during the period of current study participation, or
             has planned surgery during the course of the study.

         11. Pregnant females; breastfeeding females; females of childbearing potential not using
             effective contraception or not agreeing to continue effective contraception for at
             least 28 days after the last dose of investigational product.

         12. Other clinically significant or unstable, or severe acute or chronic medical or
             psychiatric/psychological condition or laboratory abnormality that may increase the
             risk associated with study participation or investigational product administration or
             may interfere with the interpretation of study results and, in the judgment of the
             Investigator, would make the subject inappropriate for entry into this study.

         13. In the case of incidental findings the patient and his/her treating physician will be
             informed and asked to undertake action if necessary. If a patient does not want to be
             informed about possible incidental findings, nor wants his treating physician to be
             informed, he or she cannot participate in this study.
      "
NCT02165826,completed,,1,phase 3,['chronic obstructive pulmonary disease (copd)'],"[""['G91.1', 'I42.1', 'N11.1', 'J05.0', 'P28.42', 'G47.33', 'J44.9']""]","['roflumilast', 'roflumilast placebo', 'standard of care copd treatment']",['C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F'],"
        Inclusion Criteria:

          1. In the opinion of the investigator, the participant is capable of understanding and
             complying with protocol requirements.

          2. The participant or, when applicable, the participant's legally acceptable
             representative signs and dates a written, informed consent form and any required
             privacy authorization prior to the initiation of any study procedures.

          3. Has a history of chronic obstructive pulmonary disease (COPD) (according to Global
             Initiative for Chronic Obstructive Lung Disease (GOLD) 2013) for at least 12 months
             prior to Screening (Visit V0) associated with chronic productive cough for 3 months in
             each of the 2 years prior to Screening (Visit V0, with other causes of productive
             cough excluded).

          4. Shows a post-bronchodilator forced expiratory volume in 1 second (FEV1) of ≤50% of
             predicted.

          5. Shows an FEV1/forced vital capacity (FVC) ratio (post-bronchodilator) <70%.

          6. Has at least one documented COPD exacerbation within one year prior to Screening
             (Visit V0).

          7. Is on standard of care COPD maintenance treatment including Long Acting β2-Agonist
             (LABAs), long-acting anticholinergics, or any combination thereof taken on a constant
             daily dose within 12 weeks prior to Screening (Visit V0).

          8. Must be a former smoker (defined as smoking cessation at least one year ago) or
             current smoker both with a smoking history of at least 10 pack years.11

          9. Is male or female and aged 40 or older.

         10. A female participant of childbearing potential who is sexually active with a
             nonsterilized male partner agrees to use routinely adequate contraception from signing
             of informed consent throughout the duration of the study.

        Exclusion Criteria:

        Criteria affecting the read-out parameters of the study

          1. Has a COPD exacerbation ongoing at the Screening (Visit V0), or has a COPD
             exacerbation between V0 and V1.

          2. Has a lower respiratory tract infection not resolved 4 weeks prior to Screening (Visit
             V0).

          3. Has a diagnosis of asthma and/or other relevant lung disease (eg, history of primary
             bronchiectases, cystic fibrosis, bronchiolitis, lung resection, lung cancer,
             interstitial lung disease [eg, fibrosis, silicosis, sarcoidosis], or active
             tuberculosis).

          4. Has a known α1-antitrypsin deficiency.

          5. Has taken roflumilast within 6 months of Screening (Visit V0).

             Criteria within ethical considerations in terms of general health

          6. Has clinically relevant abnormal laboratory values suggesting an undiagnosed disease
             requiring further clinical evaluation (as assessed by the investigator).

          7. Has a history of severe psychiatric or neurological disorders.

          8. Has a history of depression associated with suicidal ideation or behavior.

          9. Has congestive heart failure severity grade IV according to New York Heart Association
             (NYHA) Functional Classification.

         10. Has hemodynamically significant cardiac arrhythmias or heart valve deformations.

         11. Has computed tomography (CT) or chest x-ray findings indicating an acute pulmonary
             disease other than COPD (eg, tuberculosis, severe bronchiectasis, tumors).

         12. Has severe immunological diseases (eg, known human immune deficiency virus (HIV)
             infection, multiple sclerosis, lupus erythematosus, progressive multifocal
             leukoencephalopathy).

         13. Has liver impairment Child-Pugh B or C and/or active viral hepatitis.

         14. Has severe acute infectious diseases (eg, tuberculosis, or acute hepatitis).

         15. Has a history of malignant disease (except basal cell carcinoma) within 5 years before
             Screening (Visit V0).

         16. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol
             abuse within one year before Screening (Visit V0).

         17. Has a history of hypersensitivity or allergies to roflumilast or rescue medication or
             ingredients thereof, or any other contraindication for the use thereof.

         18. If female, the participant is pregnant or lactating or intending to become pregnant
             before, during, or within 12 weeks after participating in this study; or intending to
             donate ova during such time period.

         19. Intends to donate blood, organs, or bone marrow during the course of the study.

         20. Has received any investigational compound within 30 days prior to Screening (Visit
             V0), is currently participating in another interventional clinical study, or has been
             previously enrolled in this study.

         21. Is suspected to be unable or unwilling to comply with study procedures (eg, language
             problems, psychological disorders, number and timing of visits at the center).

         22. Suffers from any concomitant disease that might interfere with study procedures or
             evaluations.

         23. Is required to take excluded medications.

         24. Is an immediate family member, study center employee, or is in a dependent
             relationship with a study site employee who is involved in conduct of this study (eg,
             spouse, parent, child, sibling), or may consent under duress.
      "
NCT02161185,terminated,"
    study terminated due to slow enrollment. there were no safety concerns.
  ",0,phase 3,['epilepsy'],"[""['G40.803', 'G40.804', 'G40.911', 'G40.919', 'G40.B11', 'G40.B19', 'G40.801']""]",['usl261'],['CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F'],"
        Inclusion Criteria:

          1. Has a competent, adult caregiver(s) who is able to recognize and observe the subject's
             seizure cluster episodes

          2. Has an established diagnosis of partial or generalized epilepsy that includes all the
             following:

               -  A documented history of seizure clusters lasting a minimum of 10 minutes, seizure
                  cluster pattern is observable, stereotyped, and recognizably different from the
                  subject's other non-cluster seizure activity (if any)

               -  A second seizure in the seizure cluster typically occurs within 6 hours from the
                  time of recognition

               -  A seizure cluster pattern composed of multiple (≥ 2) partial or generalized
                  seizures

               -  A seizure cluster pattern established >3 months before Visit 1

               -  A frequency of ≥ 3 stereotyped seizure clusters during the year before Visit 1

               -  At least 1 stereotyped seizure cluster occuring ≤ 4 months before Visit 1

          3. Currently on a stable regimen of AED(s) that includes a benzodiazepine

          4. Weight is 40 kg to 125 kg, inclusive

        Exclusion Criteria:

          1. Has a neurological disorder that is likely to progress in the next year

          2. Has a severe chronic cardio-respiratory disease

          3. Has a psychogenic, non-epileptic seizure(s) within the 5 years before Visit 1

          4. Has a history of their stereotypical seizure cluster progressing to status epilepticus
             within 2 years before Visit 1

          5. Has a history of acute narrow-angle glaucoma

          6. Has had active suicidal plan/intent or active suicidal thoughts in the 6 months before
             Visit 1 or a suicide attempt in the past 5 years
      "
NCT02168842,completed,,0,phase 3,['parkinson disease'],"[""['G20']""]","['isradipine', 'placebo (for isradipine)']",['CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC'],"
        Inclusion Criteria:

          -  Subjects with early idiopathic PD (presence of at least two out of three cardinal
             manifestations of PD). If tremor is not present, subjects must have unilateral onset
             and persistent asymmetry of the symptoms

          -  Age equal or greater than 30 years at the time of diagnosis of PD

          -  Hoehn and Yahr stage less than or equal to 2

          -  Diagnosis of PD less than 3 years.

          -  Currently NOT receiving dopaminergic therapy (levodopa, dopamine agonist or MAO-B
             inhibitors) and NOT projected to require PD symptomatic therapy for at least 3 months
             from the baseline visit

          -  Use of amantadine and/or anticholinergics will be allowed provided that the dose is
             stable for 8 weeks prior to the baseline visit

          -  If subject is taking any central nervous system acting medications (e.g.,
             benzodiazepines, antidepressants, hypnotics) regimen must be stable for 30 days prior
             to the baseline visit

          -  Women of childbearing potential may enroll but must use a reliable measure of
             contraception and have a negative serum pregnancy test at the screening visit

        Exclusion Criteria:

          -  Subjects with a diagnosis of an atypical Parkinsonism

          -  Subjects unwilling or unable to give informed consent

          -  Exposure to dopaminergic PD therapy within 60 days prior to baseline visit or for
             consecutive 3 months or more at any point in the past

          -  History of clinically significant orthostatic hypotension or presence of orthostatic
             hypotension at the screening or baseline visit defined as greater than or equal to 20
             mmHg change in systolic BP and greater than or equal to 10 mmHg change in diastolic BP
             from sitting position to standing after 2 minutes, or baseline sitting BP less than
             90/60

          -  History of congestive heart failure

          -  Clinically significant bradycardia

          -  Presence of 2nd or 3rd degree atrioventricular block or other significant ECG
             abnormalities that in the investigator's opinion would compromise participation in
             study

          -  Clinically significant abnormalities in the Screening Visit laboratory studies or ECG

          -  Presence of other known medical or psychiatric comorbidity that in the investigator's
             opinion would compromise participation in the study

          -  Prior exposure to isradipine or other dihydropyridine calcium channel blockers within
             6 months of the baseline visit

          -  Subjects on greater than 2 concomitant antihypertensive medications. If a history of
             hypertension, then a maximum of 2 other antihypertensive agents will be allowed
             provided that the dosages of concomitant anti HTN therapy can be reduced/adjusted
             during the study based on the BP readings in consultation with the subject's primary
             care provider or cardiologist. Use of any concomitant calcium channel blockers will
             not be allowed from the baseline visit and for the duration of the study

          -  Use of grapefruit juice, ginkgo biloba, St. John's wort or ginseng will be prohibited
             starting from the screening visit and for the duration of the study (as they interfere
             with the metabolism of isradipine)

          -  Use of clarithromycin, telithromycin and erythromycin will be prohibited starting from
             the screening visit and for the duration of the study as the combination of
             clarithromycin, telithromycin or erythromycin and calcium channel blockers has been
             reported to be associated with increased risk of kidney and heart injury

          -  Presence of cognitive dysfunction defined by a Montreal Cognitive assessment (MoCA)
             score of less than 26 at screening

          -  Subjects with clinically significant depression as determined by a Beck Depression
             Inventory II (BDI) score greater than 15 at the screening visit

          -  History of exposure to typical or atypical antipsychotics or other dopamine blocking
             agents within 6 months prior to the baseline visit

          -  History of use of an investigational drug within 30 days prior to the screening visit

          -  History of brain surgery for PD

          -  Allergy/sensitivity to isradipine or its matching placebo or their formulations

          -  Pregnant or lactating woman
      "
NCT02691494,completed,,1,phase 3,"['uterine fibroids', 'heavy menstrual bleeding']","[""['G43.831', 'G43.839', 'G43.821', 'G43.829', 'N94.9', 'N94.89']""]","['elagolix', 'placebo for estradiol/norethindrone acetate', 'estradiol/norethindrone acetate', 'placebo for elagolix']","['CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)O)C4=C(C(=CC=C4)OC)F', 'Status: 400', 'Status: 503']","
        Inclusion Criteria:

          -  Subject is a premenopausal female at the time of Screening.

          -  Subject has a diagnosis of uterine fibroids documented by a pelvic ultrasound
             (transabdominal ultrasound/transvaginal ultrasound).

          -  Subject has heavy menstrual bleeding associated with uterine fibroids as evidenced by
             menstrual blood loss > 80 mL during each of two screening menses as measured by the
             alkaline hematin method.

          -  Subject has negative urine and/or serum pregnancy test in Screening and just prior to
             first dose.

          -  Subject has an adequate endometrial biopsy performed during Screening, the results of
             which show no clinically significant endometrial pathology.

        Exclusion Criteria:

          -  Subject has screening pelvic ultrasound or saline infusion sonohysterography results
             that show a clinically significant gynecological disorder.

          -  Subject has history of osteoporosis or other metabolic bone disease.

          -  Subject has clinically significant abnormalities in clinical chemistry, hematology, or
             urinalysis.

          -  Subject has a history of major depression or post-traumatic stress disorder (PTSD)
             within 2 years of screening, OR a history of other major psychiatric disorder at any
             time (e.g., schizophrenia, bipolar disorder).

          -  Subject is using any systemic corticosteroids for over 14 days within 3 months prior
             to Screening or is likely to require treatment with systemic corticosteroids during
             the course of the study. Over the counter and prescription topical, inhaled,
             intranasal or injectable (for occasional use) corticosteroids are allowed.
      "
NCT03162055,completed,,0,phase 3,['chronic obstructive pulmonary disease copd'],"[""['G91.1', 'I42.1', 'N11.1', 'J05.0', 'P28.42', 'G47.33', 'J44.9']""]","['glycopyrronium/formoterol fumarate', 'umeclidinium/vilanterol']","['Status: 400', 'Status: 400']","
        Inclusion criteria:

          -  Age 40-95 years at screening

          -  Current or former smoker with a history of at least 10 pack-years of cigarette smoking

          -  Current clinical diagnosis of COPD, with COPD symptoms > 1 year prior to screening, as
             defined by GOLD criteria or other current guidelines

          -  COPD Severity defined by FEV1/FVC ratio <0.70 and FEV1 <80% of predicted normal value
             at screening and at randomisation

          -  COPD treatment with rescue medication only, or stable dose of maintenance monotherapy
             (LAMA, LABA or ICS), or stable dose of double maintenance therapy (LAMA/LABA or
             ICS/LABA), for one month prior to screening

          -  COPD Assessment Test (CAT) score ≥10 at randomisation

          -  Documentation of a chest x-ray (as per local practice) or computed tomography (CT)
             within 6 months prior to screening, with no clinically significant pulmonary
             abnormalities other than related to COPD

        Exclusion criteria:

          -  Respiratory disease other than COPD, including:

          -  Current diagnosis of asthma

          -  Alpha-1 Antitrypsin Deficiency as the cause of COPD

          -  Other respiratory disorders and conditions as listed in the protocol

          -  Severe COPD exacerbation (resulting in hospitalisation) not resolved within 8 weeks
             prior to screening, or moderate exacerbation not resolved within 4 weeks, or during
             screening

          -  Pneumonia or lower respiratory tract infection that required antibiotics within 8
             weeks prior to screening, or during screening.

          -  Significant diseases or conditions other than COPD which may put the patient at risk,
             or influence the results of the study or the patient's ability to participate,
             including cardiac disease, advanced renal disease, and cancer that has not been in
             complete remission for at least 5 years.

          -  Patients who have needed additions or alterations to their usual maintenance therapy
             for COPD due to worsening symptoms within 1 month prior to and during screening

          -  Treatment with depot corticosteroids within 6 weeks, or other systemic corticosteroids
             within 4 weeks, prior to screening. (Patients maintained on an equivalent of 5 mg
             prednisone per day for at least 3 months prior to screening are allowed.)
      "
NCT02755597,completed,,1,phase 3,['relapsed/refractory multiple myeloma'],"[""['G35', 'M15.3', 'M67.49', 'M89.09', 'M89.59', 'M94.29', 'Q78.6']""]","['placebo', 'bortezomib', 'dexamethasone', 'venetoclax']","['B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C', 'CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C']","
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance score less than or equal to 2

          -  Participant has documented relapsed or progressive multiple myeloma on or after any
             regimen or who are refractory to the most recent line of therapy. Relapsed myeloma is
             defined as previously treated myeloma that progresses and requires initiation of
             salvage therapy, but does not meet the criteria for refractory myeloma. Refractory
             myeloma is defined as disease that is non responsive (failure to achieve minimal
             response or development of progressive disease [PD]) while on primary or salvage
             therapy, or progresses within 60 days of last therapy.

          -  Participant must have received prior treatment with at least one, but no more than
             three, prior lines of therapy for multiple myeloma. A line of therapy consists of
             greater than or equal to 1 complete cycle of a single agent, a regimen consisting of
             combination of several drugs, or a planned sequential therapy of various regimens.

          -  Prior treatment with bortezomib or other proteasome inhibitor is allowed, provided ALL
             of the following criteria are met: Disease is NOT refractory to any proteasome
             inhibitor, defined as no disease progression (i.e., PD, per IMWG or European Society
             for Blood and Marrow Transplantation [EBMT] criteria) while receiving proteasome
             inhibitor therapy or within 60 days after the last dose, AND best response achieved
             with any proteasome inhibitor therapy (alone or in combination) was at least a PR, AND
             participant did not discontinue any proteasome inhibitor due to intolerance or greater
             than or equal to Grade 3 related toxicity.

          -  Participant has measurable disease at Screening, defined as at least one of the
             following: Serum M-protein greater than or equal to 0.5 g/dL, OR Urine M-protein
             greater than or equal to 200 mg in 24-hours, OR serum immunoglobulin free light chain
             (FLC) greater than or equal to 10 mg/dL provided serum FLC ratio is abnormal.

        Exclusion Criteria:

          -  Participant is refractory to any proteasome inhibitor, defined as progression on or
             within 60 days of the last dose of a proteasome inhibitor-containing regimen.

          -  Participant has had prior treatment with proteasome inhibitor within 60 days prior to
             first dose of study drug.

          -  Participant has any of the following conditions:

        Non-secretory multiple myeloma, active plasma cell leukemia i.e., either 20% of peripheral
        white blood cells or greater than 2.0 X 10^9/liter (L) circulating plasma cells by standard
        differential, waldenstrom's macroglobulinemia, amyloidosis, POEMS syndrome (polyneuropathy,
        organomegaly, endocrinopathy, monoclonal protein, and skin changes), known Human
        Immunodeficiency Viral (HIV) infection, active hepatitis B or C infection based on blood
        screen tests, significant cardiovascular disease, including uncontrolled angina, severe or
        uncontrolled arrhythmia, recent myocardial infarction within 6 months of randomization, or
        congestive heart failure New York Heart Association (NYHA) Class greater than or equal to
        3, Major surgery within 4 weeks prior to randomization, acute infections requiring
        parenteral therapy (antibiotic, antifungal, or antiviral) within 14 days prior to
        randomization, peripheral neuropathy greater than or equal to Grade 3 or greater than or
        equal to Grade 2 with pain within 2 weeks prior to randomization, uncontrolled diabetes or
        uncontrolled hypertension within 14 days prior to randomization, any other medical
        condition that, in the opinion of the Investigator, would adversely affect the
        participant's participation in the study

          -  Participant has a history of other active malignancies, including myelodysplastic
             syndrome (MDS), within the past 3 years prior to study entry, with the following
             exceptions: Adequately treated in situ carcinoma of the cervix uteri or the breast,
             basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin,
             prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific Antigen
             (PSA) levels off treatment, previous malignancy with no evidence of disease confined
             and surgically resected (or treated with other modalities) with curative intent and
             unlikely to impact survival during the duration of the study

          -  If participant had prior allogeneic stem cell transplant (SCT), participant has
             evidence of ongoing graft-versus-host disease (GvHD).
      "
NCT02750306,completed,,1,phase 3,"['sleep initiation and maintenance disorders', 'alzheimer disease']","[""['Y93.E9', 'Y93.H9']"", ""['G30.8', 'G30.9', 'G30.0', 'G30.1']""]","['suvorexant', 'placebo']",['CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl'],"
        Inclusion Criteria:

          -  Diagnosis of probable Alzheimer's disease based on either a) the National Institute on
             Aging - Alzheimer's Association (NIA-AA) criteria or b) the Diagnostic and Statistical
             Manual of Mental Disorders, 5th Edition, (DSM-5) criteria for AD.

          -  Have sleep complaints that meet DSM-5 criteria for a diagnosis of insomnia (e.g.,
             difficulty initiating or maintaining sleep, and/or early morning awakenings with
             inability to return to sleep for at least 3 nights per week for ≥ the past 3 months
             prior to study start, despite adequate opportunity for sleep) based on the
             investigator's judgment and by the participant's sleep history, as assessed by the
             sleep items on the Insomnia Diagnostic Interview and Sleep History assessments.

          -  Be willing to stay overnight in a sleep laboratory and must be willing to stay in bed
             for at least 8 hours for PSG testing

          -  Regular bedtime is between 8 pm and 1 am and is willing to maintain it for the
             duration of the trial

          -  Be able and willing to wear an activity/sleep watch on the wrist throughout the day
             and night

          -  Based on the investigator's judgment the participant should: a) be able to speak,
             read, and understand the language of the trial staff and the informed consent form; b)
             possess the ability to respond verbally to questions, follow instructions, and
             complete study assessments; c) be able to adhere to dose and visit schedules.

          -  Have a reliable and competent trial partner (e.g., spouse, family member, or other
             caregiver) who:

          -  a) Signs their own informed consent, after the trial has been explained to them, and
             before Screening assessments;

          -  b) Is not diagnosed with dementia;

          -  c) Resides with the participant overnight and has a close relationship with the
             participant (defined as daily face-to-face contact, at least 15 waking hours a week
             for at least 3 months prior to Visit 1);

          -  d) Accompanies the participant to and from trial visits and stays overnight at the
             sleep laboratory for the 3 PSG visits;

          -  e) Assumes responsibility for trial medication procedures (e.g., witnessing and/or
             helping to administer trial medication, assessing compliance), for completion of the
             sleep e-diary each morning, and oversight of the activity/sleep watch worn throughout
             the trial;

          -  f) Answers questions regarding the trial partner's sleep quality and trial partner's
             distress related to the subject's behaviors.

          -  If female, not of childbearing potential as indicated by one of the following: has
             reached natural menopause, defined as:

          -  a) ≥45 years of age with either: ≥12 months of spontaneous amenorrhea OR ≥6 months of
             spontaneous amenorrhea with serum follicle stimulating hormone (FSH) levels > 40 IU/L
             as determined by the central laboratory

          -  b) has had a hysterectomy;

          -  c) has had bilateral tubal ligation; or

          -  d) has had a bilateral oophorectomy (with or without a hysterectomy) and greater than
             6 weeks have passed since the surgery

          -  Be willing to provide a blood sample for Apolipoprotein E (APOE) genotyping

        Exclusion Criteria:

          -  Apnea Hypopnea Index (AHI) score > 30 or Periodic Leg Movements with Arousal per hour
             of Sleep (PLMA) > 30.

          -  Resides in a nursing home (or similar institutional facility); assisted-living
             facilities are not excluded if full-time nursing care is not required.

          -  Has a Modified Hachinski Ischemia Scale (MHIS) Score > 4 at Screening (i.e., evidence
             of vascular dementia)

          -  Has a known history of recent (or past) stroke that in the investigator's opinion
             confounds the diagnosis of either AD or insomnia

          -  Has evidence of a clinically relevant neurological disorder other than the disease
             being studied (i.e., probable AD) at Screening, including but not limited to: vascular
             dementia, parkinsonism, frontotemporal dementia, Huntington's disease, amyotrophic
             lateral sclerosis, multiple sclerosis, progressive supranuclear palsy, neurosyphilis,
             dementia with Lewy bodies, other types of dementia, mental retardation, hypoxic
             cerebral damage, cognitive impairment due to other disorders, or history of head
             trauma with loss of consciousness that either led to persistent cognitive deficits or
             in the opinion of the investigator confounds the diagnosis of either AD or insomnia.

          -  Has a history of seizures or epilepsy within the last 5 years before study start

          -  Has a history or diagnosis of any of the following conditions, in the opinion of the
             investigator:

          -  Narcolepsy

          -  Cataplexy (familial or idiopathic)

          -  Circadian Rhythm Sleep Disorder

          -  Parasomnia including nightmare disorder, sleep terror disorder, sleepwalking disorder

          -  Rapid eye movement (REM) behavior disorder

          -  Significant degree of sleep-related Breathing Disorder (i.e., AHI >30, and/or use of
             Continuous Positive Airway Pressure [CPAP] or Bilevel Positive Airway Pressure
             [BIPAP])

          -  Periodic Limb Movement Disorder

          -  Restless Legs Syndrome

          -  Primary Hypersomnia

          -  Excessive Daytime Sleepiness (EDS) characterized by uncharacteristic chronic and
             persistent sleepiness throughout the day

          -  Has a clinically significant movement disorder, such as akinesia, that would affect
             the activity/sleep watch differentiation of sleep and wakefulness

          -  In the opinion of the investigator, has difficulty sleeping primarily due to a
             confounding medical condition. NOTE: ""Medical Conditions"" may include chronic pain
             syndromes, chronic migraine, cardiac disease, nocturia (> 3 times/night), asthma,
             gastroesophageal reflux disease (GERD), or hot flashes.

          -  Has evidence of a current episode of major depression based on investigator's
             judgment. Major depression in remission is not exclusionary.

          -  Has any of the following based on clinician interview and DSM-5 criteria:

          -  Lifetime history of bipolar disorder, a primary psychotic disorder, or posttraumatic
             stress disorder; or,

          -  A psychiatric condition requiring treatment with a prohibited medication; or,

          -  Other psychiatric condition that, in the investigator's opinion, would interfere with
             the subject's ability to participate in the study.

          -  Is at imminent risk of self-harm, based on clinical interview and responses on the
             Columbia-Suicide Severity Rating Scale (C-SSRS), or of harm to others in the opinion
             of the investigator. Subjects must be excluded if they report suicidal ideation with
             intent, with or without a plan or method in the past 2 months or suicidal behavior in
             the past 6 months.

          -  Has a history of alcoholism or drug dependency/abuse within the last 5 years of study
             start

          -  Has a recent history (within the 6 months prior to Screening) of regular consumption
             (3 or more days per week) of either:

          -  More than 2 alcoholic beverages per day or alcohol consumption within 3 hours prior to
             bedtime

          -  More than > 600 mg caffeine a day (e.g., 4 standard 8-ounce cups of brewed coffee, or
             consumes caffeine after 4pm (16:00)

          -  Consumes the equivalent of >15 cigarettes a day and the investigator confirms that the
             participant's insomnia is in part the result of tobacco consumption (e.g.,
             participants unable to refrain from smoking during the night, participants who
             interrupt sleep to smoke or use tobacco products, or participants who require a
             cigarette within 30 minutes of waking in the morning).

          -  Has a history of excessive daytime napping (defined as more than 3 hours a day for
             more than 3 days of the week based on trial partner estimates, on average for the past
             4 weeks).

          -  Has a recent or ongoing, uncontrolled, clinically significant medical condition or
             major surgery where participation in the trial would pose a significant medical risk
             to the subject within 3 months of study start, such as: conditions including but not
             limited to diabetes, hypertension, Human Immunodeficiency Virus (HIV) or other
             relevant infections, thyroid or endocrine disease, Chronic Obstructive Pulmonary
             Disease (COPD), delirium, congestive heart failure, angina, cardiac or
             gastrointestinal disease, or renal disease requiring dialysis. Note: controlled
             co-morbid conditions (including diabetes, hypertension, heart disease, etc.) are not
             exclusionary if stable within 3 months of the study start. All concomitant
             medications, supplements, or other substances must be kept as stable as medically
             possible during the trial. Urinary tract infections at study start are not
             exclusionary if adequately treated.

          -  Major surgery including not limited to abdominal, thoracic, cardiac or orthopedic
             surgery, or any procedure requiring general anesthesia

          -  Has a history of hepatitis or liver disease that, in the opinion of the investigator,
             has been active within the 6 months prior to study start.

          -  Has a known allergy or hypersensitivity to suvorexant or to any of the formulation
             components

          -  Has a history of hypersensitivity or idiosyncratic reaction to more than 3 chemical
             classes of drugs, including prescriptions and over-the-counter medications.

          -  Has donated blood products or has had phlebotomy of >300 mL within 8 weeks of study
             start, or intends to donate or receive blood products during participation in the
             study.

          -  History of malignancy within the 5 years prior to study start, except for adequately
             treated basal cell or squamous cell skin cancer, in situ cervical cancer, localized
             prostate cancer, who has undergone potentially curative therapy with no evidence of
             recurrence for >=3 year post-therapy, and who is deemed at low risk for recurrence by
             her/his treating physician.

          -  Is pregnant, is attempting to become pregnant, or is nursing children

          -  Has a Body Mass Index (BMI) > 40 kg/m^2

          -  Is currently participating or has participated in a study with an investigational
             compound or device within 30 days of signing informed consent
      "
NCT02139098,terminated,"
    recruiting problems because of the time expenditure required for participating and the strict
    criteria of inclusion and exclusion
  ",0,phase 3,['insomnia'],"[""['F51.01', 'F51.02', 'F51.03', 'F51.04', 'G47.00', 'G47.09', 'A81.83']""]","['amitriptyline', 'zolpidem', 'amitriptyline', 'placebo']","['CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31', 'CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C', 'CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31']","
        Inclusion Criteria:

          1. age between 18 years to 69 years

          2. fluent in German language

          3. provide written informed consent

          4. ability to understand the explanations and instructions given by the study physician
             and the investigator

        Exclusion Criteria:

          1. Sleep disorders caused by medical factors (e.g. sleep apnea, restless legs syndrome,
             narcolepsy, substance-induced insomnia)

          2. Contraindications to study medication intake according to the information sheet for
             health professionals (Summary of medicinal Product Characteristics, SmPC;
             Fachinformation in Germany) assessed by physical examination (including ECG) and
             medical history

               -  allergies to amitriptyline hydrochloride or any of its ingredients

               -  allergies to zolpidem or any of its ingredients

               -  acute intoxication with alcohol, analgetics, hypnotics or any other psychotropic
                  drug

               -  urinary retention

               -  delirium

               -  untreated closed-angle glaucoma

               -  prostatic hyperplasia

               -  pyloric stenosis

               -  paralytic ilius

               -  suicidal thoughts

               -  liver/ kidney/ pulmonary insufficiency

               -  myasthenia gravis

               -  hypokalemia

               -  bradycardia

               -  coronary heart disease, cardiac arrhythmias, long QT syndrome or other clinically
                  relevant cardiac disorders

               -  increased risk of seizures/ history of seizures

               -  substance dependence syndrome/ history of substance dependence syndrome

          3. Allergies to ingredients of placebo or novel-tasting drink (CS)

          4. currently pregnant (verified by urine pregnancy test) or lactating

          5. patients scoring ≥12 on the Epworth Sleepiness Scale

          6. patients scoring below 8 or above 21 on the Insomnia Severity Index

          7. patients suffering from a mental disorder as verified by the SCID (major depression;
             psychosis; brain injury; substance abuse or dependency syndrome during the last 6
             months before V1)

          8. nicotine consumption > 10 cigarettes/day

          9. unwillingness to refrain from alcohol consumption throughout the study

         10. Concomitant medication interfering with study medication intake due to potential
             interactions (all psychotropic medication including analgetics and muscle relaxants,
             hypericum derivatives; antihypertensives; anti-arrhythmic agents; antibiotics;
             cisaprid; anti-malaria drugs; diuretics; imidazole antifungals; cumarin derivatives;
             antihistaminics; calcium channel blockers; medications that enlarge the QT interval or
             may lead to hypokalemia)

         11. change in concomitant medication regime during the last 2 weeks prior to visit 1 or
             after randomization

         12. intake of psychotropic medication during the last 3 months

         13. participation in any other clinical trial 3 months prior to visit 1

         14. women of childbearing age not using 2 highly effective contraceptive methods

         15. employee of the Sponsor or the principal investigator
      "
NCT02136914,completed,,1,phase 3,"['dyskinesia', 'levodopa induced dyskinesia (lid)', ""parkinson's disease""]","[""['K22.4', 'G24.01']"", ""['K22.4', 'G24.01']"", ""['G20']""]",['ads-5102'],['C1C2CC3CC1CC(C2)(C3)N.Cl'],"
        Inclusion Criteria:

          -  Signed a current IRB/REB/IEC-approved informed consent form

          -  Parkinson's disease, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical
             Diagnostic Criteria

          -  On a stable regimen of antiparkinson's medications for at least 30 days prior to
             screening, including a levodopa preparation administered not less than three times
             daily, and willing to continue the same doses and regimens during study participation

          -  Following diary training, the subject is willing and able to understand and complete
             the 24-hour PD home diary (caregiver/study partner assistance allowed)

          -  Any other current and allowed prescription/non-prescription medications and/or
             nutritional supplements taken regularly must have been at a stable dose and regimen
             for at least 30 days prior to screening, and subject must be willing to continue the
             same doses and regimens during study participation (this criterion does not apply to
             medications that are being taken pre-study only on an as-needed basis)

        Exclusion Criteria:

          -  History of neurosurgical intervention related to Parkinson's disease (e.g. deep brain
             stimulation)

          -  History of seizures within 2 years prior to screening

          -  History of stroke or transient ischemic attack (TIA) within 2 years prior to screening

          -  History of cancer within 5 years prior to screening, with the following exceptions:
             adequately treated non-melanomatous skin cancers, localized bladder cancer,
             non-metastatic prostate cancer or in situ cervical cancer

          -  Presence of cognitive impairment, as evidenced by a Mini-Mental Status Examination
             (MMSE) score of less than 24 during screening

          -  If female, is pregnant or lactating

          -  If a sexually active female, is not surgically sterile or at least 2 years
             post-menopausal, or does not agree to utilize an effective method of contraception
             from screening through at least 4 weeks after the completion of study treatment.

          -  Treatment with an investigational drug or device within 30 days prior to screening

          -  Treatment with an investigational biologic within 6 months prior to screening

          -  Current participation in another clinical trial
      "
NCT02525874,completed,,1,phase 3,"['multiple sclerosis, relapsing-remitting', 'multiple sclerosis']","[""['G35', 'G93.81', 'K74.1', 'Q85.1', 'G12.21', 'G12.23', 'M34.0']"", ""['G35', 'C81.18']""]",['dimethyl fumarate'],['COC(=O)C=CC(=O)OC'],"
        Key Inclusion Criteria:

          -  Subjects of childbearing potential (including female subjects who are post-menopausal
             for less than 1 year) must practice effective contraception during the study and be
             willing and able to continue contraception for 30 days after their last dose of study
             treatment.

          -  Must have a confirmed diagnosis of RRMS according to the revised McDonald criteria
             (2010) [Polman 2011]

        Key Exclusion Criteria:

          -  History of or positive test result at Screening for:

          -  human immunodeficiency virus

          -  hepatitis C virus antibody

          -  hepatitis B infection

          -  Drug or alcohol abuse within 1 year prior to Screening.

          -  Prior treatment with any of the following:

          -  cladribine

          -  mitoxantrone

          -  total lymphoid irradiation

          -  alemtuzumab

          -  T-cell or T-cell receptor vaccination

          -  any therapeutic monoclonal antibody, with the exception of natalizumab or daclizumab

          -  Treatment with any of the following medications or procedures within 6 months prior to
             Baseline (Day 1):

          -  DMF (given as Fumaderm®) or BG00012; enrollment will be limited to no more than 40
             subjects (out of 200) with prior DMF exposure

          -  cyclosporine

          -  azathioprine

          -  methotrexate

          -  mycophenolate mofetil

          -  intravenous (IV) Ig

          -  plasmapheresis or cytapheresis

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
      "
NCT02783729,completed,,1,phase 3,['insomnia'],"[""['F51.01', 'F51.02', 'F51.03', 'F51.04', 'G47.00', 'G47.09', 'A81.83']""]","['lemborexant', 'lemborexant', 'lemborexant-matched placebo', 'zolpidem tartrate', 'zolpidem-matched placebo']","['CC1=NC(=NC=C1OCC2(CC2C(=O)NC3=NC=C(C=C3)F)C4=CC(=CC=C4)F)C', 'Status: 503', 'CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C.C(C(C(=O)O)O)(C(=O)O)O']","
        Inclusion Criteria

          1. Male age 65 years or older or female age 55 years or older at the time of informed
             consent

          2. Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
             criteria for Insomnia Disorder, as follows:

               -  Complains of dissatisfaction with nighttime sleep, in the form of difficulty
                  staying asleep and/or awakening earlier in the morning than desired despite
                  adequate opportunity for sleep (Note that if the complaint is limited to
                  difficulty initiating sleep, the participant is not eligible)

               -  Frequency of complaint ≥ 3 times per week

               -  Duration of complaint ≥ 3 months

               -  Associated with complaint of daytime impairment

          3. History of subjective wake after sleep onset (sWASO) typically ≥ 60 minutes on at
             least 3 nights per week in the previous 4 weeks

          4. Reports regular time spent in bed, either sleeping or trying to sleep, between 7 and 9
             hours

          5. Reports habitual bedtime, defined as the time the participant attempts to sleep,
             between 21:00 and 24:00 and habitual waketime between 05:00 and 09:00

          6. Insomnia Severity Index (ISI) score ≥ 13

          7. Confirmation of current insomnia symptoms as determined from responses on the Sleep
             Diary before the second screening visit

          8. Confirmation of regular bedtime and waketime as determined from responses on the Sleep
             Diary

          9. Confirmation of sufficient duration of time spent in bed, as determined from responses
             on the Sleep Diary

         10. Objective (polysomnography [PSG]) evidence of insomnia as follows:

             a) Wake after sleep onset (WASO) average ≥ 60 minutes on the 2 consecutive PSGs, with
             neither night < 45 minutes

         11. Willing and able to comply with all aspects of the protocol, including staying in bed
             for at least 7 hours each night

         12. Willing not to start a behavioral or other treatment program for the treatment of
             insomnia during the participant's participation in the study

        Exclusion Criteria

          1. A current diagnosis of sleep-related breathing disorder including obstructive sleep
             apnea (with or without continuous positive airway pressure [CPAP] treatment), periodic
             limb movement disorder, restless legs syndrome, circadian rhythm sleep disorder, or
             narcolepsy, or an exclusionary score on screening instruments to rule out individuals
             with symptoms of certain sleep disorders other than insomnia as follows:

               1. STOPBang score ≥5

               2. International Restless Legs Scale score ≥16

               3. Epworth Sleepiness Scale score >15 (scores of 11 to 15 require excessive daytime
                  sleepiness to be recorded in participant's Medical History)

          2. Reports symptoms potentially related to narcolepsy, that in the clinical opinion of
             the investigator indicates the need for referral for a diagnostic evaluation for the
             presence of narcolepsy

          3. On the Munich Parasomnia Scale (MUPS), endorsed the item that corresponds to a history
             of sleep-eating or reports a history of sleep-related violent behavior, sleep-driving,
             or symptoms of another parasomnia that in the investigator's opinion make the
             participant unsuitable for the study

          4. Apnea-Hypopnea Index > 15 or Periodic Limb Movement with Arousal Index >15 as measured
             on the PSG at the second screening visit

          5. Beck Depression Inventory - II (BDI-II) score >19 at Screening

          6. Beck Anxiety Index (BAI) score >15 at Screening

          7. Habitually naps during the day more than 3 times per week

          8. Is a female of childbearing potential Note: All females will be considered to be of
             childbearing potential unless they are postmenopausal (defined as amenorrheic for at
             least 12 consecutive months, and are postmenopausal without other known or suspected
             cause), or have been sterilized surgically (i.e., bilateral tubal ligation, total
             hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before
             dosing).

          9. Excessive caffeine use that in the opinion of the investigator contributes to the
             participant's insomnia, or habitually consumes caffeine-containing beverages after
             18:00 and is unwilling to forego caffeine after 18:00 for the duration of his/her
             participation in the study.

         10. History of drug or alcohol dependency or abuse within approximately the previous 2
             years

         11. Reports habitually consuming more than 14 drinks containing alcohol per week (females)
             or more than 21 drinks containing alcohol per week (males), or unwilling to limit
             alcohol intake to no more than 2 drinks per day or forego having alcohol within the 3
             hours before bedtime for the duration of his/her participation in the study

         12. Known to be positive for human immunodeficiency virus

         13. Active viral hepatitis (B or C) as demonstrated by positive serology at Screening

         14. A prolonged QT/QTcF interval (QTcF >450 milliseconds [ms]) as demonstrated by a
             repeated electrocardiogram (ECG) at Screening (repeated only if initial ECG indicates
             a QTcF interval >450 ms)

         15. Current evidence of clinically significant disease (e.g., cardiac; respiratory
             including chronic obstructive pulmonary disease, acute and/or severe respiratory
             depression; gastrointestinal; severe hepatic impairment; renal including severe renal
             impairment; neurological including myasthenia gravis; psychiatric disease; or
             malignancy within the past 5 years other than adequately treated basal cell carcinoma)
             or chronic pain that in the opinion of the investigator(s) could affect the
             participant's safety or interfere with the study assessments, including the ability to
             perform tasks on the cognitive performance assessment battery (PAB). Participants for
             whom a sedating drug would be contraindicated for safety reasons because of the
             participant's occupation or activities are also excluded.

         16. Comorbid nocturia resulting in frequent need to get out of bed to use the bathroom
             during the night

         17. Any history of a medical or psychiatric condition that in the opinion of the
             investigator(s) could affect the participant's safety or interfere with the study
             assessment, including the ability to perform the PAB.

         18. Any suicidal ideation with intent with or without a plan, at the time of or within 6
             months before the electronic Columbia-Suicide Severity Rating Scale (eC-SSRS)
             administration during the Prerandomization Phase (i.e., answering ""Yes"" to questions 4
             or 5 on the Suicidal Ideation section of the eC-SSRS)

         19. Any suicidal behavior in the past 10 years (per the Suicidal Behavior section of the
             eC-SSRS)

         20. Scheduled for surgery during the study

         21. Used any prohibited prescription or over-the-counter concomitant medications within 1
             week or 5 half lives, whichever is longer, before the first dose of study medication
             (Run-in Period).

         22. Used any modality of treatment for insomnia, including cognitive behavioral therapy or
             marijuana within 1 week or 5 half-lives, whichever is longer, before the first dose of
             study medication (Run-in Period)

         23. Failed treatment with suvorexant (Belsomra®) (efficacy and/or safety) following
             treatment with an appropriate dose and of adequate duration in the opinion of the
             investigator

         24. Transmeridian travel across more than 3 time zones in the 2 weeks before Screening, or
             between Screening and Baseline, or plans to travel across more than 3 time zones
             during the study

         25. A positive drug test at Screening, Run-In, or Baseline, or unwilling to refrain from
             use of recreational drugs during the study

         26. Hypersensitivity to lemborexant or zolpidem or to their excipients

         27. Currently enrolled in another clinical trial or used any investigational drug or
             device within 30 days or 5× the half-life, whichever is longer preceding informed
             consent

         28. Previously participated in any clinical trial of lemborexant
      "
NCT02783573,terminated,"
    an independent assessment concluded the trial was not likely to meet the primary endpoint upon
    completion and therefore, trial stopped for futility.
  ",0,phase 3,"[""alzheimer's disease""]","[""['G30.8', 'G30.9', 'G30.0', 'G30.1']""]","['lanabecestat', 'placebo']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Participant must meet the National Institute on Aging (NIA) and the Alzheimer's
             Association (AA) (NIA-AA) criteria for probable AD dementia.

          -  MMSE score of 20 to 26 inclusive at screening visit.

          -  For a diagnosis of mild AD dementia, participant must have a CDR global score of 0.5
             or 1, with the memory box score ≥0.5 at screening.

          -  Evidence of amyloid pathology.

          -  The participant must have a reliable study partner with whom he/she cohabits or has
             regular contact.

        Exclusion Criteria:

          -  Significant and/or current neurological disease affecting the central nervous system,
             other than AD, that may affect cognition or ability to complete the study, including
             but not limited to, other dementias, repetitive head trauma, serious infection of the
             brain, Parkinson's disease, epilepsy, or cervicocranial vascular disease.

          -  Participants with any current primary psychiatric diagnosis other than AD if, in the
             judgment of the investigator, the psychiatric disorder or symptom is likely to
             confound interpretation of drug effect, affect cognitive assessment, or affect the
             participant's ability to complete the study. Participants with history of
             schizophrenia or other chronic psychosis are excluded.

          -  Within 1 year before the screening visit or between screening and randomization, any
             of the following: myocardial infarction; moderate or severe congestive heart failure,
             New York Heart Association class III or IV; hospitalization for, or symptoms of,
             unstable angina; syncope due to orthostatic hypotension or unexplained syncope; known
             significant structural heart disease (such as, significant valvular disease,
             hypertrophic cardiomyopathy); or hospitalization for arrhythmia.

          -  Congenital QT prolongation.

          -  Intermittent second- or third-degree atrioventricular (AV) heart block or AV
             dissociation or history of ventricular tachycardia.

          -  A corrected QT (QTcF) interval measurement >470 milliseconds (men and women) at
             screening (as determined at the investigational site).

          -  History of malignant cancer within the last 5 years.

          -  History of vitiligo and/or current evidence of post-inflammatory hypopigmentation.

          -  Calculated creatinine clearance <30 milliliters per minute (Cockcroft-Gault formula;
             Cockcroft and Gault 1976) at screening.

          -  Currently enrolled in any other clinical trial involving an investigational product or
             any other type of medical research judged not to be scientifically or medically
             compatible with this study.
      "
NCT02484001,completed,,1,phase 3,['epilepsy'],"[""['G40.803', 'G40.804', 'G40.911', 'G40.919', 'G40.B11', 'G40.B19', 'G40.801']""]","['esl 800 mg', 'esl 1200 mg', 'esl 1600 mg', 'esl 400 mg']","['Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

        For inclusion in the extension study, subjects must fulfill all of the following at Visit 1
        (Day 1, start of the open-label extension study):

          1. Participated in the preceding double-blind study and were still ongoing at the time of
             unblinding.

          2. Have signed informed consent before undergoing any activities related to the
             open-label extension study.

          3. Demonstrated cooperation and willingness to complete all aspects of the study.

          4. Female subjects without childbearing potential (2 years postmenopausal, bilateral
             oophorectomy or tubal ligation, or complete hysterectomy) are eligible. Female
             subjects with childbearing potential must not be pregnant as confirmed by a negative
             serum ß-human chorionic gonadotropin (hCG) test and sexually active females must be
             using a medically acceptable effective non-hormonal method of contraception for the
             duration of the study and until the Post-study Visit (PSV).

        Exclusion Criteria:

        Subjects having any of the following at Visit 1 are to be excluded from the study:

          1. Excluded from the double-blind study due to seizure in the Maintenance or Extension
             Phase, or at dose level C (either CBZ-CR or ESL), or discontinued prematurely due to
             any other reason in the double-blind study.

          2. Presence of any major protocol violation during the double-blind study which may have
             an impact on the compliance during this extension study.

          3. Judged clinically to have a suicidal risk in the opinion of the investigator based
             upon a clinical interview and the Columbia Suicide-Severity Rating Scale (C-SSRS).

          4. Occurrence of an adverse event (AE) indicating a suspected presence of
             atrioventricular block (2nd degree and above) or of any other AEs during the
             double-blind study which are judged by the investigator as contraindicative to further
             participation in the open-label extension study.

          5. Events of alcohol, drug, or medication abuse during the preceding double-blind study.

          6. Relevant clinical laboratory abnormalities (e.g. sodium <125 mmol/L, alanine or
             aspartate transaminases >2 x the upper limit of normal, white blood cell count <3000
             cells/mm3) (as reported at Visit 1).

          7. Pregnancy or lactating.

          8. Any other condition or circumstance that, in the opinion of the investigator, could
             compromise the subject's ability to comply with the extension-study protocol.
      "
NCT02483585,completed,,1,phase 3,['migraine'],"[""['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']""]","['erenumab', 'placebo']",['Status: 503'],"
        Inclusion Criteria:

          -  History of migraines (with or without aura) for ≥ 12 months

          -  Migraine frequency: ≥ 4 and < 15 migraine days per month on average acrossthe 3 months
             prior to screening

          -  Headache (ie, migraine and non-migraine headache) frequency: < 15 headache days per
             month on average across the 3 months prior to screening

          -  Demonstrated compliance with the eDiary

        Exclusion Criteria:

          -  Older than 50 years of age at migraine onset.

          -  History of cluster headache or hemiplegic migraine headache.

          -  Unable to differentiate migraine from other headaches

          -  No therapeutic response with > 2 categories for prophylactic treatment of migraine
             after an adequate therapeutic trial.

          -  Concomitant use of 2 or more medications with possible migraine prophylactic effects
             within 2 months prior to the start of the baseline phase or during the baseline phase.
             If only 1 prophylactic medication is used, the dose must be stable within 2 months
             prior to the start of the baseline phase and throughout the study

          -  Used a prohibited medication, device, or procedure within 2 months prior to the start
             of the baseline phase or during the baseline phase.

          -  Received botulinum toxin

          -  Anticipated to require any excluded medication, device, or procedure during the study.

          -  Active chronic pain syndromes (such as fibromyalgia and chronic pelvic pain).

          -  History of major psychiatric disorder.

          -  History of seizure disorder or other significant neurological conditions other than
             migraine.

          -  Human immunodeficiency virus (HIV) infection by history.

          -  Myocardial infarction (MI), stroke, transient ischemic attack (TIA), unstable angina,
             or coronary artery bypass surgery or other revascularization procedure within 12
             months prior to screening.

          -  The subject is at risk of self-harm or harm to others. Previously randomized into an
             AMG 334 study.

          -  Unlikely to be able to complete all protocol required study visits or procedures,
             and/or to comply with all required study procedures.
      "
NCT02486627,completed,,1,phase 3,"['complicated urinary tract infection', 'acute pyelonephritis']","[""['H26.20', 'B05.0', 'B05.1', 'B05.2', 'G44.59', 'B05.3', 'B50.8']"", ""['N10']""]","['plazomicin', 'meropenem', 'levofloxacin (oral)']","['Status: 503', 'CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)O)C(C)O']","
        Key Inclusion Criteria:

          -  Pyuria

          -  Have a pretreatment baseline urine culture obtained within 36 hours before the start
             of administration of the first dose of study drug

          -  Clinical signs and/or symptoms of acute pyelonephritis or complicated urinary tract
             infection

          -  Normal renal function or moderate renal impairment

        Key Exclusion Criteria:

          -  Confirmed fungal urinary tract infection at the time of randomization

          -  Known urinary tract infection or colonization with Gram-positive pathogens

          -  Current cUTI or AP is known to be caused by a pathogen resistant to meropenem

          -  Female participants of childbearing potential if they are known to be pregnant or have
             a positive pregnancy test at screening, breastfeeding, or unable or unwilling to use a
             highly effective method of birth control during the study and for at least 30 days
             following the last dose of study medication

          -  Any rapidly progressing disease or immediately life-threatening illness

          -  Documented presence of immunodeficiency or an immunocompromised condition

          -  Documented or known history of otologic surgery or disease including use of hearing
             aid, head injury leading to otologic damage, Ménière's disease, tumor of the head,
             neck, or auditory system, perilymphatic fistula, or autoimmune disease of the inner
             ear, or family history of hearing loss (excluding age-related hearing loss [onset
             after age of 65 years])
      "
NCT02484547,terminated,"
    study was discontinued based on futility analysis done and not based on safety concerns.
    follow-up visits and closing out study activities are completed
  ",0,phase 3,"[""alzheimer's disease""]","[""['G30.8', 'G30.9', 'G30.0', 'G30.1']""]","['aducanumab (biib037)', 'aducanumab (biib037)', 'placebo']",['Status: 503'],"
        Key Inclusion Criteria:

          -  Must meet all of the following clinical criteria for MCI due to AD or mild AD and must
             have:

          -  A Clinical Dementia Rating (CDR)-Global Score of 0.5.

          -  Objective evidence of cognitive impairment at screening

          -  An MMSE score between 24 and 30 (inclusive)

          -  Must have a positive amyloid Positron Emission Tomography (PET) scan

          -  Must consent to apolipoprotein E (ApoE) genotyping

          -  If using drugs to treat symptoms related to AD, doses must be stable for at least 8
             weeks prior to screening visit 1

          -  Must have a reliable informant or caregiver

        Key Exclusion Criteria:

          -  Any medical or neurological condition (other than Alzheimer's Disease) that might be a
             contributing cause of the subject's cognitive impairment

          -  Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of
             consciousness in the past 1 year

          -  Clinically significant unstable psychiatric illness in past 6 months

          -  History of unstable angina, myocardial infarction, advanced chronic heart failure, or
             clinically significant conduction abnormalities within 1 year prior to Screening

          -  Indication of impaired renal or liver function

          -  Have human immunodeficiency virus (HIV) infection

          -  Have a significant systematic illness or infection in past 30 days

          -  Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities

          -  Any contraindications to brain magnetic resonance imaging (MRI) or PET scans

          -  Alcohol or substance abuse in past 1 year

          -  Taking blood thinners (except for aspirin at a prophylactic dose or less)

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
      "
NCT02614261,completed,,1,phase 3,['chronic migraine'],"[""['G43.711', 'G43.719', 'G43.701', 'G43.709']""]","['galcanezumab', 'placebo']",['Status: 503'],"
        Inclusion Criteria:

        Main Study:

          -  Have a diagnosis of chronic migraine as defined by International Headache Society
             (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines
             (1.3) (ICHD-3 2013), with a history of migraine headaches of at least 1 year prior to
             screening, and migraine onset prior to age 50.

        Israel addendum:

          -  Participants must have completed all phases of main study, including the 4-month
             post-treatment follow-up phase, during which no investigational product was
             administered.

          -  Participants also must be considered by the investigator to have benefited from
             galcanezumab treatment and must have exhausted alternative therapies for the
             prevention of migraine.

        Exclusion Criteria:

          -  Are currently enrolled in or have participated within the last 30 days or within 5
             half-lives (whichever is longer) in a clinical trial involving an investigational
             product.

          -  Current use or prior exposure to galcanezumab or another calcitonin gene-related
             peptide (CGRP) antibody.

          -  Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
             proteins, or to galcanezumab.

          -  History of persistent daily headache, cluster headache or migraine subtypes including
             hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine
             with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.
      "
NCT02614196,completed,,1,phase 3,['migraine'],"[""['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']""]","['galcanezumab', 'placebo']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Have a diagnosis of migraine as defined by International Headache Society (IHS)
             International Classification of Headache Disorders (ICHD)-3 beta version (1.1 or 1.2)
             (ICHD-3 2013), with a history of migraine headaches of at least 1 year prior to
             screening, migraine onset prior to age 50 and MONTHLY frequency of 4-14 MHD.

        Exclusion Criteria:

          -  Are currently enrolled in or have participated within the last 30 days or within 5
             half-lives (whichever is longer) in a clinical trial involving an investigational
             product.

          -  Current use or prior exposure to galcanezumab or another Calcitonin Gene-Related
             Peptide (CGRP) antibody.

          -  Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
             proteins, or to galcanezumab.

          -  History of persistent daily headache, cluster headache or migraine subtypes including
             hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine
             with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.
      "
NCT02614183,completed,,1,phase 3,['migraine'],"[""['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']""]","['galcanezumab', 'placebo']",['Status: 503'],"
        Inclusion Criteria:

          -  Have a diagnosis of episodic migraine as defined by International Headache Society
             (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines (1.1
             or 1.2) (ICHD-3 2013), with a history of migraine headaches of at least 1 year prior
             to screening, migraine onset prior to age 50 and MONTHLY frequency of 4-14 Migraine
             Headache Days (MHD).

        Exclusion Criteria:

          -  Are currently enrolled in or have participated within the last 30 days or within 5
             half-lives (whichever is longer) in a clinical trial involving an investigational
             product.

          -  Current use or prior exposure to Galcanezumab or another CGRP antibody.

          -  Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
             proteins, or to Galcanezumab.

          -  History of persistent daily headache, cluster headache or migraine subtypes including
             hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine
             with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.
      "
NCT04248465,terminated,"
    the idmc recommended the study be discontinued due to lack of efficacy with ravulizumab.
  ",0,phase 3,"['amyotrophic lateral sclerosis', 'als']","[""['G12.21']""]",['placebo'],['Status: 503'],"
        Key Inclusion Criteria:

          1. A diagnosis of sporadic or familial ALS, defined by the El Escorial criteria
             (possible, laboratory-supported probable, probable, or definite ALS).

          2. ALS onset ≤ 36 months from Screening.

          3. Documented meningococcal vaccination not more than 3 years prior to, or at the time
             of, initiating study treatment.

          4. Upright slow vital capacity ≥ 65% predicted at Screening.

          5. If on riluzole, participant must be on a stable dose for 30 days; if on edaravone,
             participant must be on a stable dose for 60 days (2 cycles).

          6. Body weight ≥ 40 kilograms at Screening.

          7. Contraceptive use by men or women should be consistent with local regulations
             regarding the methods of contraception for those participating in clinical studies.

        Key Exclusion Criteria:

          1. History of Neisseria meningitidis infection.

          2. Human immunodeficiency virus (HIV) infection (evidenced by HIV 1 or HIV 2 antibody
             titer).

          3. Dependence on invasive or non-invasive mechanical ventilation.

          4. Previously or currently treated with a complement inhibitor.

          5. Exposure to an investigational drug or device within 30 days of Screening or 5 half
             lives of the study drug, whichever is greater.
      "
NCT02867709,completed,,1,phase 3,"['migraine, with or without aura']","[""['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']""]","['ubrogepant', 'placebo-matching ubrogepant']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  At least a 1-year history of migraine with or without aura consistent with a diagnosis
             according to the International Classification of Headache Disorders, 3rd edition, beta
             version

          -  Migraine onset before age 50

          -  History of migraines typically lasting between 4 and 72 hours if untreated or treated
             unsuccessfully and migraine episodes are separated by at least 48 hours of headache
             pain freedom

          -  History of 2 to 8 migraine attacks per month with moderate to severe headache pain in
             each of the previous 3 months.

        Exclusion Criteria:

          -  Difficulty distinguishing migraine headache from tension-type other headaches

          -  Has taken medication for acute treatment of headache (including acetaminophen,
             nonsteroidal anti-inflammatory drugs [NSAIDs], triptans, ergotamine, opioids, or
             combination analgesics) on 10 or more days per month in the previous 3 months

          -  Has a history of migraine aura with diplopia or impairment of level of consciousness,
             hemiplegic migraine, or retinal migraine

          -  Has a current diagnosis of new persistent daily headache, trigeminal autonomic
             cephalgia (eg, cluster headache), or painful cranial neuropathy

          -  Required hospital treatment of a migraine attack 3 or more times in the previous 6
             months

          -  Has a chronic non-headache pain condition requiring daily pain medication

          -  Has a history of malignancy in the prior 5 years, except for adequately treated basal
             cell or squamous cell skin cancer, or in situ cervical cancer

          -  Has a history of any prior gastrointestinal conditions (eg, diarrhoea syndromes,
             inflammatory bowel disease) that may affect the absorption or metabolism of
             investigational product; participants with prior gastric bariatric interventions which
             have been reversed are not excluded

          -  Has a history of hepatitis within previous 6 months.
      "
NCT03158688,completed,,1,phase 3,"['relapsed multiple myeloma', 'refractory multiple myeloma']","[""['G35', 'M15.3', 'M67.49', 'M89.09', 'M89.59', 'M94.29', 'Q78.6']"", ""['D46.4', 'I20.2', 'D46.1', 'D46.A', 'D46.0', 'D46.20', 'D46.21']""]","['dexamethasone', 'daratumumab', 'carfilzomib']","['Status: 503', 'CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4']","
        Inclusion Criteria:

          -  Criteria 1 Relapsed or progressive multiple myeloma after last treatment

          -  Criteria 2 Males or females ≥ 18 years of age

          -  Criteria 3 Measurable disease with at least 1 of the following assessed within 21 days
             prior to randomization:

          -  IgG multiple myeloma: serum monoclonal paraprotein (M-protein) level ≥ 1.0 g/dL,

          -  IgA, IgD, IgE multiple myeloma: serum M-protein level ≥ 0.5 g/dL,

          -  urine M-protein ≥ 200 mg/24 hours,

          -  in subjects without measurable serum or urine M- protein, serum free light chain
             (SFLC) ≥ 100 mg/L (involved light chain) and an abnormal serum kappa lambda ratio

          -  Criteria 4 Received at least 1 but not more than 3 prior lines of therapy for multiple
             myeloma (induction therapy followed by stem cell transplant and
             consolidation/maintenance therapy will be considered as 1 line of therapy

          -  Criteria 5 Prior therapy with carfilzomib is allowed as long as the patient had at
             least a partial response (PR) to most recent therapy with carfilzomib, was not removed
             due to toxicity, did not relapse within 60 days from discontinuation of carfilzomib,
             and will have at least a 6-month carfilzomib treatment-free interval from last dose
             received until first study treatment. (Patients may receive maintenance therapy with
             drugs that are not proteasome inhibitors or CD38 antibodies during this 6-month
             carfilzomib treatment free interval)

          -  Criteria 6 Prior therapy with anti-CD38 antibodies is allowed as long as the patient
             had at least a PR to most recent therapy with CD38 antibody, was not removed due to
             toxicity, did not relapse within 60 days from intensive treatment (at least every
             other week) of CD38 antibody therapy, and will have at least a 6 month CD38 antibody
             treatment-free interval from last dose received until first study treatment

          -  Other inclusion criteria may apply

        Exclusion Criteria:

          -  Criteria 1 Waldenström macroglobulinemia

          -  Criteria 2 Multiple myeloma of IgM subtype

          -  Criteria 3 POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal
             protein, and skin changes)

          -  Criteria 4 Plasma cell leukemia (> 2.0 * 10^9/L circulating plasma cells by standard
             differential)

          -  Criteria 5 Myelodysplastic syndrome

          -  Criteria 6 Known moderate or severe persistent asthma within the past 2 years

          -  Criteria 7 Known chronic obstructive pulmonary disease (COPD) with a FEV1 < 50% of
             predicted normal

          -  Criteria 8 Active congestive heart failure (New York Heart Association [NYHA] Class
             III to IV), symptomatic ischemia, uncontrolled arrhythmias, clinically significant
             electrocardiogram (ECG) abnormalities, screening ECG with corrected QT interval (QTc)
             of > 470 msec, pericardial disease, or myocardial infarction within 4 months prior to
             randomization

          -  Other exclusion criteria may apply
      "
NCT02442765,completed,,1,phase 3,"[""agitation in patients with dementia of the alzheimer's type""]","[""['G30.8', 'G30.9', 'G30.0', 'G30.1']""]","['avp-786', 'placebo']",['Status: 503'],"
        Inclusion Criteria:

          -  Diagnosis of probable Alzheimer's Disease (AD) according to the 2011 National
             Institute on Aging-Alzheimer's Association (NIA-AA) working groups criteria

          -  The participant has clinically significant, moderate/severe agitation at the time of
             screening and for at least 2 weeks prior to randomization

          -  The diagnosis of agitation must meet the International Psychogeriatric Association
             (IPA) provisional definition of agitation

          -  Either out patients or residents of an assisted-living facility or a skilled nursing
             home

          -  Clinical Global Impression of Severity of Illness (CGIS) score assessing Agitation is
             >= 4 (moderately ill) at screening and baseline

          -  Mini-Mental State Examination (MMSE) score is between 6 and 26 (inclusive) at
             screening and baseline

          -  Caregiver who is able and willing to comply with all required study procedures. In
             order to qualify as a reliable informant (i.e., caregiver) capable of assessing
             changes in participant's condition during the study, the individual must spend a
             minimum of 2 hours per day for 4 days per week with the participant.

        Exclusion Criteria:

          -  Participant has dementia predominantly of non-Alzheimer's type (e.g., vascular
             dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia)

          -  Participants with co-existent clinically significant or unstable systemic diseases
             that could confound the interpretation of the safety results of the study (e.g.,
             malignancy, poorly controlled diabetes, poorly controlled hypertension, unstable
             pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated
             cardiomyopathy, or unstable valvular heart disease)

          -  Participant with myasthenia gravis
      "
NCT02256215,unknown status,,0,phase 2/phase 3,['restless legs syndrome'],"[""['G25.81']""]",['vitamin d'],['Status: 503'],"
        Inclusion Criteria:

          1. Newly diagnosed or already diagnosed patients with primary RLS and vitamin D
             deficiency.

          2. Patients that are not currently receiving any treatment for RLS or vitamin D
             replacement therapy.

          3. Patients from 18 to 75 years old.

          4. Patients otherwise are in good general health.

        Exclusion Criteria:

          1. Patients diagnosed with secondary RLS. i.e.: patients with:

        1. Iron deficiency anemia 2. End-stage renal disease. 3. Diabetes mellitus (DM). 4.
        Peripheral neuropathy. 5. Multiple sclerosis (MS). 6. Pregnancy.

        2. Patients with other mimicking disorders or primary sleep disorders. E.g.:

          1. Arthritis.

          2. Deep venous thrombosis.

          3. Varicose veins or venous insufficiency.

          4. Habitual foot tapping.

        3. Patients receiving medications that can trigger RLS. i.e.:

          1. Anti hypertensive medications. E.g. Use of thiazide diuretics at a total dose greater
             than 37.5 mg/day.

          2. Anti convulsion medications.e.g. Use of anticonvulsant drug started within 6 months of
             screening. Stable regimen of anticonvulsants is allowed.

          3. Antinausea drugs (prochlorperazine or metoclopramide).

          4. Antipsychotic drugs (haloperidol or phenothiazine derivatives).

          5. Anti depressants (SSRIs).

          6. Antihistamines as in cold and allergy medications.

        4. Patients with current medications or conditions that would interfere with vitamin D
        absorption:

        1. Celiac disease. 2. Chron's disease. 3. Chronic pancreatitis. 4. Cystic fibrosis. 5.
        Weight-loss drug e.g. orlistat. 6. Cholesterol-lowering drug e.g. cholestyramine

        5. Patients with contraindications for vitamin D supplements. i.e.:

          1. Hyperparathyroidism.

          2. Kidney stones.

          3. Liver diseases.

          4. Granulomatous disorders (sarcoidosis, tuberculosis)

        6. Patients 17 years old and younger.

        7. Use of supplements containing vitamin D at total doses higher than 1000 IU/day within 12
        weeks of the baseline visit initiating the protocol and unwillingness to limit vitamin D
        supplementation dosage to no higher than 1000 IU/day for the duration of the study.

        8. Use of supplements containing calcium at total doses higher than 600 mg/day within 1
        week of the baseline visit initiating the protocol and unwillingness to limit calcium
        supplementation dosage to no more than 600 mg/day for the duration of the study.

        9. History of intolerance to vitamin D supplements.

        10. Women only: A. Pregnancy (past 1 year by report or positive pregnancy test at
        screening), intent to become pregnant in the next 4 years or unprotected intercourse.
        History of gestational diabetes is not an exclusion criterion.

        B. Currently breastfeeding. C. Use of oral contraceptives or menopausal hormone therapy
        started within 3 months of baseline. Stable regimen of oral contraceptives or any other
        hormonal method of contraception (e.g. implantable) is allowed.
      "
NCT02680756,completed,,1,phase 3,"['anemia, iron-deficiency', 'inflammatory bowel disease', ""crohn's disease""]","[""['D50.9', 'D50.0']"", ""['M06.4', 'G61.89', 'G61.9', 'M35.81', 'G61.81', 'K75.9', 'M27.2']"", ""['K50.90', 'K50.913', 'K50.914', 'K50.911', 'K50.912', 'K50.918', 'K50.919']""]","['ferric maltol', 'ferric carboxy maltose']","['Status: 503', 'Status: 503']","
        All of the following criteria must be met to randomize a subject in the study:

          1. Subjects must be competent to understand the information given in the Independent
             Ethics Committee (IEC) or Institutional Review Board (IRB) approved informed consent
             form and must sign and date the informed consent prior to any study mandated procedure

          2. Subjects must be willing and able to comply with study requirements

          3. Age ≥ 18 years

          4. Subjects must have a confirmed diagnosis of IBD (endoscopic and/or biopsy)

          5. Subjects must be considered suitable for intravenous iron treatment by the
             Investigator

          6. Subjects must have iron deficiency anaemia defined by the following criteria:

               1. Hb 8.0 g/dL and ≤11.0 g/dL for women OR a Hb 8.0 g/dL and ≤12.0 g/dL for men

               2. AND Ferritin <30ng/ml OR Ferritin <100 ng/ml WITH Transferrin saturation (TSAT)
                  <20%

          7. Female subjects of childbearing potential (including perimenopausal females who have
             had a menstrual period within 1 year prior to screening) must agree to use a reliable
             method of contraception until they have completed the study and for at least 4 weeks
             following their final study visit. Reliable contraception is defined as a method which
             results in a low failure rate, i.e., less than 1% per year when used consistently and
             correctly, such as implants, injectables, some intrauterine contraceptive devices
             (IUDs), complete sexual abstinence, or a vasectomized partner. Oral contraceptive
             medications are allowed in this study. Female subjects who are surgically sterile
             (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or postmenopausal
             (defined as no menstrual period within 1 year of screening) are also allowed to
             participate.

        A subject who meets any of the following criteria is not eligible for participation in the
        study.

          1. Subject with anaemia due to any cause other than iron deficiency, including, but not
             limited to:

               1. Untreated or untreatable severe malabsorption syndrome

               2. Immunosuppressant use. Immunosuppressants are permitted so long as there is no
                  clinical evidence or suspicion of the immunosuppressant contributing to the
                  subject's anaemia or affecting erythropoiesis.

             Variations to dosing are permitted at the discretion of the investigator so long as
             there is no clinical evidence or suspicion of the immunosuppressant contributing to
             the subject's anaemia or affecting erythropoiesis

          2. Subject who has received prior to screening:

               1. Within 8 weeks intramuscular or intravenous (IV) iron or administration of depot
                  iron preparation

               2. Within 2 weeks a blood transfusion

               3. Oral iron supplementation, taken specifically to treat anaemia, within the
                  previous 4 weeks (Over the Counter (OTC) multivitamins containing iron are
                  permitted)

          3. Subjects with active inflammatory bowel disease as defined by a SCCAI score greater
             than 5 at Screening or a CDAI score greater than 300 in the Screening period (as
             assessed using the Screening haematocrit (HCT) and CDAI diary card completed by the
             subject for 7 days prior to planned randomization).

          4. Subjects with known hypersensitivity or allergy to either the active substance or
             excipients of ferric maltol capsules or ferric carboxymaltose solution for IV
             administration

          5. Subjects who have had serious adverse reactions to previous doses of ferric
             carboxymaltose or any other intravenous iron.

          6. Subjects with contraindication for treatment with iron preparations, e.g.
             hemochromatosis, chronic hemolytic disease, sideroblastic anaemia, thalassemia, or
             lead intoxication induced anaemia.

          7. Subjects with vitamin B12 or folic acid deficiency as determined by the central
             laboratory screening results. Subjects may start vitamin B12 or folate replacement and
             rescreen after at least 2 weeks.

          8. Subjects who are pregnant or breast feeding.

          9. Concomitant medical conditions with significant active bleeding likely to initiate or
             prolong anaemia.

         10. Participation in any other interventional clinical study within 30 days prior to
             screening.

         11. Subject with cardiovascular, liver, renal, haematologic, gastrointestinal,
             immunologic, endocrine, metabolic, or central nervous system disease that, in the
             opinion of the Investigator, may adversely affect the safety of the subject or
             severely limit the lifespan of the subject (i.e. unlikely to complete the full
             duration of the study).

         12. Subject with significant neurologic or psychiatric symptoms resulting in
             disorientation, memory impairment, or inability to report accurately that might
             interfere with treatment compliance, study conduct or interpretation of the results
             (e.g., Alzheimer's disease, schizophrenia or other psychosis, active or current
             alcohol or drug abuse)

         13. Subject who is an inmate of a psychiatric ward, prison, or other state institution.

         14. Subject who is an Investigator or any other team member involved directly or
             indirectly in the conduct of the clinical study.

         15. Subjects with severe renal impairment: creatinine clearance <30 mL/min. (Applicable to
             US sites Only)
      "
NCT02402530,completed,,0,phase 2/phase 3,"['complex regional pain syndrome, type i']","[""['G90.50', 'G90.511', 'G90.512', 'G90.513', 'G90.519', 'G90.521', 'G90.522']""]","['placebo', 'neridronic acid 62.5 mg']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Informed consent signed.

          -  Male or female participant between 18 years and 80 years of age.

          -  A diagnosis of complex regional pain syndrome type I according to the clinical
             diagnostic criteria using the International Association for the Study of Pain clinical
             diagnostic criteria (Budapest criteria).

          -  Baseline Pain Intensity Score of 4 or greater using an 11-point Numerical Rating Scale
             referring to the CRPS-affected limb.

          -  In stable treatment and follow-up therapy for CRPS type I for at least 1 month.

          -  Participant has undergone a recent regular dental examination.

          -  Women of child-bearing potential must have a negative urine ß-HCG pregnancy test at
             enrollment.

          -  Women of child-bearing potential must practice protocol defined acceptable methods of
             birth control during the trial.

          -  Participants must be able to communicate meaningfully, be able to differentiate with
             regard to location and intensity of the pain, and be able to answer the questions in
             the questionnaires used in this trial.

          -  Compliance with the use of electronic diary assessed prior to allocation to treatment.

        Exclusion Criteria:

          -  A diagnosis of complex regional pain syndrome type II.

          -  Documented history or diagnosis of peripheral neuropathy, including diabetic
             peripheral neuropathy or other metabolic or toxic neuropathy, or any other chronic
             pain condition that would significantly affect a participant's ability to report
             CRPS-related pain.

          -  Body weight less than 40 kg.

          -  Evidence of renal impairment or a history of chronic kidney disease.

          -  Serum calcium or magnesium outside of the central laboratory's reference range;
             history of hypocalcemia; any metabolic disorder anticipated to increase risk for
             hypocalcemia.

          -  Vitamin D deficiency. Participants with vitamin D deficiency prior to enrollment may
             be enrolled with appropriate supplementation during the enrollment period.

          -  Corrected QT interval greater than 470 milliseconds; treatment with medications within
             the last 30 days prior to allocation to IMP that have potential to prolong the QT
             interval or anticipated need for such medications during the course of the trial.

          -  Any prior use of a bisphosphonate for treatment of CRPS, any prior administration of
             intravenous bisphosphonate, administration of oral bisphosphonate within the previous
             year, anticipated requirement for treatment with oral or intravenous bisphosphonate
             for another condition such as osteoporosis during the trial, or administration of
             denosumab (Prolia) or other bone turnover suppressing drugs within the past 6 months.

          -  History of any allergic or hypersensitivity reaction to neridronic acid or other
             bisphosphonate, or to vitamin D or calcium supplements.

          -  Recent tooth extraction, unhealed or infected extraction site, or significant
             dental/periodontal disease that may pre-dispose to need for tooth extraction or other
             invasive dental procedures during the trial.

          -  Evidence of denture-related gum trauma or improperly fitting dentures causing injury.

          -  Prior radiation therapy of the head or neck (within 1 year of enrollment).

          -  Recent treatment with high doses of systemic steroids or anticipated need for
             concomitant high-dose steroid treatment during the trial.

          -  History of malignancy within 2 years before enrollment with the exception of basal
             cell carcinoma.

          -  Daily intake of long- and short-acting or controlled-release opioid analgesics of more
             than 200 mg morphine equivalents, regimens combining high-dose opioids and
             benzodiazepines, or any other treatment regimen considered unstable, unsafe, or have
             potential to affect the interpretation of the trial.

          -  Use of nerve blocks, ketamine infusions, intravenous immunoglobulin, acupuncture,
             electromagnetic field treatment, or initiation/implementation of radiofrequency
             ablation or other sympathectomy procedures, or peripheral nerve stimulation within 6
             weeks prior to allocation to investigational medicinal product.

          -  Evidence of current alcohol or drug abuse, or history of alcohol or drug abuse within
             2 years of enrollment, based on participant history and physical examination and
             according to the investigator's judgment.

          -  Any other severe medical condition, including severe depression, or any other severe
             mood disorder, that in the opinion of the investigator may affect efficacy or safety
             assessments or may compromise the participant's safety during trial participation.

          -  Participant is engaged in litigation related to their disability from CRPS in which
             monetary gain or loss (or other compensation) may affect their objective participation
             in the trial.

          -  Women who are pregnant or breastfeeding.

          -  Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater
             than 2-fold upper limit of normal (ULN), or evidence or history of liver disease.

          -  Participation in an investigational drug trial within 3 months prior to enrollment, or
             prior participation in this trial with receipt of any infusion of IMP, even a partial
             infusion.
      "
NCT02407236,completed,,1,phase 3,"['colitis, ulcerative', 'inflammatory bowel diseases']","[""['K51.80', 'K51.813', 'K51.814', 'K51.90', 'K51.913', 'K51.914', 'K51.811']"", ""['M06.4', 'G61.89', 'G61.9', 'M35.81', 'G61.81', 'K75.9', 'M27.2']""]","['placebo iv', 'placebo sc', 'ustekinumab iv', 'ustekinumab sc']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Has a clinical diagnosis of Ulcerative Colitis (UC) at least 3 months before Screening

          -  Has moderately to severely active UC, defined as a Baseline (Week 0) Mayo score of 6
             to 12, including a Screening endoscopy subscore of the Mayo score greater than or
             equal to (>=) 2 as determined by a central reading of the video endoscopy

          -  Have failed biologic therapy, that is, have received treatment with 1 or more tumour
             necrosis factor (TNF) antagonists or vedolizumab at a dose approved for the treatment
             of UC, and have a documented history of failure to respond to or tolerate such
             treatment; OR Be naïve to biologic therapy (TNF antagonists or vedolizumab) or have
             received biologic therapy but have not demonstrated a history of failure to respond
             to, or tolerate, a biologic therapy and have a prior or current UC medication history
             that includes at least 1 of the following: a. Inadequate response to or failure to
             tolerate current treatment with oral corticosteroids or immunomodulators
             (6-mercaptopurine [6-MP] or azathioprine [AZA]) OR b. History of failure to respond
             to, or tolerate, at least 1 of the following therapies: oral or IV corticosteroids or
             immunomodulators (6-MP or AZA) OR c. History of corticosteroid dependence (that is, an
             inability to successfully taper corticosteroids without a return of the symptoms of
             UC)

          -  Before the first administration of study agent, the following conditions must be met:
             vedolizumab must have been discontinued for at least 4 months and anti-tumor necrosis
             factors (TNFs) for at least 8 weeks

        Exclusion Criteria:

          -  Has severe extensive colitis and is at imminent risk of colectomy

          -  Has UC limited to the rectum only or to < 20 centimeters (cm) of the colon

          -  Presence of a stoma or history of a fistula

          -  Participants with history of extensive colonic resection (for example, less than 30 cm
             of colon remaining) that would prevent adequate evaluation of the effect of study
             agent on clinical disease activity

          -  Participants with history of colonic mucosal dysplasia. Participants will not be
             excluded from the study because of a pathology finding of ""indefinite dysplasia with
             reactive atypia''
      "
NCT02153632,terminated,,0,phase 3,"[""parkinson's disease"", 'levodopa induced dyskinesia (lid)']","[""['G20']"", ""['K22.4', 'G24.01']""]","['amantadine hcl er', 'placebo']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Signed Institutional Review Board (IRB)/ Independent Ethics Committee (IEC) informed
             consent form.

          -  Idiopathic Parkinson's disease per the United Kingdom (UK) Parkinson's Disease Society
             Brain Bank criteria.

          -  Male or female 30 to 85 years old.

          -  Levodopa induced, predictable peak-effect dyskinesia considered problematic and/or
             disabling.

          -  Screening serum creatinine level within normal range

          -  On stable doses of all oral anti-Parkinson's medication, including any levodopa
             preparation, for 30 days and be willing to remain on the same doses throughout the
             trial.

          -  The subject/caregiver must demonstrate the ability to complete an accurate home diary
             based on training and evaluation during the screening period.

        Exclusion Criteria:

          -  Secondary parkinsonian syndrome, such as vascular, postinflammatory,drug-induced,
             neoplastic and post-traumatic parkinsonism or any atypical parkinsonian syndrome
             (e.g., Progressive Supranuclear Palsy, Multi-System Atrophy, etc.);

          -  Use of amantadine within 14 days before study start, or previously had an adverse
             event to amantadine

          -  Currently taking neuroleptics and atypical antipsychotic agents, acetylcholinesterase
             inhibitors, apomorphine, rimantadine, memantine and dextromethorphan and quinidine if
             used in combination for treating dyskinesia.

          -  History of neurosurgical intervention for treating Parkinson's s disease (i.e.
             pallidotomy or implanted with a deep brain stimulator)

          -  Any medical condition or past medical history that would increase the risk of exposure
             to Amantadine HCl Extended Release Tablets or interfere with safety and efficacy
             evaluations.

          -  History of cancer within 5 years of screening with following exceptions: adequately
             treated non-melanomatous skin cancers, localized bladder cancer, non-metastatic
             prostate cancer or in situ cervical cancer.

          -  History or current diagnosis of schizophrenia or bipolar disorder;

          -  Inadequately treated Major Depressive Disorder. Subjects on stable doses of selective
             serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors
             (SNRIs) are eligible for the study;

          -  Is at imminent risk of suicide or had a suicide attempt within 6 months of screening

          -  History or current diagnosis of Impulse Control Disorder

          -  Calculated plasma creatinine clearance of <60 mL/min at screening

          -  History of or currently has any of the following clinically significant conditions,
             cardiovascular, respiratory, renal, hepatic, or gastrointestinal disease

          -  Any clinically significant vital sign, ECG, or laboratory abnormalities;

          -  A positive test for HIV antibody or history of HIV; hepatitis B surface antigen unless
             the positive test followed a recent (<28 days) vaccination for hepatitis B; hepatitis
             C antibody;

          -  A positive urine drug test.

          -  Pregnant or breastfeeding at screening or has a positive pregnancy test

          -  If a sexually active female, is not surgically sterile or at least 2 years
             post-menopausal, or does not agree to utilize an effective method of contraception
             from the screening visit to at least 4 weeks after the completion of study treatment.

          -  History of alcohol or narcotic substance abuse ≤1 year before screening.

          -  Has dementia or another psychiatric illness that prevents provision of informed
             consent.

          -  Has a known hypersensitivity to the study treatment(s), based on known allergies to
             drugs of the same class including rimantadine HCl and memantine HCl.

          -  Has participated in other studies involving investigational drugs or surgeries within
             the last 30 days or investigational biologics within the last 6 months prior to
             screening.

          -  Plans to undergo major elective surgery during the course of the study.

          -  Received administration of Live Attenuated Influenza Vaccine (LAIV) within 2 weeks.

          -  Cognitive impairment, as evidenced by a score <26 on the Montreal Cognitive Assessment
             (MoCA) at the screening visit.
      "
NCT02155660,completed,,0,phase 3,['moderate to very severe chronic obstructive pulmonary disease'],"[""['G91.1', 'I42.1', 'N11.1', 'J05.0', 'P28.42', 'G47.33', 'J44.9']""]","['benralizumab arm a', 'benralizumab arm b', 'benralizumab arm c', 'placebo']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:.

          -  Informed consent.

          -  Subjects 40-85 y.o.

          -  Moderate to very severe COPD with Post Bronchodilator (BD) FEV1>20% and ≤65%.

             -≥2 moderate or ≥1 severe COPD exacerbation(s) required treatment or hospitalization
             within 2-52 weeks prior to Visit1.

          -  Modified Medical Research Council (mMRC) score ≥1 at Visit 1.

          -  Treatment with double or triple therapy throughout the year prior to Visit 1, constant
             2 weeks prior to Visit 1.

          -  Tobacco history of ≥10 pack-years.

          -  Women of childbearing potential must use a highly effective form of birth control from
             Visit 1 until 16 weeks after their last dose, and negative serum pregnancy test result
             at Visit 1.

          -  Male subjects who are sexually active must be surgically sterile one year prior to
             Visit 1 or use an adequate method of contraception from the first Investigational
             Product (IP) dose until 16 weeks after their last dose.

          -  Compliance with maintenance therapy during run-in ≥70%.

          -  Blood eosinophils due to subject's stratification and cap for blood eosinophil
             levels.When any eosinophil cohort is full, subjects in the completed cohort will not
             be randomised and will be withdrawn from the study.

        Exclusion criteria:

          -  Clinically important pulmonary disease other than COPD or another diagnosed pulmonary
             or systemic disease associated with elevated peripheral eosinophil counts.

          -  Any disorder or major physical impairment that is not stable by Investigator opinion
             and/or could affect: - subject safety-study findings or their interpretation or
             subject's ability to complete the entire study duration.

          -  Unstable ischemic heart disease, arrhythmia, cardiomyopathy, or other relevant
             cardiovascular disorder that in Investigator's judgment may put the patient at risk or
             negatively affect the study outcome.

          -  Treatment with systemic corticosteroids and/or antibiotics, and/or hospitalization for
             a COPD exacerbation within 2 weeks prior to Visit1 or during the enrolment and run-in
             period.

          -  Acute upper or lower respiratory infection requiring antibiotics within 2 weeks prior
             to Visit1 or during the enrolment and run-in period.

          -  Pneumonia within 8 weeks prior to Visit1 or during the enrolment and run-in period.

          -  Pregnant, breastfeeding, or lactating women.

          -  Risk factors for pneumonia

          -  History of anaphylaxis to any other biologic therapy.

          -  Long term oxygen therapy with signs and/or symptoms of cor pulmonale, right
             ventricular failure.

          -  Use of immunosuppressive medication within 2 weeks prior to Visit1 and/or during the
             enrolment and run-in period.

          -  Receipt of any investigational non-biologic product within 30 days or 5 half-lives
             prior to Visit 1.

          -  Evidence of active tuberculosis (TB) without an appropriate course of treatment.

          -  Lung volume reduction surgery within the 6 months prior to Visit 1. History of partial
             or total lung resection (single lobe or segmentectomy is acceptable).

          -  Asthma as a primary or main diagnosis according to the Global Initiative for Asthma
             (GINA) guidelines or other accepted guidelines.

          -  Previous treatment with benralizumab.

          -  Helminth parasitic infection diagnosed within 24 weeks prior to Visit 1.
      "
NCT03108729,withdrawn,"
    the study was not withdrawn for safety reasons. the sponsor received approval for the treatment
    of partial-onset seizures in patients 4 years of age and older
  ",0,phase 3,['epilepsy'],"[""['G40.803', 'G40.804', 'G40.911', 'G40.919', 'G40.B11', 'G40.B19', 'G40.801']""]",['eslicarbazepine acetate'],['Status: 503'],"
        Inclusion Criteria:

          1. Subject is male or female, 4 to < 18 y at enrollment, and weighs at least 11 kg at
             Screening and on the first day of ESL dosing.

          2. The informed consent must be signed by the parent or legal guardian, and, when
             appropriate and/or required by state or local law, minor subjects must give written
             informed assent prior to participation in the study. All subjects in the United States
             (US) must have a parent or legal guardian, sign a Health Insurance Portability and
             Accountability Act (HIPAA) form.

          3. Confirmed diagnosis of epilepsy with partial onset seizures as defined in the
             Classification of Seizures of the International League Against Epilepsy:

               1. Epilepsy with partial onset seizures with observable motor component, or complex
                  partial seizures, with or without secondary generalization

               2. Documented EEG recording without generalized epileptiform abnormalities and with
                  demonstrated focal abnormalities (done within 5 years prior to screening)

          4. Documented magnetic resonance imaging (MRI) scan conducted within 5 years (older scans
             may be acceptable with consent of Medical Monitor) prior to screening, showing either
             normal results or static focal abnormalities.

          5. Documented seizure frequency of at least 6 seizures per month prior to screening as
             reported by a caregiver and documented in subject's seizure history. Note:
             Retrospective reporting of seizure frequency does not require diary documentation.

          6. Stable treatment with 1 to 3 AEDs (excluding carbamazepine and oxcarbazepine) for ≥ 2
             weeks prior to screening and at least 4 weeks prior to the first ESL dose. Vagal nerve
             stimulation (if present) does not count as an AED.

          7. Subject and/or caregiver are willing and able to complete a daily seizure diary for
             the duration of the study and comply with study procedures.

          8. A female subject is eligible to enter and participate in the study if she is of:

               1. Non-childbearing potential because she is premenarchal (as assessed by physical
                  examination) and < 7 y; or

               2. Non-childbearing potential because she is premenarchal (as assessed by physical
                  examination), ≥ 7 y, and has a negative urine pregnancy test at screening; or

               3. Childbearing potential; has a negative serum pregnancy test at screening and
                  agrees to satisfy one of the following requirements:

                  • Complete abstinence from intercourse as a component of a habitually abstinent
                  lifestyle; a minimum of 4 weeks prior to administration of the first dose of
                  study drug, throughout the treatment period, and for a minimum of 8 weeks after
                  completion or premature discontinuation from the study drug (abstinence must be
                  part of an established abstinent lifestyle), and agrees to use a double-barrier
                  method if she becomes sexually active; or

                  • Established use of acceptable methods of contraception; a minimum of 4 weeks
                  prior to administration of the first dose of study drug, throughout the treatment
                  period, and for a minimum of 8 weeks after completion or premature
                  discontinuation from the study drug. Acceptable methods of birth control are
                  those with established failure rates of < 1%per year and include:

                    -  Double barrier birth control, which is limited to a condom plus spermicide
                       or a condom plus diaphragm.

                    -  Intrauterine device (IUD). Note: Female subjects who are ≥ 7 y and
                       premenarchal will not routinely undergo serum pregnancy tests and will only
                       be administered a urine pregnancy test. A positive urine pregnancy test
                       should be confirmed by a serum test in these subjects regardless of weight.
                       Female subjects who are < 7 y will not undergo a serum or a urine pregnancy
                       test.

             Note: ESL may interfere with the action of hormonal contraceptive and therefore
             hormonal contraceptives are not sufficient for this protocol.

          9. Males must be willing to remain sexually abstinent (consistent with lifestyle) or use
             an effective method of birth control (eg, male using condom and female using
             diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine
             device) from signing informed consent to at least 7 days after the last dose of study
             drug has been taken.

         10. Stable environment with caregiver who can assist in completion of seizure diary and
             other study assessments, if needed.

         11. Subject and/or caregiver must read and write and possess an educational level and
             degree of understanding of the local language at a level sufficient to complete study
             related assessments or communicate suitably with the Investigator and study
             coordinator. For subjects who do not meet this criterion, a caregiver must be able to
             meet this requirement on the subject's behalf.

        Inclusion Criteria for Monotherapy Conversion Subjects (at or after Month 6)

          1. Subject is < 18 years-old at time of taper/conversion.

          2. Subject has a satisfactory response to ESL at ≥ 6months of treatment in present study
             (based on tolerability and reduction in seizures, as determined by the Investigator).

          3. Subject is receiving 1 or 2 background AEDs (not including benzodiazepine or
             barbiturate).

          4. Subject does not have history of status epilepticus in the previous 3 years.

        Exclusion Criteria:

          1. Subject has had prior exposure to or previously participated in a clinical study with
             ESL.

          2. Subject has a history of allergic reaction to oxcarbazepine or carbamazepine, or a
             history of serious allergic reaction (Stevens Johnson syndrome, Drug Reaction with
             Eosinophilia and Systemic Symptoms [DRESS] or similar) to any AED, or a history of
             serious allergic reactions to other medications.

          3. Subject has had an EEG showing generalized discharges.

          4. Subject has had any of the following seizure types at any time: myoclonic, absence, or
             atonic.

          5. Subject has Lennox-Gastaut Syndrome or other secondary generalized epilepsy (including
             inborn errors of metabolism), or Benign Rolandic Epilepsy.

          6. Subject has a current diagnosis or a history of psychogenic seizures.

          7. Subject has current seizures related to an acute medical illness.

          8. Subject has purely subjective seizures.

          9. Subject has had status epilepticus while taking any seizure medicine in the 3 years
             prior to screening.

         10. Subject should not have had febrile illness ≤ 2 weeks prior to screening.

         11. Subject is currently taking more than 3 AEDs or is taking carbamazepine or
             oxcarbazepine.

         12. Subject is taking any protocol-prohibited medication within 4 weeks of first ESL dose.

         13. Subject has any confounding factor such as pseudoseizures or syncope.

         14. Subject has a known progressive structural CNS lesion(s) or progressive
             encephalopathy.

         15. Subject (≥ 6 y) has an active suicidal plan or intent (in the Investigator's opinion)
             in the past 4 weeks prior to screening.

         16. Subject has a history of suicide attempt in the last 2 years prior to screening.

         17. Subject is at imminent risk of suicidal or homicidal action (in the Investigator's
             opinion).

         18. Subjects who meet the Diagnostic and Statistical Manual of Mental Disorders, 5th
             edition text revision (DSM-V-TR) defined criteria for major depressive episode (MDE)
             within the last 6 months. Subjects with mild, chronic depression without recent
             hospitalization who are being maintained on a stable dose of a single antidepressant
             are acceptable.

         19. Subject has a significant psychiatric disorder or history of recurrent episodes of
             severe depression requiring pharmacologic treatment or hospitalization within 2 years
             prior to screening.

         20. Subject has a history of alcohol or substance abuse within 2 years prior to screening
             for study participation, or subjects currently using alcohol, drugs of abuse, or any
             prescribed or over-the-counter medication in a manner, which, in the opinion of the
             Investigator, indicates abuse. Subjects who are regular users of medical marijuana are
             excluded; use during participation is prohibited.

         21. Subject has a positive urine drug screen (UDS) at screening. Note: Subjects with a
             positive drug screen for amphetamines, opiates, or benzodiazepines, who have a
             prescribed medication for at least 4 weeks prior to screening, may be eligible to
             participate in the study upon approval from the Medical Monitor.

         22. Subject has a major medical illness other than epilepsy that would prevent safe
             participation in this study, at the discretion of the Investigator, such as (but not
             limited to) chronic liver or kidney impairment.

         23. Subject has a disorder or history of a condition that may interfere with drug
             absorption, distribution, metabolism, or excretion (eg, malabsorption,
             gastrointestinal surgery, clinically significant abnormality of the hepatic or renal
             system). Note: Active medical conditions that are minor or well-controlled are not
             exclusionary if they do not affect risk to the subject or the study results. In cases
             in which the impact of the condition upon risk to the subject or study results is
             unclear, the Medical Monitor should be consulted.

        Subject has a history or presence of abnormal ECG, which in the Investigator's opinion is
        clinically significant or QTcB of ~ 450 msec per screening central over read ECG.

        25. Subject is known to have tested seropositive for the human immunodeficiency virus
        (HIV).

        26. Subject has a positive history for the hepatitis B surface antigen or hepatitis C
        antibody.

        27. Subject has a history of hypothyroidism, hyperthyroidism, or has values for thyroid
        testing (free T3, free T4, thyroid stimulating hormone [TSH]) indicating the presence of
        significant thyroid dysfunction.

        28. Subjects has the following abnormal laboratory tests (not limited to, but including the
        following): a. Aspartate aminotransferase (ALT)/alanine aminotransferase (AST) > 1.5 times
        the upper limit of normal (ULN) b. White blood cell (WBC) count of < 2500 cells/μL c.
        Platelet count of < 100 × 103 cells/μL

        Note: Subjects with stable platelet counts over the last 3 months prior to screening in the
        range of 80 × 103 to 100 × 103 cells/μL are eligible to participate in the study.

        d. Subjects have estimated creatinine clearance by modified Schwartz GFR of 77.8
        mL/min/1.73m2.

        e. Subject has a sodium level of < 130 mEq/L.

        Note: If any laboratory exclusion criteria are outside the normal range, the necessity for
        a repeat test should be discussed with the Medical Monitor. If upon retesting the value
        remains outside the protocol-specified range, the significance of this value may be
        discussed with the Medical Monitor for enrollment consideration.

        29. Subject has difficulty providing blood samples due to poor venous access or cannot
        safely provide a sufficient quantity of blood.

        30. Subjects of Asian ancestry must not be carriers of HLA b*1502. Either: a)
        subjects/caregivers must give written informed consent for genotyping, and test negative,
        or b) subjects/caregivers must provide documentation of prior testing confirming non
        carrier status and documented in subject's medical history.

        31. Subject is a female who is currently breastfeeding or intending to breastfeed during
        the study period, or within 3 months postpartum at the time of signing informed consent.

        32. Subject has participated in any investigational study within 30 days prior to
        screening, as documented in subject's medical history.

        33. Subject is unable to comply with study visit schedules or study procedures, except
        those that can be performed by a caregiver.

        34. Subject is a Clinical or Investigational Site staff member or relative of a staff
        member.

        35. Subject has experienced significant blood loss within 60 days or has donated plasma
        within 72 hours prior to Visit 1 or intends to donate blood or undergo elective surgery
        during the study or within 60 days following the study.
      "
NCT03103087,completed,,1,phase 3,"['heavy menstrual bleeding', 'uterine fibroid']","[""['G43.831', 'G43.839', 'G43.821', 'G43.829', 'N94.9', 'N94.89']""]","['relugolix', 'estradiol/norethindrone acetate', 'relugolix placebo', 'estradiol/norethindrone acetate placebo']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Key Inclusion Criteria:

          1. Premenopausal female aged 18 to 50 years old (inclusive) on the day of signing and
             dating the informed consent form.

          2. Has regularly occurring menstrual periods of ≤ 14 days duration with a cycle of 21 to
             38 days from the start of 1 menstrual period until the start of the next, by
             participant history for at least 3 months prior to the first screening visit.

          3. Has a diagnosis of uterine fibroids that is confirmed by a transvaginal and/or
             transabdominal ultrasound performed during the screening period.

          4. Has heavy menstrual bleeding associated with uterine fibroids as evidenced by an MBL
             of ≥ 160 milliliter (mL) during 1 cycle or ≥ 80 mL per cycle for 2 menstrual cycles as
             measured by the alkaline hematin method during the screening period.

        Key Exclusion Criteria:

          1. Has transvaginal and/or transabdominal ultrasound during the screening period
             demonstrating pathology other than uterine fibroids that could be responsible for or
             contributing to the participant's heavy menstrual bleeding.

          2. Has known rapidly enlarging uterine fibroids in the opinion of the investigator.

          3. Has a weight that exceeds the weight limit of the DXA scanner or has a condition that
             precludes an adequate DXA measurement at the lumbar spine and proximal femur.

          4. Has a history of or currently has osteoporosis, or other metabolic bone disease,
             hyperparathyroidism, hyperprolactinemia, hyperthyroidism, anorexia nervosa, or low
             traumatic (from the standing position) or atraumatic fracture (toe, finger, skull,
             face and ankle fractures are allowed). A history of successfully treated
             hyperparathyroidism, hyperprolactinemia, or hyperthyroidism is allowed if the
             participant's bone mineral density is within normal limits.

          5. Has a history of the use of bisphosphonates, calcitonin, calcitriol, ipriflavone,
             teriparatide, denosumab, or any medication other than calcium and vitamin D
             preparations to treat bone mineral density loss.

          6. Has been a participant in an investigational drug or device study within the 1 month
             prior to the first screening visit.
      "
NCT03461757,completed,,1,phase 3,"['migraine, with or without aura']","[""['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']""]","['rimegepant', 'placebo']","['Status: 503', 'Status: 503']","
        Key Inclusion Criteria:

        1. Subject has at least 1 year history of migraines (with or without aura), consistent with
        a diagnosis according to the International Classification of Headache Disorder, 3rd
        Edition, Beta version [1] including the following:

          1. Migraine attacks present for more than 1 year with the age of onset prior to 50 years
             of age

          2. Migraine attacks, on average, lasting about 4-72 hours if untreated

          3. Not more than 8 attacks of moderate to severe intensity per month within the last 3
             months

          4. Consistent migraine headaches of at least 2 migraine headache attacks of moderate or
             severe intensity in each of the 3 months prior to the Screening Visit and maintains
             this requirement during the Screening period

          5. Less than 15 days with headache (migraine or non-migraine) per month in each of the 3
             months prior to the Screening Visit and maintains this requirement during the
             Screening Period.

          6. Subjects on prophylactic migraine medication are permitted to remain on therapy
             provided they have been on a stable dose for at least 3 months prior to screening
             visit and the dose is not expected to change during the course of the study.

          7. Subjects with contraindications for use of triptans may be included provided they meet
             all other study entry criteria.

        Key Exclusion Criteria:

          1. Subject with a history of HIV disease

          2. Subject history with current evidence of uncontrolled, unstable or recently diagnosed
             cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and
             cerebral ischemia. subjects with Myocardial Infarction (MI), Acute Coronary Syndrome
             (ACS), Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient
             ischemic attack (TIA) during the 6 months prior to screening

          3. Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however
             subjects can be included who have stable hypertension and/or diabetes for at least 3
             months prior to being enrolled)

          4. Subject has a current diagnosis of major depression, other pain syndromes, psychiatric
             conditions (e.g., schizophrenia), dementia, or significant neurological disorders
             (other than migraine) that, in the Investigator's opinion might interfere with study
             assessments.

          5. Subject has a history of gastric, or small intestinal surgery (including Gastric
             Bypass, Gastric Banding, Gastric Sleeve, Gastric Balloon, etc.), or has disease that
             causes malabsorption

          6. The subject has a history of current or evidence of any significant and/ or unstable
             medical conditions (e.g., history of congenital heart disease or arrhythmia, known
             suspected infection, hepatitis B or C, or cancer) that, in the investigator's opinion,
             would expose them to undue risk of a significant adverse event (AE) or interfere with
             assessments of safety or efficacy during the course of the trial.

          7. History of, treatment for, or evidence of, alcohol or drug abuse within the past 12
             months or subjects who have met DSM-V criteria for any significant substance use
             disorder within the past 12 months from the date of the screening visit.

          8. Subjects are excluded if they have previously participated in any BHV-30000
             (rimegepant) study within the last 2 years.

          9. Participation in any other investigational clinical trial while participating in this
             clinical trial
      "
NCT03009019,completed,,1,phase 3,['migraine headache'],"[""['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']""]",['dfn-15 active'],['Status: 503'],"
        Inclusion Criteria:

          1. A history of episodic migraine, who experience 2 to 8 migraine attacks per month for
             at least the past 12 months, with no more than 14 headache days per month, and with 48
             hours of headache-free time between migraine attacks.

          2. Patients who have migraine with or without aura with onset before age 50 years

          3. Report usual migraine pain of 2 (moderate) or 3 (severe) on headache pain severity
             scale without treatment.

          4. Subjects who are willing and able to:

               1. Evaluate and record pain, migraine symptoms, and study drug effectiveness
                  information in real-time using a subject eDiary for the duration of the study;

               2. Record each instance of the use of study drug and rescue medication in real-time
                  using a subject eDiary for the duration of the study;

               3. Comply with all other study procedures and scheduling requirements.

        Exclusion Criteria:

          1. Minors, even if they are in the specified study age range

          2. Medication overuse:

               1. Opioids greater than or equal to 10 days during the 90 days prior to screening

               2. Combination medications (e.g., Fiorinal®) greater than or equal to 10 days during
                  the 90 days prior to screening (applies only if includes opioid and/or
                  barbiturate)

               3. Nonsteroidal Anti-inflammatory Drugs or other simple medications greater than 14
                  days a month during the 90 days prior to screening

               4. Triptans or ergots greater than or equal to 10 days a month during the 90 days
                  prior to screening

          3. Treated with onabotulinumtoxin A (Botox®) for migraine within 4 months prior to
             screening. (If treated for cosmetic reasons, subjects may be included).

          4. Current treatment with antipsychotics or use of antipsychotics within 30 days prior to
             randomization.

          5. Patients who have received treatment with an investigational drug or device within 30
             days of randomization, or participated in a central nervous system clinical trial
             within 2 months prior to randomization

          6. Patients with positive screening test for human immunodeficiency virus [HIV], positive
             hepatitis B surface antigen (HBsAg), or positive hepatitis C virus [HCV] antibody

          7. Subjects who are employees or immediate relatives of the employees of the Sponsor, any
             of its affiliates or partners, or of the clinical research study site.
      "
NCT03006276,completed,,1,phase 3,['migraine headache'],"[""['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']""]",['dfn-15 active'],['Status: 503'],"
        Inclusion Criteria:

          1. A history of episodic migraine, who experience 2 to 8 migraine attacks per month for
             at least the past 12 months, with no more than 14 headache days per month, and with 48
             hours of headache-free time between migraine attacks.

          2. Patients who have migraine with or without aura with onset before age 50 years

          3. Report usual migraine pain of 2 (moderate) or 3 (severe) on headache pain severity
             scale without treatment.

          4. Subjects who are willing and able to:

               1. Evaluate and record pain, migraine symptoms, and study drug effectiveness
                  information in real-time using a subject eDiary for the duration of the study;

               2. Record each instance of the use of study drug and rescue medication in real-time
                  using a subject eDiary for the duration of the study;

               3. Comply with all other study procedures and scheduling requirements.

        Exclusion Criteria:

          1. Minors, even if they are in the specified study age range

          2. Medication overuse:

               1. Opioids greater than or equal to 10 days during the 90 days prior to screening

               2. Combination medications (e.g., Fiorinal®) greater than or equal to 10 days during
                  the 90 days prior to screening (applies only if includes opioid and/or
                  barbiturate)

               3. Nonsteroidal Anti-inflammatory Drugs or other simple medications greater than 14
                  days a month during the 90 days prior to screening

               4. Triptans or ergots greater than or equal to 10 days a month during the 90 days
                  prior to screening

          3. Treated with onabotulinumtoxin A (Botox®) for migraine within 4 months prior to
             screening. (If treated for cosmetic reasons, subjects may be included).

          4. Current treatment with antipsychotics or use of antipsychotics within 30 days prior to
             randomization.

          5. Patients who have received treatment with an investigational drug or device within 30
             days of randomization, or participated in a central nervous system clinical trial
             within 2 months prior to randomization

          6. Patients with positive screening test for human immunodeficiency virus [HIV], positive
             hepatitis B surface antigen (HBsAg), or positive hepatitis C virus [HCV] antibody

          7. Subjects who are employees or immediate relatives of the employees of the Sponsor, any
             of its affiliates or partners, or of the clinical research study site.
      "
NCT03745898,terminated,"
    low feasibility of completion within the study period due to delayed site activation and slow
    participant accrual
  ",0,phase 3,"['heart failure', 'central sleep apnea']","[""['I50.814', 'I09.81', 'I50.82', 'I50.89', 'I50.9', 'T86.22', 'I11.0']"", ""['G47.31', 'P28.31', 'G47.37']""]",['oxygen'],['Status: 503'],"
        Inclusion Criteria:

          -  Aged ≥ 21 years at the date of consent.

          -  History of chronic, stable heart failure with reduced ejection fraction with left
             ventricular ejection fraction (LVEF) ≤ 50% determined by echocardiography,
             radionuclide angiography, left ventriculography, or cardiac magnetic resonance
             imaging, within the year prior to enrollment.

          -  Central sleep apnea, defined using as an apnea-hypopnea index (AHI) > 15/h with ≥ 50%
             central events (apnea and hypopneas).

          -  New York Heart Association (NYHA) Class III or IV, or NYHA Class II with any of the
             following:

               1. at least one hospitalization for heart failure within the 24 months prior to
                  enrollment or;

               2. a BMI corrected BNP ≥ 300 pg/ml or a corrected NT-proBNP ≥ 1500 pg/ml or;

               3. an ED visit for HF exacerbation where the patient has received an IV diuretic
                  within 12 months of enrollment.

          -  Treatment with stable, optimized guideline-directed medical therapies (GDMT) according
             to applicable guidelines in the U.S. and Canada, where stable is defined as the
             addition of no new class of disease-modifying drug for ≥ 30 days prior to
             randomization (reasons for intolerance to GDNT must be documented).

          -  In the investigator's opinion, willing and able to comply with all study requirements.

          -  Able to fully understand study information and sign an Institutional Review Board
             (IRB) approved informed consent (including HIPAA authorization in the U.S.).

        Exclusion Criteria:

          -  Current positive airway pressure use or predominantly obstructive rather than central
             sleep apnea.

          -  Oxygen saturation < 90% at rest during the day.

          -  Nocturnal oxygen saturation < 88% for > 5 continuous minutes unaccompanied by apneas
             or hypopneas.

          -  Chronic daytime or nighttime use of supplemental oxygen.

          -  Participants and their bed-partners who currently smoke in the bedroom.

          -  Severe pulmonary disease requiring continuous home oxygen therapy or the continuous or
             frequent intermittent use of oral steroids or documented severe chronic obstructive
             pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) < 50%.

          -  Cardiac surgery, percutaneous coronary intervention, myocardial infarction or unstable
             angina within the previous 3 months.

          -  Transient ischemic attack or stroke within the previous 3 months.

          -  Cardiac resynchronization therapy implantation scheduled or performed within 3 months
             prior to randomization.

          -  Primary hemodynamically-significant uncorrected valvular heart disease (obstructive or
             regurgitant) or any valvular disease expected to require surgery during the trial.

          -  Acute myocarditis/pericarditis or other cause of potentially reversible cardiomyopathy
             (e.g., post-partum cardiomyopathy, tachycardia-induced cardiomyopathy), within the
             previous 6 months.

          -  End-stage (Stage D) heart failure (HF) requiring continuous outpatient intravenous
             (IV) inotropic therapy, placement of ventricular assist device, listing for cardiac
             transplantation, or end-of-life care (e.g. hospice care).

          -  Pregnancy or of child bearing potential without a negative pregnancy test within 10
             days prior to enrollment.

          -  Life expectancy < 1 year for diseases unrelated to chronic HF.

          -  Enrolled or planning to enroll in another study that may conflict with protocol
             requirements or confound subject results in this trial.
      "
NCT02665273,completed,,1,phase 3,['migraine'],"[""['G43.B1', 'G43.D1', 'G43.B0', 'G43.D0', 'G43.A1', 'G43.411', 'G43.419']""]",['bupivacaine'],['Status: 503'],"
        Inclusion Criteria:

          -  ED patient with acute migraine or probable migraine

          -  Fail first line therapy with metoclopramide

        Exclusion Criteria:

          -  Can't obtain consent

          -  Concern for secondary headache

          -  Skull defect

          -  Propensity for bleeding

          -  Overlying infection

          -  Pregnancy

          -  Allergy, intolerance study medication
      "
NCT02397473,completed,,1,phase 3,['episodic cluster headache'],"[""['G44.011', 'G44.019']""]","['galcanezumab', 'placebo']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Have a diagnosis of cluster headache as defined by International Headache Society
             (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines with
             a history of episodic cluster headache with at least two cluster periods lasting from
             7 days to 1 year (when untreated) and separated by pain-free remission periods of >=1
             month.

          -  Participants are able to distinguish cluster headache attacks from other headaches.

        Exclusion Criteria:

          -  Current enrollment in or discontinuation within the last 30 days from, a clinical
             trial involving any investigational drug or device.

          -  Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP)
             antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF).

          -  Are taking indomethacin and/or are suspected of having another distinct trigeminal
             autonomic cephalalgia.

          -  A history of migraine variants that could implicate or could be confused with
             ischemia.

          -  Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
             proteins.

          -  A history or presence of other medical illness that indicates a medical problem that
             would preclude study participation.

          -  Evidence of significant active or unstable psychiatric disease, in the opinion of the
             investigator.

          -  Women who are pregnant or nursing.
      "
NCT03063671,completed,,1,phase 2/phase 3,['acute pain'],"[""['G89.12', 'G89.18', 'G89.11', 'G89.3']""]","['ketamine, bupivacine,dexmedetomidine']",['Status: 503'],"
        Inclusion Criteria:

          -  Patients scheduled for modified radical mastectomy.

          -  ASA Physical status I, II and III.

        Exclusion Criteria:

          -  Patients' refusal.

          -  Uncooperative patients & severe psychiatric illness (cannot evaluate their own pain
             intensity using visual analogue scale (VAS).

          -  Patients with history of drug allergy.

          -  severe renal or liver impairment, unstable ischemic heart disease

          -  Any contraindications to epidural analgesia (coagulopathy, recent -less than 1
             week-treatment with thrombolytic or potent antiplatelet drugs as clopidogrel, and
             local infection).
      "
NCT03068754,terminated,"
    as recommended by the study's independent data and safety monitoring board (dsmb)
  ",0,phase 2/phase 3,['amyotrophic lateral sclerosis'],"[""['G12.21']""]","['acthar', 'placebo']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          1. Is 18-75 years of age at Screening

          2. Has ALS symptom onset within 2 years prior to Screening

          3. Has forced vital capacity (FVC) no higher than 60% at screening

          4. If taking riluzole, is on a stable dose for 4 weeks before Screening

        Exclusion Criteria:

          1. Has tracheostomy, diaphragm pacing, or an ongoing need for assisted ventilation of any
             type

          2. Has used any medication within a time period not allowed per protocol

          3. Has history of Type 1 or Type 2 diabetes mellitus, or any clinically significant
             infection

          4. Used edaravone less than 1 week before Screening

          5. Received any stem cell replacement therapy

          6. Used steroids within a time period not allowed per protocol
      "
NCT02141035,completed,,0,phase 2/phase 3,"['carpal tunnel syndrome', 'compression neuropathy']","[""['G56.00', 'G56.01', 'G56.02', 'G56.03']""]","['acetyl-l-carnitine', 'placebo']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Patients will be recruited from the University of Alberta Hospital referred for CTS.
             Inclusion criteria will include adult patients (over age 18) with at least one of the
             following symptoms:

               1. numbness and parenthesis in the median nerve distribution;

               2. Precipitation of those symptoms by repetitive motions that are relieved by
                  rubbing and or shaking the hands;

               3. Nocturnal awakening by those sensory symptoms, or

               4. Weakness of thumb abduction and thenar atrophy.

        Exclusion Criteria:

          1. Motor unit loss in the median nerve less than 2 SD below the mean for the age as
             determined by nerve conduction studies.

          2. The presence of other neurologic conditions

          3. Previous carpal tunnel release surgery

          4. Cognitive impairment that renders the patient unable to provide informed consent;

          5. Pregnancy
      "
NCT02654054,completed,,1,phase 3,"['uterine fibroids', 'heavy menstrual bleeding']","[""['G43.831', 'G43.839', 'G43.821', 'G43.829', 'N94.9', 'N94.89']""]","['elagolix', 'placebo for estradiol/norethindrone acetate', 'estradiol/norethindrone acetate', 'placebo for elagolix']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Subject is a premenopausal female at the time of Screening.

          -  Subject has a diagnosis of uterine fibroids documented by a pelvic ultrasound
             (transabdominal ultrasound/transvaginal ultrasound).

          -  Subject has heavy menstrual bleeding associated with uterine fibroids as evidenced by
             menstrual blood loss > 80 mL during each of two screening menses as measured by the
             alkaline hematin method.

          -  Subject has negative urine and/or serum pregnancy test in Screening and just prior to
             first dose.

          -  Subject has an adequate endometrial biopsy performed during Screening, the results of
             which show no clinically significant endometrial pathology.

        Exclusion Criteria:

          -  Subject has screening pelvic ultrasound or saline infusion sonohysterography results
             that show a clinically significant gynecological disorder.

          -  Subject has history of osteoporosis or other metabolic bone disease.

          -  Subject has clinically significant abnormalities in clinical chemistry, hematology, or
             urinalysis.

          -  Subject has a history of major depression or post-traumatic stress disorder (PTSD)
             within 2 years of screening, OR a history of other major psychiatric disorder at any
             time (e.g., schizophrenia, bipolar disorder).

          -  Subject is using any systemic corticosteroids for over 14 days within 3 months prior
             to Screening or is likely to require treatment with systemic corticosteroids during
             the course of the study. Over the counter and prescription topical, inhaled,
             intranasal or injectable (for occasional use) corticosteroids are allowed.
      "
NCT02656875,completed,,1,phase 3,['acute pain'],"[""['G89.12', 'G89.18', 'G89.11', 'G89.3']""]",['trv130'],['Status: 503'],"
        Inclusion Criteria include:

          -  Moderate to severe acute pain for which parenteral opioid therapy is warranted

          -  Able to understand and comply with the procedures and study requirements, and to
             provide written informed consent before any study procedure.

        Exclusion Criteria include:

          -  Clinically significant medical, surgical, postsurgical, psychiatric or substance abuse
             condition or history of such condition that would confound the interpretation of
             safety, tolerability, or efficacy data in the study.

          -  Hemodynamic instability or respiratory insufficiency.

          -  Advanced cancer in palliative or end-of-life care.

          -  Another current painful condition (other than acute pain for which parenteral opioid
             therapy is warranted) that would confound the interpretation of safety, tolerability,
             or efficacy data in the study.

          -  Clinically significant, immune-mediated hypersensitivity reaction to opioids.
      "
